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Abstract 
Balancing systemic iron levels within narrow limits is critical for human health, as both 
iron deficiency and overload lead to serious disorders. There are no known 
physiologically controlled pathways to eliminate iron from the body and therefore iron 
homeostasis is maintained by modifying dietary iron absorption. Several dietary factors, 
such as polyphenols, are known to greatly affect iron absorption. Furthermore, it is 
proposed that polyphenols can affect iron status by regulating expression and activity of 
proteins involved in either the systemic regulation of iron metabolism or iron 
absorption. To reveal how polyphenols affect iron metabolism, experiments which 
included intraperitoneal (IP) or forced feeding (gavage) treatment of Sprague Dawley 
rats with quercetin, polyphenol which is plentiful in the diet, were performed. These 
treatments were followed by the evaluation of iron-related genes and iron content in 
duodenum, liver, spleen, kidney and serum. Results revealed that quercetin treatment, 
IP or gavage, provoked iron deficiency. Oral treatment mainly affected iron absorption, 
mostly by changing the expression of iron transporters. Additionally, with in vivo 
uptake studies it was shown that quercetin reduces duodenal iron uptake by direct 
chelation of iron consequently increasing apical iron uptake and decreasing basolateral 
iron release from enterocyte. IP treatment mainly affected systemic iron homeostasis, 
mainly through up-regulation of hepcidin expression in liver and kidney. Additionally, 
in in vitro studies quercetin metabolites and other polyphenols showed a notable effect 
on hepcidin expression in human liver HepG2 cells, as well as on inflammatory and 
iron-related genes in THP1 cells. Results showed that polyphenols have multiple effects 
on iron homeostasis. Thus, polyphenols may have important consequences for 
conditions that are low in iron such as anaemia. Alternatively, polyphenols have 
therapeutic potential for iron overload diseases, potentially as a part of chelato-therapy. 
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1. INTRODUCTION 
1.1 Biological importance of iron 
Studying chemistry of iron in detail, it is easy to see why iron is essential for life. 
Namely, under physiological conditions, iron is mainly present in two forms, ferrous 
(Fe
2+
) and ferric (Fe
3+
). The Fe
2+
/Fe
3+
 system facilitates variety of redox potentials 
that can be fine adjusted by different ligands (from about -0.5 V to about +0.6 V), 
which almost entirely corresponds to the redox potential range of utmost importance 
for biological systems. That is why iron complexes are uniquely suitable for a variety 
of catalytic processes and reactions which are of great biological significance, such 
as electron transfer and acid-base reactions (Crichton, 2001; Lieu et al., 2001). 
Iron carries out a variety of significant roles in biological systems, mostly as a part of 
iron-containing proteins. Haemoproteins are a large group of iron-containing proteins 
where the iron is bound to a porphyrin molecule (haem) which is bound to the 
different proteins with diverse functions. There are three main categories of 
haemoproteins: oxygen carriers (haemoglobins, myoglobins and neuroglobins), 
activators of molecular oxygen (cytochrome oxidase, cytochrome P450s, catalases 
and peroxidases) and electron transport proteins (cytochromes; Yehuda and 
Mostofsky, 2010; Ying–Wu and Jiangyun, 2013). 
The second group of iron-containing proteins is the iron-sulphur proteins (Fe–S 
proteins), where iron is bound to sulphur by thiol groups from cysteine or inorganic 
sulphide. Fe–S proteins are widespread in all living organisms and express numerous 
actions. Namely, they are included in redox and non-redox reactions as part of 
12 
different enzymes, like succinate dehydrogenase and aconitase, and proteins involved 
in the electron transfer chain (Crichton, 2001; Lill and Muhlenhoff, 2006). 
The third class of iron-containing proteins presents a diverse group of proteins that 
do not contain iron in a haem or Fe–S form. One group is mononuclear non-haem 
iron enzymes, which include lipoxygenases, aromatic amino-acid hydroxylases, 
prolyl and lysyl hydroxylases, etc. Additionally, there is the dinuclear non-haem iron 
protein group, consisting of ribonucleotide reductase and ferritins or proteins 
involved in iron transport, such as transferrins (Crichton, 2001). 
Summing activities of the above mentioned proteins, it is apparent that iron is crucial 
for many important processes, such as: oxygen transport and storage, cellular 
respiration and energy production, the electron transport chain of mitochondria, 
synthesis of DNA, RNA and proteins, regulation of gene expression, cell 
proliferation and differentiation. In addition, iron is indispensable for normal brain 
function, psychomotor development and cognitive performance (especially in 
infants), endurance and physical performance, the inflammatory response (iron 
deficiency greatly reduces resistance to infection), pregnancy (40% of all maternal 
prenatal deaths are linked to anaemia), thyroid function, production and metabolism 
of catecholamines and other neurotransmitters, drug metabolism, etc. Hence it is 
evident that nearly every cell and organism require iron for life (World Health 
Organization, 2001; Dunn et al, 2007; Sharp and Srai, 2007; Yehuda and Mostofsky, 
2010). 
On the other hand the property of iron to easily change its oxidative stage can also be 
toxic, mainly due to its ability to produce free radicals when it is not bound by 
13 
proteins and is free in a labile iron pool. Iron takes part in a reaction, known as the 
Fenton reaction, where the hydroxyl radical (HO
•
) is the end product. HO
•
 is the most 
toxic reactive oxygen species (ROS) which can damage all classes of biomolecules. 
Consequently, unrestrained production of HO
•
 leads to cell injuries and death and 
gives rise to numerous severe pathological states (Halliwell and Gutteridge, 2007). 
The Fenton reaction initiates the chain reaction (equation 1), which is then followed 
by the reactions (equations 2 and 3) in which more and more HO
•
 is produced 
(Koppenol, 2001). 
Fe
2+
 + H2O2 → Fe
3+
 + HO• + HO
-
 equation 1 
HO• + H2O2 → H2O + O2
•- + H
+
 equation 2 
O2
•- + H
+
 + H2O2 → O2 + HO
• + H2O equation 3 
Thus, balancing systemic iron levels within narrow limits in an organism is crucial, 
as both iron deficiency and iron overload lead to serious haematological, metabolic 
and neurodegenerative disorders, which belong to the most frequent disorders 
worldwide, as well as carcinogenesis (Hentze et al., 2004). 
1.2 Distribution and homeostasis of body iron 
The total iron content of the adult human organism is estimated around 4 g (~ 35 
mg/kg woman, ~ 45 mg/kg for men). About 52% of total body iron is found as part 
of haemoglobin in circulating erythrocytes or erythrocyte precursors, 40% in 
complex with ferritin or hemosiderin as intracellular pool (liver and reticulo-
endothelial macrophages), 7.5% in muscle as part of myoglobin, 0.5% as part of the 
catalytic centre of a variety of enzymes (cytochromes, catalase, peroxidases, 
14 
flavoproteins, etc.) and 0.1% as transferrin-bound iron in the circulation (see Figure 
1–1; Andrews, 1999; Lieu et al., 2001). 
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Figure 1–1 Distribution of body iron 
The adult human body have approximately 4 g of iron, with more than half (>2 g) 
incorporated in the haemoglobin of developing erythroid precursors (300 mg) and 
mature circulating erytrocytes (1800 mg). Remaining body iron is found in a transit 
pool in reticulo-endothelial macrophages (600 mg) or stored in hepatocytes (1000 
mg) complexed with ferritin. A smaller part is present in muscles within myoglobin 
(300 mg), while only a minor amount is present in plasma bound to transferin (3 mg) 
or incorporated in other proteins and enzymes that include iron in their structures. 
Approximately, 10–20 mg of iron is daily consumed by diet, from which only 1–2 
mg is absorbed. The same amount is lost every day by blood loss of different 
etiology, shedding of the skin and sloughed enterocytes. 
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Body iron homeostasis is maintained by regulating the iron levels in plasma 
(transferrin-bound iron), which is determined by four coordinated processes: 
duodenal iron absorption, macrophage iron recycling, hepatic iron storage and 
erythropoiesis. Erythropoiesis, the production of red blood cells in bone marrow, 
requires nearly 30 mg iron each day, the main part of which comes from the 
recycling of iron via reticulo-endothelial macrophages (> 28 mg/day). Macrophages 
ingest old or damaged erythrocytes, process them and release recycled iron to plasma 
transferrin. The pool of transferrin-bound iron (~ 3 mg) is very dynamic and 
undergoes recycling more than 10 times daily. Furthermore, when in balance, each 
day the body absorbs 1–2 mg of iron by duodenal enterocytes and at the same time 
loses 1–2 mg of iron by nonspecific iron losses, such as exfoliation of enterocyte, 
skin and hair loss, menstruation and some gastrointestinal blood loss (see Figure 1–
1). Bearing in mind that there is no known physiologic mechanism for controlling 
iron excretion and that macrophage-mediated iron recycling cannot be sufficient for 
maintaining erythropoiesis over the long term, absorption of dietary iron in 
duodenum is of great importance in keeping iron homeostasis in balance 
(Papanikolaoua and Pantopoulos, 2005; Beaumont and Delaby, 2009). 
1.3 Mechanism of dietary iron uptake 
Nutritional iron absorption occurs primarily in the duodenum, on the apical (luminal) 
membrane of the enterocytes, and is tightly regulated by bioavailable iron, iron 
stores, erythropoietic drive and inflammation. The average diet daily contains about 
10–20 mg of iron from which only 1–2 mg is absorbed. There are two types of 
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dietary iron: non-haem iron, which is present in food from both animal or plant 
origin, and haem iron, which is present only in food of animal origin. 
Absorption of non-haem iron in the intestine comprises the following (Srai et al., 
2002; see Figure 1–2): 
1. Reduction of Fe3+ and uptake of Fe2+ from the diet through the apical membrane 
of enterocytes. In the diet iron is mainly present as Fe
3+
. However, the absorption 
of Fe
2+
 is more efficient than Fe
3+
. In order to increase Fe
3+
 bioavailability, Fe
3+ 
firstly needs to be reduced. Duodenal cytohrome b (Dcytb) is an iron-regulated 
ferric reductase, highly expressed on the apical membrane of duodenal 
enterocytes (described in detail in Section 1.3.1.1; McKie et al., 2001). After 
being reduced by Dcytb, Fe
2+
 is transported across the apical membrane by the 
divalent metal transporter 1 (DMT1; described in detail in Section 1.3.1.2; 
Gunshin et al., 1997). 
2. Intracellular processing of iron and iron transport to the basolateral membrane 
of enterocytes. There is not much information about the mechanism of 
intracellular iron transport. However, it is supposed that it is closely related to 
vesicular transport. The fate of absorbed iron is closely related to the body’s 
demands for iron. If there is a need for more iron, then iron is exported from the 
cell via the basolateral membrane of enterocytes which is followed by iron 
binding to transferrin (Tf; described in detail in Section 1.3.1.6) and transport to 
peripheral tissues that require iron. If there is no need for additional iron in the 
body, iron is stored in the cell in the form of ferritin (described in detail in Section 
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1.3.1.3), the main iron storage protein, and returned to the lumen at a time when 
the villus enterocytes die (Sharp and Srai, 2007). 
3. Transfer of iron through the basolateral membrane to the circulation. The 
mechanism of Fe
2+
 transport through the basolateral membrane includes 
synchronized activity of two proteins, ferroportin (FPN; described in detail in 
Section 1.3.1.4; Abboud and Haile, 2000; Donovan et al., 2000; McKie et al., 
2000) and transmembrane copper-dependent ferroxidase, hephaestin (Heph; 
described in detail in Section 1.3.1.5; Vulpe et al., 1999; Chen et al., 2004). 
Before entering the circulation, Fe
2+
 firstly needs to be oxidized to the Fe
3+ 
state, 
which is catalyzed by hephaestin, the intestinal ferroxidase. Fe
3+ 
then binds to the 
serum glycoprotein Tf (described in detail in Section 1.3.1.6; MacGillivray et al., 
1983), the key iron transporting protein in the serum and extracellular fluids. 
The uptake mechanism for non-haem and haem iron differs across the apical 
membrane of the enterocyte, while it follows the same pathway once iron is inside 
the cell (see Figure 1–2). Even though the mechanism of haem absorption is not fully 
characterized, haem carrier protein 1 (HCP1) was identified as protein for haem 
uptake on the apical membrane of duodenal enterocytes (Shayeghi et al., 2005). Once 
inside the cell, haem is degraded by haem oxygenase (HO–1; Tenhunen et al., 1969) 
and the released iron enters an intracellular iron pool. After that, absorbed iron from 
the haem source follows the pathway of absorbed non-haem iron. 
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Figure 1–2 Mechanism of non-haem and haem iron absorption in duodenal cells 
Non-haem iron from food is firstly reduced by the ferric reductase Dcytb yielding 
Fe
2+
, which afterwards enters the enterocytes via DMT1. On the other hand, haem is 
absorbed via HCP1, subsequently broken down by HO–1, after which free Fe2+ from 
haem joins a common cell iron pool with iron from the non-haem source. If body 
iron stores are high, iron may be stored in the cell complexed with ferritin as Fe
3+
 
and eventually lost when the cell is discarded from the intestinal villus tip. 
Otherwise, iron efflux into the circulation via FPN, subsequently being re-oxidised 
through Heph to enable loading into Tf, after which it is transferred to peripheral 
tissues that require iron. 
1.3.1 Proteins involved in iron absorption and transport 
1.3.1.1 Duodenal cytochrome B (DcytB) 
Dcytb (or Cybrd1) is an iron-regulated protein with ferric reductase activity, highly 
expressed on the human duodenal apical membrane next to DMT1. The primary role 
of Dcytb is to reduce non-haem iron (Fe
3+
 to Fe
2+
) prior to its transport inside the cell 
via DMT1 (see Figure 1–2; McKie, 2008). The structure of the Dcytb protein 
consists of 286 amino acids with six transmembrane domains and was revealed using 
a subtractive cloning strategy by McKie et al. in 2001. Furthermore, it has been 
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shown in vitro that Dcytb expresses dual, ferric and cupric reductase activity 
(Wyman et al., 2008). 
Dcytb mRNA and protein levels are up-regulated by hypoxia (described in detail in 
Section 1.4.3) and iron deficiency, which strongly supports its role in iron uptake and 
metabolism (Zoller et al., 2003; Wyman et al., 2008). Recently it has been shown 
that the transcriptional modulation of Dcytb expression can be regulated by 
transcriptional factor hypoxia-inducible factor (Hif) –2α (Shah et al., 2009). 
Specifically, the activity of enzymes that modulate Hif–2α ubiquitination is 
supported by ascorbate, Fe
2+
 and O2. Thus, low ascorbic acid levels, iron deficiency 
and hypoxia, hold back Hif–2α ubiquitination, enhance Hif–2α levels and support 
Dcytb expression. In addition, ascorbic acid has been recognized as a Dcytb helper 
by supplying electrons for Fe
3+
 reduction, and thus has a dual role in regulation of 
Dcytb activity (Oakhill et al., 2008; Luo et al., 2014). 
Interestingly, in contrast to other genes important for iron uptake, such as DMT1 and 
FPN, Dcytb transcript lacks an iron-responsive element (IRE), one of the key players 
in the control of iron metabolism (described in detail in 1.4.1). 
Moreover, it was shown that over-expression of Dcytb in Caco–2 or MDCK (Madin–
Darby canine kidney) cells, significantly increased iron absorption, clearly indicating 
that Dcytb plays an important role in iron transport (Latunde–Dada et al., 2008; 
Wyman et al., 2008). Also, it was shown that Dcytb is increased in the duodenum of 
iron-deficient patients, which is associated with a desirable increase of iron 
absorption. On the other side, it was shown that in iron-overload patients, Dcytb 
levels in the duodenum are decreased (Zoller et al., 2003). However, the essential 
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role of Dcytb in iron uptake in humans was the subject of uncertainty. Namely, there 
are no reports on a direct connection between mutations in human Dcytb and iron 
metabolism disorders. Additionally, it was shown that there was no significant 
disturbance of iron homeostasis in Dcytb knockout mice. Still, absence of iron 
deficiency in humans with mutated Dcytb and Dcytb knockout mice could be 
explained by the presence of other reductase enzymes in the gut and substrates that 
could reduce iron, such as ascorbic acid (Gunshin et al., 2005). However, to date 
Dcytb still remains the only known reductase in the human duodenum that is 
regulated by increased physiological demands for iron.  
1.3.1.2 Divalent metal transporter 1 (DMT1) 
DMT1 (Nramp2 or DCT1) is a divalent metal protein transporter located on the 
apical membrane of enterocytes which, after reduction of iron by Dcytb, transports 
Fe
2+
 inside the cell (see Figure 1–2). DMT1 was first identified in 1995 (Gruenheid 
et al., 1995), but its activity as an iron transporter was revealed subsequently when a 
DMT1 mRNA construct was transfected into Xenopus oocytes and iron uptake 
activity was observed (Gunshin et al., 1997). It is believed that DMT1 acts as proton 
symporter, transporting one H
+
 for each Fe
2+
, and therefore iron uptake is supported 
by the mildly acidic environment of the duodenum (Gunshin et al., 1997). Moreover, 
DMT1 is confirmed to have the ability to transport other divalent metals, such as 
Mn
2+
, Cu
2+
, Cd
2+
, Zn
2+
, Co
2+
, Ni
2+
 and Pb
2+
 (Garrick et al., 2003). 
The importance of DMT1 in iron uptake was highlighted by study with DMT1 gene 
mutations in two animal models, microcytic anaemia mice and Belgrade rats 
(Fleming et al. 1997; Fleming et al., 1998). Both models showed a severe iron 
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deficiency phenotype due to impaired iron uptake. Moreover, humans with DMT1 
mutations exhibited hypochromic microcytic anemia, which undoubtedly indicates a 
significant role for DMT1 in iron homeostasis (Mims et al., 2005; Lam–Yuk–Tseung 
et al., 2006). 
Humans have two types of DMT1 proteins, with 561 and 570 amino acids, having 12 
transmembrane domains. Two variants of mRNA differ at their C-terminus by the 
presence or absence of a specific IRE sequence on the 3’ untranslated region (UTR). 
Thus, +IRE and -IRE DMT1 types are controlled by both the intracellular iron pool 
or an IRE-independent mode of metal regulation, respectively (described in detail in 
Section 1.4.1; Gunshin et al., 1997; Fleming et al., 1998; Lee et al., 1998; Au et al., 
2008). However, it was shown in vitro in an intestinal Caco–2 cell line that hepcidin, 
a main controller of systemic iron homeostasis, is a negative regulator of DMT1 
expression of both RNA and protein levels (Yamaji et al., 2004; Mena et al., 2008). 
Recently it was revealed that duodenal DMT1 is down-regulated by hepcidin via 
proteasome internalization and degradation, similar to FPN in macrophages 
(described in detail in Sections 1.3.1.4 and 1.4.2; Brasse–Lagnel et al., 2011). 
Hepcidin is a small, liver-secreted hormone which plays a central role in iron 
metabolism by inhibiting iron absorption in the duodenum, liberation of iron from 
macrophages after recycling of senescent erythrocytes and iron which is stored in 
hepatocytes (described in detail in Section 1.4.2). Additionally, it was recently shown 
that Hif–2α, but not Hif–1α, induces DMT1 transcription, in the same manner as 
Dcytb, which is evidence that DMT1 levels are also controlled by hypoxia (described 
in detail in Section 1.4.3; Mastrogiannaki et al., 2009). 
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1.3.1.3 Ferritin 
Ferritin is the main intracellular iron storage protein present in almost all living 
organisms and expressed in numerous cell types. Ferritin was discovered more than 
70 years (1937) by the French scientist Laufberger who crystallized ferritin from 
horse spleen (Laufberger, 1937). Inside the cell (e.g. the enterocyte) surplus iron is 
stored by ferritin in a redox inactive form, thus preventing formation of new free 
radicals, which can be highly toxic for the cell. However, under conditions of iron 
demand in the cell or organism, iron can be released from ferritin. In other words, in 
humans ferritin acts as a buffer against cell iron deficiency and iron overload. 
Ferritin is in the form of a shell with a cavity (a.k.a. nanocage structure) where up to 
4500 iron atoms can be loaded in a form of ferric oxide, Fe2O3 (Theil, 2011). It 
comprises 24 subunits of two types: H (heavy; 21 kDa) and L (light; 19 kDa) which 
combine in different ratios with a tissue-specific distribution. Prior to iron storage, 
oxidation of Fe
2+
 to Fe
3+
 occurs in the ferritin H subunit (Arosio et al., 2009; Bou–
Abdallah, 2010). 
The ferritin structure is highly conserved in bacteria, plants and animals and follows 
the same pattern of expression regulation: iron availability and oxidative stress. In 
mammals, post-transcriptional regulation is based on the presence of an IRE 
sequence on both H and L ferritin mRNA 5’UTRs, which facilitate up-regulation of 
ferritin synthesis when iron is present in excess. In contrast, during iron deficiency 
ferittin synthesis is blocked in order to increase iron bioavailability (described in 
detail in Section 1.4.1; Theil, 2007). Oxidative stress regulates levels of ferritin at the 
transcriptional level by an upstream antioxidant responsive element (ARE) on ferritin 
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genes. Both nuclear factor erythroid 2-related factor (Nrf2) and JunD transcriptional 
factors are involved in the transcriptional activation of H and L ferritin via ARE after 
oxidative stress, therefore protecting cells from oxidative stress induced by higher 
levels of iron. Moreover, the Nrf2 pathway is enhanced by haem through which 
haem also up-regulates ferritin levels on transcription level (described in detail in 
Section 1.4.3; Hintze et al., 2007). Additionally, ferritin levels are up-regulated by 
the cytokines tumour necrosis factor-α (TNF–α) and interleukin (IL)–6 and 
inflammation (Torti and Torti, 2002). 
1.3.1.4 Ferroportin (FPN) 
FPN is the single known mammalian iron exporter which facilitates efflux of iron to 
the circulation through the basolateral membrane of the enterocyte together with the 
coordinated action of a ferrioxidase Heph (see Figure 1–2). Besides, being essential 
for iron absorption from the diet, FPN is the crucial iron exporter in different cell 
types, such as hepatocytes and macrophages, thus takes part in the distribution of 
iron between tissues (Ward and Kaplan, 2012). FPN is a protein comprising 571 
amino acids with a mass of 62 kD, whose discovery was made at the same time by 
three independent groups, using three different methods, and thus was given three 
different names: metal transporter 1, iron-regulated protein 1 and FPN1 (Abboud and 
Haile 2000, McKie et al., 2000, Donovan et al., 2000, respectively). In this work, the 
name ferroportin or its abbreviation FPN will be used. 
The mechanism of iron transport via FPN is not fully understood. However, it is 
considered that Fe
2+
 is substrate for FPN, because FPN needs additional ferroxidase 
activity in order to provide iron for Tf (Ward and Kaplan, 2012). 
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The pivotal role of FPN in iron homeostasis has been extensively documented 
showing that the absence of FPN provokes disruption of iron homeostasis. An 
experiment with mice, where removal of FPN was done in utero, resulted in viable 
but underdeveloped mice with severe iron deficiency. Specifically, selective 
inactivation of FPN in the duodenum resulted in low iron concentrations right after 
the birth, demonstrating that FPN is of great importance for iron absorption. Also, 
general inactivation of FPN in an organism revealed iron overload in the liver, spleen 
and duodenum, provoking anaemia and pointing out that FPN is a major iron 
exporter in the body (Donovan et al., 2005). The connection between mutations in 
FPN and loss of its function and subsequently iron retention in Kupffer cells and 
macrophages in humans was first identified by Montosi et al. 2001, and was named 
“FPN disease“. Nowadays, this disorder is classified as most common non-
haemochromatosis protein (HFE) haemochromatosis (HH), which belongs to the 
group of hereditary iron loading disorders associated with the reduction in levels of 
the peptide hormone hepcidin (described in detail in 1.4.2 and 1.4.4; Pietrangelo, 
2010; Pietrangelo et al., 2011). 
FPN levels are regulated by a number of mechanisms. Like Dcytb and DMT1, FPN 
transcription is also supported by the presence of Hif–2α induced by hypoxia 
(described in detail in Section 1.4.3; Mastrogiannaki et al., 2009). Also, like ferritin, 
the FPN gene contains an ARE promoter and its transcription is controlled by 
oxidative stress through the Nrf2 pathway. Similarly, transcription of FPN is 
demonstrated to be up-regulated by iron and haem and it is considered that these 
paths of regulation include Nrf2 transcriptional factor (described in detail in Section 
1.4.3; Marro et al., 2010; Ward and Kaplan, 2012). In addition, transcription of FPN 
is proven to be up-regulated by other metals (e.g. Zn and Cd; Troadec et al., 2010). 
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At the transcriptional level FPN is down-regulated by inflammation induced by 
lipopolysaccharide (LPS; Ludwiczek et al., 2003; Harada et al., 2011). 
Post-transcriptionaly, FPN is regulated by the IRE/IRP (iron-regulatory protein) 
system (described in detail in Section 1.4.1). mRNA of FPN has an IRE sequence at 
its 5’UTR, by which translation of FPN is inhibited by low levels of iron and 
increased by high levels of iron in the cell (Hentze et al., 2004). 
Post-translationally, FPN can be regulated by two known mechanisms. Firstly, FPN 
levels can be regulated by the hepatic hormone hepcidin. This mechanism was 
elucidated by Nemeth et al. 2004b, who demonstrated that hepcidin attached to FPN 
on the cell membrane induced its internalization (described in detail in Section 
1.4.2). Additionally, post-translational internalization of FPN can be driven by a 
hepcidin-independent mechanism. Specifically, FPN is degraded in the absence of 
the multicopper oxidase ceruloplasmin (Cp), while it is stable when Cp is present 
(Jeong and David, 2003). 
1.3.1.5 Hephaestin (Heph) 
Heph is a membrane-bound copper-dependent ferroxidase that takes part in iron 
export from the intestinal epithelium to the circulation, where it binds to Tf, in 
synchronized activity with the FPN transporter (see Figure 1–2). It is believed that 
Heph facilitates iron trafficking by oxidizing the soluble Fe
2+
 into the Fe
3+
, prior to 
its release by FPN. The role of Heph in iron export from enterocytes to the 
circulation was established by experiments with the sex-linked anaemia (sla) mouse, 
where iron export was inhibited leading to intestinal iron accumulation and systemic 
iron deficiency. The sla mouse contains a mutation that generates Heph with 
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impaired structure and thus can take up iron normally from the diet into enterocytes, 
but is unable to facilitate iron export (Vulpe et al., 1999; Chen et al., 2004). 
Heph is 50% identical with Cp, the serum multi-copper ferroxidase, which assists in 
iron export from various tissues. Both ferroxidases contain iron- and copper-binding 
sites, have similar functions but different locations. Namely, Heph is mainly 
expressed in the small intestine and anchored to the membrane where it plays an 
important role in the uptake of iron from the diet. Cp is soluble plasma protein, 
mainly expressed in liver and has a role in the redistribution of iron from the liver 
and other internal organs (Petrak and Vyoral, 2005; Chen et al., 2006). 
In contrast to most proteins involved in iron homeostasis, Heph activity is neither 
regulated via the IRE/IRP system nor hepcidin (described in detail in Sections 1.4.1 
and 1.4.2). Also, it is recognized that Heph expression is more responsive to systemic 
iron levels than to iron levels in enterocytes. In iron-deficient conditions, Heph 
mRNA levels increase, whereas in contrast, high iron concentration causes a 
decrease in Heph mRNA in vivo (Sakakibara and Aoyama, 2002; Chen et al., 2003). 
Specifically, a down-regulation of Heph expression was proven in the duodenum of 
patients with hereditary HH (Stuart et al., 2003), while mRNA and protein levels are 
up-regulated by iron deficiency, which strongly supports its role in iron uptake and 
metabolism (Zoller et al., 2003). Also, reduced interactions between FPN and Heph 
in rats after iron ingestion indicate that this is a regulatory mechanism for limiting 
further iron absorption (Yeh et al., 2011). Still, by now, no human disease has been 
associated with a Heph mutation (Petrak and Vyoral, 2005). 
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Also Heph requires copper for its structural stability and enzymatic activity and 
consequently copper levels affect Heph activity. To be exact, copper deficiency leads 
to a marked decrease in Heph expression and ferroxidase activity (Nittis and Gitlin, 
2004), while it was observed when copper is abundant an increase in Heph mRNA 
occurs (Han and Wessling–Resnick, 2002).  
1.3.1.6 Transferrin (Tf) 
Tf is monomeric non-haem iron-binding glycoprotein. Its main function is to 
transport iron safely around the body from site of iron absorption to places of iron 
storage and usage. One molecule of plasma Tf can bind reversibly two atoms of Fe
3+
 
with high affinity (Aisen et al., 1978). Chelation of iron by Tf has a few functions: it 
maintains Fe
3+
 in a soluble form under physiologic conditions, it maintains Fe
3+
 in a 
redox-inert state preventing the generation of toxic free radicals, it facilitates 
regulated iron transport and cellular uptake and it has an indirect defensive role 
against infections by making iron unavailable to potential pathogens which require 
iron for growth (Brock et al., 1987; Gkouvatsos et al., 2012). When not bound to 
iron, Tf is known as apo-transferrin (apo–Tf), while holo-transferrin (holo–Tf) is the 
iron-saturated form of Tf. Tf is mainly synthesized in liver (Zakin, 1992), while it is 
present in different body fluids, such as plasma, bile, lymph, cerebrospinal fluid, 
breast milk and amniotic fluid (Qian et al., 2002). The concentration of Tf in plasma 
ranges from 2 g/L to 3 g/L, and the in vivo half-life of the Tf is eight days (Gomme et 
al., 2005). 
At any time plasma Tf binds less than 0.1% of total body iron (3 mg; see Figure 1–
1). Two millions of new erythrocytes are produced every second by the bone 
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marrow, which requires a daily supply around 30 mg of iron. In order to meet the 
needs of erytrocyte production, plasma Tf turns over more than 10 times a day 
(Cavill, 2002). Because iron absorbed from diet is limited, the main source of plasma 
iron is the reticulo-endothelial macrophages: senescent erythrocytes are phagocytized 
by macrophages in the spleen, liver and bone marrow. Macrophages degrade 
haemoglobin, liberate Fe
2+
 and export it through FPN by synchronized iron re-
oxidation to Fe
3+
 by Cp, and load it to Tf, if the body requires extra iron (Wang and 
Pantopoulos, 2011). Tf saturation reflects body iron stores and the balance between 
reticulo-endothelial iron release and bone marrow uptake. Around 30% of the Tf 
iron-binding sites are saturated under normal conditions. This partial saturation of Tf 
presents a shield for preventing iron toxicity, because it makes it possible to tolerate 
a sudden change of plasma iron levels. In humans, Tf saturation less than 15% 
indicates iron deficiency, whereas 45% and more is sign for iron overload (Hentze 
and Muckenthaler, 2010). 
The mechanism of cellular uptake of Tf-bound iron from plasma involves diferric Tf 
binding to transferrin receptor (TfR) 1 and endocytosis of the complex Tf/TfR1. 
After releasing Fe
3+
 from Tf into the endosome, iron is reduced and transported to 
the cytosol via DMT1. Consequently, apo–Tf is exported back to the circulation, 
while TfR1 is recycled on to the cell surface ready for another iron uptake cycle. 
TfR1 is expressed in many cell types, such as developing erythroid cells, hepatocytes 
and placental syncytiotrophoblasts (Hémadi et al., 2004). 
Interestingly, holo–Tf expresses a significant regulatory function in the expression of 
hepcidin, a systemic regulator of iron homeostasis (described in detail in Section 
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1.4.2). Namely, the increase in Tf saturation (i.e. increase in holo–Tf concentration), 
but not apo–Tf provokes an increase in hepcidin excretion (Lin et al., 2007). 
Similarly to DMT1, TfR1 mRNA has an IRE on its 3’UTR, and thus is post-
transcriptionaly regulated by the IRE/IRP system (described in detail in Section 
1.4.1). Therefore in iron deficiency, IRE/IRP interactions stabilize TfR1 mRNA and 
support increased iron uptake and prevention of iron storage (Gkouvatsos et al., 
2012). Furthermore, during iron deficiency Tf synthesis is increased significantly in 
the liver (Idzerda et al., 1986). Also, levels of Tf are increased after hypoxia through 
Hif–1α (Rolfs et al., 1997).  
Additionally, besides TfR1 there is also TfR2, which differs in a couple aspects from 
the TfR1. While TfR1 is ubiquitously expressed, TfR2 expression is limited to 
hepatocytes and erythroid precursors. Unlike TfR1, TfR2 is not regulated by IRPs, as 
its mRNA does not contain IRE elements. Moreover, even though in transfected cells 
TfR2 binds holo–Tf, in vivo it does not rescue the embryo-lethality of Tfr1-/- mice, 
implying that TfR2 has a function that is distinct from TfR1 and unrelated to iron 
transport. Also, the affinity of TfR2 for holo–Tf is significantly lower than that of 
TfR1 (Fleming et al., 2000; West et al., 2000; Silvestri et al., 2014). Even though it 
seems that TfR2 does not have an important role in acquisition of iron, undoubtedly 
it has an essential role in regulation of iron homeostasis. Namely, TfR2 has an ability 
to bind HFE and this action represents a key sensor for circulating iron and activating 
hepcidin synthesis as a response to an elevated transferrin saturation (described in 
detail in Section 1.4.2). Contrary, TfR1–HFE interaction may serve to withdraw HFE 
away from participation in a hepcidin up-regulatory pathway, which is greatly 
different from TfR2–HFE interaction intention. 
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The importance of Tf in humans is evident with individuals with atransferrinaemia 
(described in detail in Section 1.4.4). Also, in humans mutation in the TfR2 gene 
lead to HH (described in detail in Section 1.4.4), while this is not a case with TfR1 
(Schmidt et al., 2008; Fleming, 2009). 
1.4 Regulation of iron homeostasis 
1.4.1 IRE/IRP system – cellular regulation of iron homeostasis 
The central role in the cellular regulation of the iron homeostasis is the post-
transcriptional IRE/IRP control machinery which is highly dependent on iron 
availability in the cell. More specifically, inside the cell iron metabolism is 
controlled by the binding of IRP1 or IRP2 to cis-regulatory mRNA sequences IREs. 
IRE/IRP interactions regulate the expression of the mRNAs which encode proteins 
important for iron acquisition (TfR1 and DMT1), storage (ferritin H and L subunit) 
and export (FPN). Additionally, this system controls expression of Hif–2α, which is 
also responsible for Dcytb, DMT1 and FPN expression (Muckenthaler et al., 2008). 
The presence of iron inside the cell is the key regulator of the IRE/IRP system. 
Namely, the IRE-binding activity of both IRP (IRP1 and IRP2) is increased when 
iron is low and decreased when iron is high. Additionally, the regulatory outcome 
depends on the position of the IRE on the mRNA sequence. Namely, if IRPs bound 
to IREs that are on the 3’UTR end of mRNA this will stimulate its translation by 
mRNA stabilization and prevention of its degradation by a ribonuclease (RNase). 
Contrary, if IRE is on the 5’UTR end of mRNA, binding of IRP will lead to 
inhibition of translation (see Figure 1–3). Specifically, when iron is limited, IRPs 
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bind to IREs which stabilize the mRNAs that have IREs on their 3’UTR (such as 
TfR1 and DMT1) and repress the translation of the mRNAs which have IREs on 
their 5’UTR (such as ferritin and FPN). Together, the sequence of these events leads 
to an increase of cellular iron uptake (i.e. absorption in duodenum, hepatocyte 
intake). In contrast, high iron levels diminish the stability of IRE-IRP complex, 
which supports translation of ferritin and FPN mRNAs, and blocks translation of 
TfR1 and DMT1 mRNAs, and eventually decreases intracellular iron levels 
(Leipuviene and Theil, 2007; Recalcati et al., 2010). 
  
 
Figure 1–3 Iron-dependent regulation of IRE/IRP system 
When iron levels are low, IRPs bind to IREs, and thus repress translation of 5’ IRE-
containing mRNAs (a) or support translation of 3’ IRE containing mRNAs (b). In 
contrast, when iron levels are high IRPs lose binding affinity to IREs, and increase 
the translation of 5’ IRE containing mRNAs (a) and the degradation of 3’ IRE-
containing mRNAs (b). 
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IREs are 26–30 nucleotide-long hairpin-forming sequences on the 3’ or 5’UTR of 
mRNA of proteins important for iron absorption. The loop sequence, which is highly 
conserved in all IREs, is presumably required for efficient IRP binding (Piccinelli 
and Samuelsson, 2007). 
IRP1 and IRP2 defer partially in their structure and mechanism of action, but have 
the same role in iron metabolism. IRP1 is a protein containing an iron-sulphur cluster 
unit, which besides its role in regulation of iron metabolism has cytosolic aconitase 
activity. In iron-deficient cells, IRP1 operates as a RNA-binding protein, but in iron-
replete cells the [4Fe–4S] cubane cluster is formed inside the IRP1, leading to 
destabilization of IRP1-IRE complex and expression of aconitase activity. During a 
change in iron levels, there is no change in IRP1 protein levels, just a change in its 
binding activity to IRE. However, IRP2 is produced de novo during iron deficiency, 
while it is rapidly degraded during high iron concentrations in the cells. IRP2 is 
highly homologous to IRP1, however IRP2 does not have a Fe–S cluster unit and 
does not display aconitase activity (see Figure 1–4). Both IRPs are present in all 
tissues, but IRP1 is mainly dominant in liver, spleen, kidney, heart, while in 
duodenum IRP1 and IRP2 are present in similar amounts (Iwai et al., 1998; Cairo 
and Pietrangelo, 2000; Volz, 2008). 
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Figure 1–4 Diferences in IRP1 and IRP2 
High iron levels favor the formation of the iron-sulphur cluster, which obstruct IRE 
binding and generate aconitase activity in IRP1, while it leads to IRP2 degradation. 
In contrast, low iron levels inhibit iron-sulphur cluster formation in IRP1 and support 
de novo synthesis of IRP2, thus facilitating IRP1 and IRP2 binding to IRE. 
There are known disorders in humans in which the molecular basis of the disease can 
be addressed to IRE/IRP system regulatory components. Namely, in the hereditary 
disease hyperferritinaemia cataract syndrome mutations in the IRE sequence of 
ferritin L-chain occur, while autosomal dominant iron overload is a consequence of a 
mutation in the apical loop sequence on the IRE sequence of ferritin H-chain (Girelli 
et al., 1995; Kato et al., 2001; Roetto et al., 2002). Also, it was shown that mice with 
no both types of the IRP gene die early during embryonic period, which indicates a 
significant function of the IRE/IRP system in development. Conversely, analysis of 
mice lacking either IRP1 or IRP2 reveals that the two IRPs can largely compensate 
the function of each other (Meyron–Holtz et al., 2004; Galy et al., 2005; Smith et al., 
2006; Galy et al., 2008). 
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1.4.2 Hepcidin – systemic regulation of iron homeostasis 
1.4.2.1 Discovery and structure of hepcidin 
Exactly thirteen years ago, two serendipitous discoveries occurred where two 
different groups of scientists isolated a new protein, one from blood (Krause et al., 
2000) and one from urine (Park et al., 2001). No one thought that the discovery of 
this new small protein would have a crucial role in iron metabolism and that it 
presented the start of a novel era in iron metabolism research. This new protein was 
named hepcidin. 
Hecidin is a 25-amino acid peptide hormone, containing four disulphide bridges, 
with weak antimicrobial activity and a highly conserved structure. It is primarily 
synthesized in hepatocytes as an 84-amino acid pre-pro-peptide which undergoes 
rapid intracellular processing into several smaller peptides, among which the 25 
residue protein with eight cysteine residues is the biologically active form of 
hepcidin (Hunter et al., 2002). 
1.4.2.2 Role of hepcidin 
Hepcidin is a main regulator of systemic iron homeostasis and its essential role in 
iron metabolism was confirmed in a number of in vivo studies. In 2001, the leading 
role of hepcidin in iron homeostasis was demonstrated by Nicolas et al. in hepcidin 
gene-knockout mice which developed severe iron overload with iron accumulation in 
liver, pancreas and heart. Furthermore, the same group demonstrated that mice over-
expressing hepcidin were born with severe iron-deficiency anaemia and died soon 
after birth (Nicolas et al., 2002). Apart from hepcidin’s role in systemic iron 
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regulation it was shown that hepcidin is in a close relationship with rate of the iron 
absorption in the duodenum. Namely, an experiment with adult rats that were 
switched from an iron-replete diet to an iron-deficient diet showed that hepcidin 
expression inversely correlates with the expression of duodenal iron transporters and 
iron absorption (Frazer et al., 2002). These findings were followed by numerous 
confirmations of the essential role of hepcidin in iron homeostasis in humans. 
Generally, the discovery of hepcidin and its role in iron homeostasis remarkably 
improved our understanding of the pathogenesis of the most common and often fatal 
iron disorders, such as HHs (described in detail in1.4.4). 
FPN, as it was described in detail in Section 1.3.1.4, is a transporter crucial for iron 
efflux from different cell types. Nowadays, it is confirmed that FPN is not only an 
iron exporter, but is also a receptor for hepcidin, which is particularly important 
during iron overload. As a result of hepcidin binding to FPN endocytosis of FPN 
occurs, leading to its proteolysis in lysosomes. This action makes hepcidin the main 
regulator of systemic iron homeostasis. Namely, hepcidin controls iron efflux from 
cells and keeps circulating iron at the proper level, preventing iron overload and 
production of toxic ROS (Nemeth et al., 2004b). By binding to FPN, hepcidin 
controls the main supply routes of iron into the circulation, such as: iron absorbed 
from diet in duodenal enterocytes, iron from macrophages liberated during recycling 
of senescent erythrocytes and iron which is stored in hepatocytes. In other words, 
when hepcidin concentrations are low, FPN is re-synthesized and re-expressed at the 
cell surface and iron enters into circulation at a high rate. When hepcidin 
concentrations are high, FPN is internalized and iron is trapped in enterocytes, 
macrophages and hepatocytes (Ganz, 2011). 
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1.4.2.3 Regulation of hepcidin expression 
The gene encoding hepcidin (HAMP) is strongly expressed in liver hepatocytes. 
However, there is slight, but not insignificant, production of hepcidin by other cell 
types, such as: macrophages, kidney, adipocytes and pancreatic -cells. To limit iron 
toxicity in periods of iron overload, hepcidin expression is physiologically induced to 
decrease circulating iron levels. Vice versa, during iron deficiency, erythropoesis and 
hypoxia, hepcidin expression is reduced to allow efficient iron mobilization 
(described in detail in Section 1.4.3). Interestingly, hepcidin production is induced 
during the inflammation process by what is believed to be related to its ability to 
lower the extracellular iron, a nutrient whose reduced availability can limit the 
proliferation of invading microorganisms (described in detail in Section 1.4.3; Viatte 
and Vaulont, 2009).  
Hepcidin mRNA does not contain an IRE, as other proteins important for iron 
homeostasis do. This indicates that hepcidin is regulated by iron and signaling 
pathways other than the IRE/IRP system. The only known routes of regulation of 
hepcidin expression are at the transcriptional level. On the basis of all the 
information on the regulation of hepcidin expression this model arises (see Figure 1–
5): (1) the membrane bone morphogenetic protein (BMP) receptor and its signaling 
components are the key regulatory machinery which control the transcription of 
hepcidin via the SMAD (mainly SMAD4) pathway in hepatocytes; (2) hemojuvelin 
(HJV) is an iron-specific adaptor ligand of the BMP receptor that boosts its 
sensitivity to BMPs; (3) neogenin binds to HJV also enhancing BMP signaling; (4) 
iron levels in the liver are sensed by BMP6, an activating ligand of the BMP 
receptor, that increases in hepatic iron overload (5) extracellular iron concentration is 
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sensed through the interaction of holo–Tf with TfR1 and TfR2, in coordination with 
HFE as a mediator of the holo–Tf uptake by TfRs; (6) TfR2 and HFE interaction 
increase the sensitivity of the BMP receptor to its ligands in a holo-Tf-dependent 
manner, perhaps by interactions with HJV; (7) transmembrane protease, serine 6 
(TMPRSS6) seems to be stabilized by iron deficiency, leading to cleavage and 
inactivation of HJV and thus inhibits further hepcidin expression (Ganz, 2011; 
Pietrangelo, 2011; Ganz and Nemeth, 2012). 
When research on hepcidin’s role in humans started to emerge, it was firstly 
discovered that patients with juvenile haemochromatosis (JHH) had negative 
hepcidin mutations generating severe iron overload (Roetto et al., 2003). Namely, 
JHH is one of several types of HH, where mutation of HJV is the major cause 
(Gkouvatsos et al., 2014). Moreover, deficiency in hepcidin is the fundamental issue 
in every HH, which confirms the essential role of hepcidin as a negative regulator of 
iron absorption and iron efflux in humans (described in detail in Section 1.4.4). 
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Figure 1–5 Regulation of hepcidin transcription by iron 
The BMP receptor and its signaling components are the key regulatory machinery 
which controls the transcription of hepcidin via the SMAD pathway in hepatocytes. 
Iron levels in the liver are sensed by BMP6, an activating ligand of the BMP 
receptor, that increases during hepatic iron overload while extracellular iron 
concentration is sensed through the interaction of holo–Tf with TfR1 and TfR2, in 
coordination with HFE as a mediator of the holo–Tf uptake by TfRs. TfR2 and HFE 
interaction increase the sensitivity of the BMP receptor to its ligands in a holo-Tf-
dependent manner, perhaps by interactions with HJV. HJV is an iron-specific adaptor 
ligand of the BMP receptor, while neogenin binds to HJV, both boosting its 
sensitivity to BMPs during iron overload. TMPRSS6 seems to be stabilized by iron 
deficiency, leading to cleavage and inactivation of HJV and thus inhibits further 
hepcidin expression. 
1.4.3 Erythropoiesis, hypoxia, inflammation and oxidative stress – 
additional regulation mechanisms of iron homeostasis 
Increased production of erythrocytes in bone marrow, in order to improve the O2-
carrying capacity of the circulation, presents a major adaptation pathway to anaemia 
and hypoxia. In order to support erythrocyte production during anaemia or hypoxia, 
up-regulation of protein erythropoietin (Epo) by kidneys and liver occurs. This event 
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decreases hepcidin levels which results in an increase absorption of dietary iron and 
mobilization of iron from macrophages and hepatocytes to maintain erythropoiesis, 
autonomously of iron stores. Even though it was proven in vitro and in vivo that Epo 
inhibits hepcidin production, the exact mechanism of action is still not fully 
understood (Pinto et al., 2008; Huang et al., 2009). 
During hypoxia, O2-regulated transcription factors Hif–1 and Hif–2 are elevated in 
order to induce erythropoiesis by activation of renal and hepatic Epo synthesis. Hif–1 
and Hif–2 comprise O2-sensitive α subunits (Hif–1α and Hif–2α) and a constitutively 
expressed β subunit (Hif–β). While O2 levels are normal (normoxia), a regulatory α 
subunit is modified by iron-dependent prolyl hydroxylases (PHDs) and degraded 
through the ubiquitin/proteasome pathway. Under hypoxia, PHD activity is inhibited 
and the α subunit is translocated into the nucleus, where it binds to the β subunit. The 
heterodimeric Hif binds to the hypoxia-response elements (HREs), the regulatory 
sequence of the target gene, supporting the transcription of corresponding genes. Epo 
is one of these target genes, while in vivo studies showed that Hif–2 is the main 
regulator of Epo. Interestingly, it was proven in vivo that HAMP suppression by the 
Hif pathway occurs indirectly via stimulation of Epo-induced erythropoiesis. 
However, even though HAMP promoter contains several HREs, Hifs binding to them 
remains controversial (Peyssonnaux et al., 2007; Liu et al., 2012a). Additionally, 
hypoxia controls expression of genes important for iron absorption in the duodenum 
through Hif–2α, such as Dcytb, DMT1 and FPN (Mastrogiannaki et al., 2009; Shah 
et al., 2009). Also, levels of Tf are increased after hypoxia through Hif–1α (Rolfs et 
al., 1997). Interestingly, expression of Hif–2α is control by IRE/IRP machinery. This 
provides evidence that different ways of iron homeostasis control are mutually 
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dependent, include many factors and make complex network of machinery for fine 
tuning of iron levels in organism. 
During infection and inflammation, hepcidin levels are increased as a host defence 
mechanism in order to reduce iron levels and make it non-available to invading 
microorganisms. Thus, inflammation has a great influence on iron homeostasis and 
by up-regulation of hepcidin cause down-regulation of intestinal iron absorption, iron 
export from macrophages and hepatocytes and thereby decreased serum iron levels. 
It was proven in vivo that IL–6 has a stimulatory effect on hepcidin transcription. 
Specifically, in urine of human volunteers levels of hepcidin increased 7-fold after 
infusion with recombinant human IL–6 which was followed with a significant 
decrease in serum iron and transferrin saturation (Nemeth et al., 2004a). 
Additionally, IL–6 knock-out mice failed to produce surplus hepcidin mRNA in 
response to induced inflammation, indicating that IL–6 is necessary for hepcidin 
induction and hypoferremia during inflammation in mice (Nemeth et al., 2004a). In a 
separate study, after individuals were injected with LPS, IL–6 was significantly up-
regulated within 3 hours after injection, which was followed by an urinary hepcidin 
increase which peaked within 6 hours and a large decrease in serum iron (Kemna et 
al., 2005). This study confirmed the previous statement and highlighted the 
importance of general inflammation in iron homeostasis. It is speculated that 
cytokines other then IL–6 may also contribute to the up-regulation of hepcidin during 
inflammation. However, this effect was not proven in vivo up to now (Armitage et 
al., 2011; Nairz et al., 2014). 
Oxidative stress presents a disturbance in the equilibrium between the presence of 
ROS and antioxidant defence mechanisms, in favour of ROS, leading to damage of 
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cell components and provoking pathogenesis of numerous disorders. However, 
oxidative stress induces a battery of genes encoding antioxidant and detoxifying 
enzymes. Nrf2 is a transcription factor which binds to ARE in response to oxidative 
stress, initiating the synthesis of enzymes that will “fight“ against elevated levels of 
reactive species. The mechanism by which the binding of Nrf2 to ARE is induced is 
still not fully understood. Though, it is known that when oxidative stress is not 
present Nrf2 forms an inactive complex with kelch-like ECH-associated protein 1 
(Keap1) in the cytoplasm. This interaction supports Nrf2 ubiquitination and 
degradation. In contrast, when increased levels of intracellular ROS occur, 
destabilization of the Keap1-Nrf2 interaction takes place, allowing Nrf2 to dissociate 
from Keap–1 and translocate to the nucleus. In the nucleus, Nrf2 will join to an 
additional transcriptional factor Maf in order to form a complex that binds to ARE on 
DNA. This will up-regulate transcription of numerous antioxidative and 
cytoprotective proteins which have ARE region, such as: HO–1, superoxide 
dismutase 1, quinone reductase (QR), catalase, sulfiredoxin, thioredoxin, 
peroxiredoxins, glutathione peroxidase, glutathione reductase, glutathione S–
transferase (GST) and γ–glutamine cysteine ligase (Halliwell and Gutteridge, 2007; 
Johnson et al., 2008; Klaassen and Reisman, 2010; Gan and Johnson, 2014). 
Oxidative stress is strongly associated with high levels of free iron in the cell. With 
this in mind, it is no surprise that in periods of oxidative stress actions that maintain 
iron export out of the cell and storage are supported. Thus, in order to avoid 
additional oxidative stress in the cell, levels of FPN and ferritin H- and L-chain are 
up-regulated by the Nrf2 pathway. Interestingly, haem acts like a stabilizer of the 
Nrf2-Maf complex and thus supports its binding to ARE. By bringing together 
knowledge about haem and its proven role in the Nrf2 pathway, it can be concluded 
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that phagocytosis of erythrocytes by reticulo-endothelial macrophages and release of 
haem up regulates: HO–1 to activate haem degradation, ferritin H- and L-chain to 
accumulate iron released from the haem and FPN to export iron out of the cell for 
further transport via circulation (Marro et al., 2010). 
1.4.4 Disorders of iron metabolism of different etiology 
In this chapter iron metabolism disorders, such as: HH, iron-refractory iron 
deficiency anaemia (IRIDA), atransferrinaemia, -thalassaemia, iron deficiency 
anaemia (IDA), anaemia of inflammation (AI) or anaemia of chronic disease (ACD), 
are described. Additionally, a description of how these disorders are treated is also 
included. 
HHs mainly belongs to disorders of hepcidin and ferroportin functions, and are 
characterized as a group of genetic disorders described by excessive absorption of 
dietary iron and its accumulation in the liver and other organs. The prime 
consequence is liver injury leading to cirrhosis and hepatocellular carcinoma. In 
addition, iron toxicity can also damage other organs. Early diagnosis and use of 
recommended therapy to maintain normal body iron stores is crucial and can prevent 
all known complications of HHs. If untreated, HHs may lead to death from cirrhosis, 
diabetes, malignant hepatoma or cardiac disease (Niederau et al., 1994). Deficiency 
of hepcidin is the fundamental issue in every HH (see Figure 1–6). In humans, there 
are several types of HH: HFE-associated, TfR2-associated, HJV-associated, FPN-
associated and HAMP-associated, as a consequence of mutation of genes for HFE, 
TfR2, HJV, FPN and hepcidin, respectively. The most severe types of HH are 
associated with HAMP and HJV. Loss of TfR2 or HFE causes an intermediate level 
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of hepcidin deficiency, while loss of FPN results in hepcidin-resistance type of HH 
(Pietrangelo, 2010).  
 
Figure 1–6 Iron absorption during some iron metabolism disorders connected 
with hepcidin 
During high and long-lasting levels of hepcidin expression in liver, caused by 
inflammatory stimuli, internalization and degradation of FPN in enterocyte occurs 
leading to impaired iron absorption through the enterocyte, intracellular iron 
accumulation and low plasma iron levels (A). While iron metabolism is in balance, 
hepcidin levels are normal and in accordance with iron demands (B). HH is a 
consequence of impaired hepcidin expression, causing increased iron import from the 
diet and overload of iron in plasma (C). 
Human iron disorder caused by mutations in the gene encoding the TMPRSS6 
enzyme is known as IRIDA. IRIDA is characterized by low iron and transferrin 
saturation and inappropriate elevation of hepcidin levels in serum. 
Atransferrinaemia, hereditary deficiency of Tf, is a rare autosomal recessive disorder 
as a consequence of Tf gene mutations. Without Tf and impaired supply of iron to 
the bone marrow, individuals develop severe, microcytic, hypochromic, iron-
deficiency anaemia. These individuals need erythrocyte transfusions from birth in 
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order to survive. This state leads to increased intestinal iron absorption. However, 
absorbed iron is transported inadequately in the plasma because non-Tf bound iron 
cannot be imported by erythroid precursors. Consequently, iron is taken up by other 
organs, which leads to a paradoxical iron overload of non-erythropoietic tissues. This 
disorder also leads to low hepcidin levels (Beutler et al., 2000; Heeney and Andrews, 
2004) 
-thalassaemia, a type of iron-loading anaemia, is a secondary disorder of hepcidin 
function in which mutation of the gene for -globin, the subunit which together with 
α-globin makes up haemoglobin, occurs. Therefore, synthesis of haemoglobin is 
impaired, facilitating ineffective erythropoiesis which is stimulated by constant high 
levels of Epo, leading to low levels of hepcidin. Thus, both significant iron overload, 
with hyper-absorption of dietary iron despite high serum transferrin, and anaemia, 
due to impairment in erythrocyte synthesis, occur. A transfusion is effective 
treatment for these patients because it increases hepcidin due to lowering of Epo 
concentrations and provides normal erythropoiesis, at least for a while (Origa et al., 
2007; Ganz, 2011). 
Standard therapies for iron overload disorders are phlebotomy and use of chelation 
therapy. During phlebotomy, around 500 mL of blood is removed once or twice 
weekly from patients until levels of ferritin falls under 20 mg/mL. This leads to 
anaemia, which induces iron mobilization from iron stores. Once the patient has 
reached a satisfactory iron levels, phlebotomy is performed several times per year 
over the lifetime (Adams and Barton, 2010; Yehuda and Mostofsky, 2010). 
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When phlebotomy is not an adequate way for iron overload treatment, chelation 
therapy is often used to remove excess iron stores. Additionally, it is considered by 
many that phlebotomy is an obsolete technique and that chelation therapy is the gold 
standard for treating iron overload of different etiologies. The aim of chelation 
therapy is to scavenge free iron from circulation and tissues by forming complexes 
which are excreted in the faeces and/or urine. Several iron chelator drugs have been 
developed, such as deferoxamine (DFO), deferiprone (DFP) and deferasirox (DFX), 
which are administrated orally or subcutaneously. DFO, DFP and DFX bind iron at a 
different molar ratio chelator : iron, 1:1, 3:1 and 2:1, respectively (see Figure 1–7). 
Today, research in the hope of finding new iron chelator drugs which could chelate 
iron from tissues more effectively is evolving (Poggiali et al., 2012). Interestingly, it 
has been confirmed that iron is a crucial element for tumour proliferation, thus the 
potential role of iron chelation therapy in the treatment of cancer should be 
considered in the near future (Hann et al., 1988; Zacharski et al., 2008). 
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Figure 1–7 Complexes of chelation therapy drugs with iron 
Contrary to iron overload disorders, there are iron deficiency disorders, generally 
known as anaemias. Commonly, anaemia is a condition in which there are not 
enough healthy erythrocytes in the circulation which leads to inadequate oxygen 
distribution and consequently disturbance in the maintenance of normal 
physiological function of tissues, such as liver, brain, muscles, etc. (World Health 
Organisation, 2007). 
There are many types of anaemia and these can arise as a result of a wide variety of 
causes that can be single, but more often coexist. Globally, the most significant 
contributor to the anaemia is iron deficiency, known as IDA. The main causes for 
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IDA are low dietary iron intake, poor absorption of iron from diet at a period of life 
when iron requirements are particularly high (described in detail in Section 1.4.5). 
Other recognized causes of anaemia, such as heavy blood loss or extensive 
menstruation are also recognized (World Health Organisation, 2008). 
Additionally, anaemia and hypoferraemia that occurs as consequence of chronic 
infections and inflammatory disorders is known as AI or ACD. AI is a systemic iron 
disorder characterized with decreased iron, iron binding capacity and intestinal iron 
absorption, as well as impaired erythropoiesis, while iron is trapped in macrophages 
and liver, indicating impaired mobilization of iron from stores. AI is a consequence 
of cytokine (mainly IL–6) mediated induction of hepcidin production as a response 
to chronic inflammation (see Figure 1–6; Franchini et al., 2010; Yehuda and 
Mostofsky, 2010). 
To be more precise, anaemia is a consequence of both poor nutrition and poor health. 
Increased risk of maternal and child mortality is one of the main concerns of severe 
anaemia. Additionally, the negative consequences of IDA on cognitive and physical 
development of infants and on general performance, particularly work productivity in 
adults, are also great concern. To be more precise, iron deficiency is the most 
common and widespread nutritional disorder in the world. The World Health 
Organization declares iron deficiency as one of the 10 leading risk factors for 
disease, disability and death in the world today. Iron deficiency affects mostly 
children and women in practically all countries. It can be estimated that most 
preschool children in non-developed countries and at least 30–40% in developed 
countries are iron-deficient, and nearly half of the pregnant women in the world are 
estimated to be anaemic (World Health Organisation, 2001; World Health 
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Organization, 2002; World Health Organisation, 2007; World Health Organisation, 
2008). 
Details on how diet habits affect iron deficiency, as well as routes how iron 
deficiency can be overcome are described in detail in Sections 1.4.5 and 1.6. 
1.4.5 Bioavailability of iron 
Mechanisms of keeping iron metabolism in homeostasis greatly differ from those of 
other metals. Namely, there is no known physiologic mechanism for iron excretion 
and thus 90% of daily needs for iron are obtained from an endogenous source, such 
as the breakdown of old or damaged erythrocytes by reticulo-endothelial 
macrophages. Unavoidably, there are regular daily iron losses, such as shedding of 
skin cells, sweating, miscellaneous bleeding in intestine, menstrual bleeding, etc. 
Thus, to keep iron in balance, it is essentially that iron is supplied by diet, especially 
during growth of infants, children and adolescents and the reproductive period in 
women, particularly during pregnancy (Hurrell and Egli, 2010; Abbaspour et al., 
2014). In  
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Table 1–1 it can be clearly seen that daily requirements of absorbed iron differ 
greatly between individuals of different age, sex and state.  
51 
Table 1–1 Daily requirements of absorbed iron in individuals of different age, 
sex and state 
age/state 
absorbed iron in duodenum
a
 
(mg/day) 
4–12 months 0.96 
13–24 months 0.61 
2–5 years 0.70 
6–11 years 1.17 
12–16 years (girls) 2.02 
12–16 years (boys) 1.82 
adult males 1.14 
women during lactation 1.31 
women during menstruating period 2.38 
women during postmenopausal period 0.96 
pregnant women 
requirement during pregnancy greatly 
depends on the woman’s iron status 
before pregnancy, these values are 
given as average 
1
st
 trimester of pregnancy 0.8 
2
nd
 & 3
rd
 trimester of pregnancy 6.3 
acalculations were done on basis on average weight (DeMaeyer et al., 1989; Abbaspour et al., 
2014) 
As mentioned previously, dietary iron occurs in two forms: haem and non-haem. 
Haem iron makes 10–15% of total iron from diet in meat-eating populations, but, it is 
estimated to contribute ≥40% of total absorbed iron. However, non-haem iron 
absorption is much lower, and it varies between 2%–20%. In contrast to non-haem 
iron whose bioavailability is highly dependent on the presence of iron absorption 
promoters or inhibitors in the diet, dietary factors have little effect on haem iron 
absorption (Hurrell and Egli, 2010). 
The low bioavailability of non-haem iron contributes greatly to IDA, which is the 
most prevalent nutritional deficiency worldwide, estimated to affect two billion 
people especially in low-income populations where consumption of meat is low 
(World Health Organisation, 2007). On the other hand, low bioavailability of non-
haem iron is a problem in population groups eating only a plant-based diet, 
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vegetarians and vegans, whose popularity is rising in modern societies. In order to 
compensate for lost iron and keep iron homeostasis in balance, it is of utmost 
importance that absorption of iron is sufficient. Thus, it is essential to understand in 
detail the mechanism of iron absorption in the duodenum as well as to target its 
promoters or inhibitors. Additionally, for individuals affected with iron deficiency it 
is important to know what food is rich in highly bioavailable iron and try to consume 
it as much as possible. In Table 1–2 it can be seen what are the average levels of total 
iron in common foods. 
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Table 1–2 Amount of total iron in common foods 
food total iron g/g 
sources of non-haem iron 
spinach 260 
tea 250 
salad rocket 154 
parsley 90 
lettuce 65 
red cabbage 61 
tomato 36 
red bean 35 
red pepper 31 
cucumber 29 
broccoli 29 
garlic 28 
banana 27 
cauliflower 25 
corn flour 25 
onion 23 
Nescafe 22 
wheat 20 
strawberry 19 
potato 15 
carrot 15 
apple 15 
eggplant 14 
flour 12 
kiwi 6 
peach juice 1.53 mg/L 
orange juice 0.68 mg/L 
sources of haem iron 
ostrich fillet 24 
lamb chop 22 
beef topside 19 
pork loin 4 
chicken breast 4 
(Lombardi–Boccia et al., 2002; Tokalıoğlu and Gürbüz, 2010) 
 
However there are recognized inhibitors of iron absorption whose occurrence in food 
should be addressed in iron-deficient individuals. Major inhibitors of iron absorption 
from the diet are phytate, polyphenols, calcium and proteins. 
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Phytate (inositol hexakisphosphate; see Figure 1–8) is a primary phosphorous storage 
molecule in plants and cannot be digested by humans. 
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Figure 1–8 Structure of phytate 
It is believed that phytate forms a complex with iron through its phosphate ester 
groups making it nonabsorbable and it is considered as the main inhibitor of non-
haem iron absorption. The inhibitory effect of phytate has been proven, but particular 
food preparation methods, such as milling, heat treatment, soaking, germination, 
fermentation, addition of ascorbic acid or enzyme phytase, can remove or degrade 
phytate and thus partially or totally eliminate its negative effect on non-haem iron 
absorption (Siegenberg et al., 1991; Hurrell et al., 2003; Hurrell, 2004; Hurrell and 
Egli, 2010). However, low concentrations of phytate (2–10 mg/meal) express a 
negative effect on non-haem iron absorption. Considering that some foods contain 
phytate in considerable concentrations (see Table 1–3), even much more than 
common food containing non-haem iron (see Table 1–2), consumption of phytate-
rich plants should be under attention. 
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Table 1–3 Phytate content in selected foods 
food phytate mg/g 
walnut 40 
pistachio nuts 28 
hazelnut 23 
wheat cereal 11 
wheat bread 3 
(Harland et al., 2004) 
Polyphenols are group of natural products greatly distributed in food of plant origin 
(described in detail in Section 1.5). It has been proven by numerous studies that 
polyhenols significantly inhibit iron absorption. The connection between polyphenols 
and iron metabolism is described in detail in1.6. 
Calcium has been shown to have an inhibitory effect on both non-haem and haem 
iron absorption. The mechanism of the inhibitory effect of calcium on iron 
absorption is not known, but it is speculated that it could block initial iron uptake by 
the enterocyte (Hallberg et al., 1992). Inhibition of iron absorption has been 
demonstrated even with a calcium concentration that is common in the daily dietary 
intake. This fact could represent a general health problem because widespread and 
recommended use of calcium supplements, manly for the prevention of osteoporosis, 
can bring about problem with iron absorption (Roughead et al., 2005; Hurrell and 
Egli, 2010). 
Particular proteins are also proven to have an inhibitory effect on iron absorption 
such as: milk, soybean and egg proteins, albumin, casein and whey (Cook and 
Monsen, 1976; Hurrell et al., 1988; Hurrell et al., 1989; Lynch et al., 1994). 
On the other hand, the main dietary enhancers of iron absorption are ascorbic acid 
and muscle tissue. It is proven that ascorbic acid improves non-haem iron absorption, 
mainly due to its ability to reduce Fe
3+
 to Fe
2+
 and thus make it available for 
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transport by DMT1. The amount of ascorbic acid that expresses a positive effect on 
non-haem iron absorption is approximately 30–100 mg daily, which corresponds to 
the recommended dietary intake for ascorbic acid. However, in foods of plant origin, 
such as, fruits and vegetables, the supporting effect of ascorbic acid might be reduced 
by the inhibiting effect of polyphenols and phytate (Gillooly et al., 1983; Ballot et 
al., 1987; Hallberg et al., 1989; Siegenberg et al., 1991; Carr and Frei, 1999; Teucher 
et al., 2004). In contrast to the positive effect of ascorbic acid on non-haem iron 
absorption after a single meal, improvement in iron status after chronic 
supplementation with ascorbic acid was not observed in humans. The reason for this 
occurrence is not yet fully understood (Cook and Reddy, 2001).  
Muscle tissue, known as “meat factor“, also showed a positive effect on non-haem 
iron absorption, the same as ascorbic acid, but it was hard to demonstrate the same 
activity after a longer consumption. There is evidence that this could be attributed to: 
cysteine-containing peptides, glycosaminoglycans and L–α–glycerophosphocholine 
and their ability to reduce and chelate iron (Hurrell et al., 2006; Storcksdieck 
Bonsmann and Hurrell 2007; Armah et al., 2008).  
Nowadays three approaches are recognized as ways to deal with IDA and they can be 
practices alone or in combination with each other: change in dietary habits by means 
of diversity and modification of the diet in order to improve nutritional value and 
iron bioavailability, supplementation (intake of iron in higher doses not with food), 
and fortification (the addition of iron into food during food processing). A change of 
dietary habits so that intake of food rich in both haem and non-haem iron, as well as 
promoters of iron absorption, is increased, while intake of inhibitors of iron uptake 
should be decreased. Even though it showed significant practical limitations, a 
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change of dietary habits is the favoured way of treating IDA. Apart from fact that it 
is hard to change individuals’ dietary preference, food rich in highly bioavailable 
iron, such as meat, is expensive especially in developing countries.  
Supplementation is an efficient and cost-effective way of treating IDA over short 
periods of time, such as pregnancy. However, insufficient coverage of all parts of the 
world and compliance is a major limitation to the effectiveness of iron 
supplementation programs (Yip and Ramakrishnan, 2002). Iron supplementation is 
carried out orally or, very rarely by injection. Frequently used forms of iron in 
supplements include Fe
2+
 and Fe
3+
 salts, such as SO4
2-
, gluconate, fumarate and 
citrate. High doses of supplemental iron may cause gastrointestinal side effects, such 
as nausea and constipation. Other forms of supplemental iron, such as haem iron, 
carbonyl iron, iron amino-acid chelates and polysaccharide-iron complexes, are also 
available and are believed to manifest fewer gastrointestinal side effects compared 
with salts (World Health Organization, 2001; Lynch, 2005). 
Iron fortification of food is considered as the most cost-effective route for lowering 
incidence of IDA all over the world. Generally, iron fortification refers to the 
addition of iron to foods consumed by all or most of the population and it is 
regulated by the government. Milled cereals are frequently the subject of iron 
fortification and showed a successful outcome in making populations less iron-
deficient. Also, it was estimated that iron fortification is economically more 
favourable than iron supplementation (Baltussen et al., 2004; Lynch, 2005). 
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1.5 Plant phenols 
Phenols are plant secondary metabolites that include a great number of structurally 
diverse compounds. Chemically speaking, phenols are compounds which contain one 
(phenol) or more (polyphenols) aromatic rings, bearing one or more hydroxyl groups, 
which can be esterified, etherified or glycosylated. Generally, phenols and 
polyphenols represent all secondary metabolites whose syntheses go through the 
shikimate/phenylpropanoid or the “polyketide“ acetate/malonate pathway, or by 
combination of two of them, producing monomeric or polymeric phenols. 
Additionally, phenols are uncommon in bacteria, fungi and algae but are ubiquitously 
present in the plant kingdom. The phenolic profile of an individual plant strongly 
depends on plant species and thus can be used as a reliable taxonomic marker 
(Cheynier et al., 2013). 
Throughout evolution, plants have developed adaptive mechanisms which are 
reflected in their ability to produce a great number of phenolic secondary 
metabolites. Though, phenols are not compulsory in the processes such as plant 
growth and development, they have pivotal role for plants’ interactions with the 
environment, reproduction and defence. From an evolutionary point of view it is easy 
to see why plants produce such a great collection of secondary compounds compared 
with animals. Namely, they cannot rely on physical mobility to escape predators or 
perform successful pollination. Thus, they had to developed exuberant chemical 
systems in order to survive. Plants need phenols for protection against herbivores, 
microbes, viruses or other plants, as signal compounds to attract pollinating or seed 
dispersing animals, protection from ultraviolet radiation or oxidants and fluctuation 
of organic and inorganic nutrients from soil. Phenols are generally soluble in polar 
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organic solvents, unless being entirely esterified, etherified or glycosylated. Also, 
most phenol glycosides are water-soluble but the corresponding aglycones are 
usually less so. Due to the presence of an aromatic ring, all phenols demonstrate 
intense absorption in the ultraviolet part of the spectrum. Furthermore, phenols that 
give colour to plants absorb light in the visible region as well. 
On the basis of the phenol skeleton, several classes of phenols have been 
categorized: C6 (phenols, benzoquinones), C6–C1 (phenolic acids), C6–C2 
(acetophenones, phenylacetic acids), C6–C3 (hydroxycinnamic acids, coumarins, 
phenylpropanes, chromones), C6–C4 (naphthoquinones), C6–C1–C6 (xanthones), C6–
C2–C6 (stilbenes, anthraquinones), C6–C3–C6 (flavonoids, isoflavonoids), (C6–C3)2 
(lignans, neolignans), (C6–C3–C6)2 (biflavonoids), (C6–C3)n (lignins), (C6)n (catechol 
melanins) and (C6–C3–C6)n (condensed tannins) (Robards, 2003; Lattanzio et al., 
2006; Cheynier et al., 2013). 
1.5.1 Flavonoids 
Flavonoids are one of the largest groups of plant phenols and, by now, more than 
8000 structures of flavonoids have been identified. These secondary metabolites are 
widely distributed in plants and are classified in a number of subgroups, of which 
one representative of flavones, flavonols, isoflavones, flavanones, flavanonols, 
flavanols, anthocyanins, chalcones and aurones subgroup is presented in Figure 1–9. 
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Figure 1–9 Structure of some classes of flavonoids 
As with other phenols, flavonoids also have numerous functions in plants, such as: 
protection against ultraviolet radiation and phytopathogens, a protective response 
during stress, signaling during development and growth, auxin transport and 
coloration of flowers for attraction of insects during pollination (Bradshaw and 
Schemske, 2003; Falcone Ferreyra et al., 2012). 
Apart of being valuable for the plant kingdom, flavonoids are also beneficial to 
human health. Namely, flavonoids have played a key role in the successful 
traditional medical treatments of ancient times and their use has continued up to the 
present day. In addition to being highly bioactive, they express low toxicity, which 
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makes their medicinal use very attractive. Flavonoids express many positive 
therapeutical properties which have been experimentally confirmed. For medicine, 
the most valuable property of flavonoids is their ability to effectively scavenge 
highly toxic free radicals. Free radical species occur in the course of numerous 
physiological processes and can initiate damage of nucleic acid, lipid and protein 
structures, resulting in disturbance of vital cellular functions and causing a wide 
range of disorders. Thus, today it is almost impossible to separate free radical 
reactions from almost any disorder. Apart from keeping biomolecules safe from free 
radical attack, flavonoids take part in many biochemical processes in an organism, 
such as: regulation of expression of cell cycle regulatory proteins, inhibition of signal 
transduction pathways or enzyme activity. As a consequence, flavonoids express 
many beneficial health actions, such as: lowering blood pressure and risk of 
cardiovascular disorders, decreasing the incidence of carcinogenesis and 
neurodegeneration, inhibiting platelet aggregation and the inflammatory response, as 
well as lowering levels of bad LDL cholesterol (Sharma, 2014).  
To give answer to question as to why flavonoids express numerous physiological 
properties is not easy, but the most probable answer lies in the fact that they are 
highly reactive and can enter into almost any type of reaction known to organic 
chemistry. Namely, they can take part in oxidation-reduction, acid-base and free-
radical reactions and hydrophobic interactions, while their substituents can modify 
electronic induction, resonance and steric hindrance. Additional, flavonoids make 
stable complexes with metal ions, such as iron, and thus express their antioxidative 
property, which is all together of particular interest for this thesis (described in detail 
in Section 1.6). 
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All flavonoids share a common origin – the amino acid phenylalanine. Initially, 
phenylalanine is synthesized in the shikimate pathway, while its further processing 
goes through the phenylpropanoid pathway until a certain flavonoid structure is 
formed (see Figure 1–10; Cheynier et al., 2013). As one of the main aims of this 
thesis is to elucidate the effect of the flavonoid quercetin on iron homeostasis, the 
biosynthesis of flavonoids in plants will be described with quercetin as an example. 
Biosynthesis of other flavonoids follows a similar route, but due to page limitations 
other routes will not be described. For the same reason, the following headings will 
be mainly concentrated on quercetin. 
Synthesis of quercetin (see Figure 1–10) starts with the shikimate pathway and its 
initial reaction of aldol condensation of phosphoenolpyruvate (PEP; glycolytic 
intermediate) and erythrose–4–phosphate (pentose phosphate pathway intermediate) 
to give a C7 sugar, 2–dehydro–3–deoxyarabinoheptulosonate–7–phosphate (DAHP), 
which will convert to shikimate. Shikimate will after phosphorylation and reaction 
with PEP give chorismate. Chorismate will transform to phenylalanine giving the 
basic phenylpropanoid skeleton. Phenylpropanoid metabolism is controlled by the 
enzyme phenylalanine ammonia–lyase (PAL), which catalyzes a non-oxidative 
deamination of phenylalanine to cinnamic acid. Hydroxylation of cinnamic acid will 
give 4–coumaric acid whose carboxyl group will be activated in a reaction with 
CoA–SH, giving 4–coumaroyl–CoA. 4–coumaroyl–CoA combines with three 
molecules of malonyl–CoA (an intermediate in fatty acid biosynthesis) forming the 
flavonoid skeleton naringenin chalcone by the enzyme chalcone synthase. 
Afterwards, enzyme chalcone isomerase catalyzes the cyclization of chalcone to the 
flavanone naringenin, a basic structure for further synthesis of all classes of 
flavonoids. Quercetin is formed after hydroxylation and oxidation of naringenin. 
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Furthermore, quercetin is glycosylated with different sugars to make glycosides, the 
main forms of quercetin in plants (Cheynier et al., 2013; Sharma, 2014). 
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Figure 1–10 Synthesis of quercetin 
1.5.2 Absorption and metabolism of flavonoids in humans 
Absorption and metabolism of flavonoids will be explained with quercetin as an 
example due to limited space and the specific aim of this thesis. However, other 
flavonoids follow the same or similar mechanism of absorption and metabolism 
described for quercetin. 
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Quercetin, the most abundant flavonol in plant diet, is mainly present in plants in its 
highly hydrophilic glycosylated forms, mainly as -glycosides of various sugars. The 
dominant types of quercetin glycosides differ in plants. However, the main forms 
present in plants are quercetin–3–O–rutinoside (rutin), quercetin–3–O–galactoside 
(hyperoside), quercetin–3–O–glucoside (isoquercitrin), quercetin–3–O–rhamnoside 
(quercitrin) and quercetin–4’–O–glucoside (spiraeoside; Lee and Mitchell, 2012). 
Prior to absorption in the gut, flavonoids first need to be freed from plant tissue by 
chewing in the oral cavity and then processed by digestive juices in the intestine or 
by microorganisms in the colon. Generally, there are two main routes of quercetin 
glycoside absorption by the enterocyte. Firstly, absorption goes via a transporter 
followed by deglycosylation within the enterocyte by cytosolic glycosidase. 
Secondly, deglycosylation can occur firstly by luminal hydrolases followed by 
transport of the aglycone by passive diffusion or via different transporters. It is 
demonstrated that quercetin glucosides can be taken up by the enterocyte through the 
sodium-dependent glucose transporter (SGLT1) with subsequent deglycosylation 
inside the enterocyte by cytosolic –glycosidase. Also, quercetin glucosides can 
firstly undergo luminal hydrolysis by lactase phlorizin hydrolase (LPH) and 
afterwards are absorbed inside the enterocyte by passive diffusion or a transporter-
mediated mechanism (Walle et al., 2000; Wolffram et al., 2002; Day et al., 2003; 
Ziberna et al., 2014). Specifically, quercetin can use glucose transporter (GLUT)–1, 
–3 and –4 to enter cells and thus operate as an inhibitor of glucose transport (Strobel 
et al., 2005). The nature of the sugar moiety greatly influences the route and rate of 
quercetin absorption in the gut. Namely, it is suggested that 3–O–glucosylation of 
quercetin improves its absorption in the small intestine, even compared with 
absorption rate of quercetin alone. On the other hand, quercetin glucosides 
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containing rhamnose (rutin) could not be absorbed in the small intestine, and are 
believed to be absorbed in the colon after deglycosylation (Hollman et al., 1999; 
Morand et al., 2000; Day et al., 2003). 
Definition of bioavailability states that bioavailability is the portion of an initially 
administered dose of drug that reaches the systemic circulation unchanged. 
Considering that, flavonoid bioavailability is very low mostly due to extensive 
metabolism at the intestinal level. Namely, further biotransformation of quercetin 
aglycone involves glucuronidation, sulfonation and methylation of hydroxyl groups, 
which primarily occur in enterocytes and hepatocytes. Specifically, the major 
quercetin metabolites detected in plasma are quercetin–3’–sulphate and quercetin–3–
glucuronide. It is assumed that they are produced in the small intestine, pass into the 
portal vein and are further converted into other metabolites in the liver, such as 
isorhamnetin–3–glucuronide, quercetin diglucuronide, quercetin glucuronide 
sulphate, methylquercetin diglucuronide, etc. After returning to the bloodstream they 
are excreted in urine via kidneys. Additionally, a portion of quercetin is converted to 
low molecular weight phenolic acids, such as 3–hydroxyphenylpropionic acid, 3,4–
dihydroxyphenylpropionic acid and 3–methoxy–4–hydroxyphenylpropionic acid 
(Olthof et al., 2003; Mullen et al., 2006). 
1.5.3 Occurrence and intake of dietary flavonoids 
Nowadays, a growing body of evidence confirms different beneficial health effects 
of dietary flavonoids. Consequently, the scientific community takes more and more 
interest in the levels and types of flavonoids that are taken up in the diet. This is 
particularly interesting in the scope of modern concept of so called “functional food”, 
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food that apart from nutritional value expresses additional functions, such as health-
promotion or disease prevention. Namely, flavanols and anthocyanidins have been 
associated with reduction of risk of cardiovascular disease, while anthocyanidins 
efficiently protect LDL cholesterol oxidation (Schroeter et al., 2010). It had been 
shown that flavonoids express organ-specificity for cancer prevention, so intake of a 
quercetin–rich diet was proven to be in positive correlation with protection against 
lung and intestinal cancer (Lam et al., 2010; Ekström et al., 2011). 
Flavonoids are present in nearly all edible fruits, vegetables and other foods of plant 
origin. Generally, the human population is consuming notable amounts of flavonoids 
on a daily basis being more in regions where the diet is mainly based on plant 
sources. It is estimated that the average daily intake of flavonoids in the United 
States of America is 20–34 mg, in Finland 24 mg, Japan 63 mg and Netherlands 73 
mg (Beecher, 2003). The daily intake of quercetin in the Western diet was estimated 
to be approximately 15 mg. In Table 1–4 contents of dominant dietary flavonoids 
and quercetin in selected foods that are regularly consumed in Western diet are 
listed. 
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Table 1–4 Flavonoids and quercetin content of selected foods 
food 
mg of flavonoid aglycone
*
/ 
100 g of fresh weight 
of edible portion 
mg of quercetin aglycone/ 
100 g of fresh weight 
of edible portion 
red onion 56.61 39.21 
onion 26.02 20.30 
cranberry 132.08 14.84 
blueberry 180.82 7.67 
fig 8.07 5.47 
lettuce 4.63 4.16 
apple 15.15 4.01 
spinach 11.44 3.97 
broccoli 11.96 3.26 
tomato 5.95 2.76 
green tea 137.93
**
 2.49
**
 
black tea 118.27
**
 2.19
**
 
red wine 171.88
***
 2.11
***
 
garlic 3.61 1.74 
cauliflower 1.02 0.54 
potato 0.49 0.49 
strawberry 13.35 0.48 
red cabbage 210.67 0.36 
parsley 233.16 0.28 
red pepper 0.86 0.23 
carrot 0.6 0.21 
banana 13.69 0.06 
cucumber 0.17 0.04 
eggplant 85.73 0.04 
kiwi 2.18 0.04 
white wine 2.22
***
 0.04
***
 
*total content represents sum of 26 dominant dietary flavonodis (isorhamnetin, kaempferol, 
myricetin, quercetin, apigenin, luteolin, eriodictyol, hesperetin, naringenin, catechin, 
gallocatechin, epicatechin, epigallocatechin, epicatechin–3–gallate, epigallocatechin–3–
gallate, theaflavin, theaflavin–3–gallate, theaflavin–3’–gallate, theaflavin–3,3’–digallate, 
thearubigins, cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin) 
**values for tea are given as mg/100 g (100 mL) of tea infusions, while tea was prepared 
with 1 g tea leaves/100 mL boiling water 
***values are converted from liquid to weight basis 
(Bhagwat et al., 2014) 
1.6 The connections between quercetin and iron homeostasis 
Flavonoids are known for their numerous health benefits which are mostly attributed 
to their ability to scavenge highly reactive free radical species. However, flavonoids’ 
antioxidative potential is, at least partially, associated with their ability to chelate 
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iron. By chelating iron, flavonoids reduce the accessibility of iron to oxygen and 
consequently diminish oxygen high toxicity, e.g. by inhibiting production of HO
•
 in 
Fenton reaction (Mladěnka et al., 2011). Like most other flavonoids, it was proven 
that quercetin possesses a high ability to chelate iron (Leopoldini et al, 2006). As one 
of the main aims of this thesis is to investigate the effect of quercetin on iron 
homeostasis, this section will be mainly concentrated on quercetin in the light of iron 
metabolism. The preferred site for iron chelation by quercetin is its 3–hydroxyl and 
4–carbonyl group. Specifically, for complexes containing one iron and one quercetin, 
the binding strength has an order 3–4 > 4–5 > 3’–4’. Moreover, the 3–4 chelation site 
is also preferred for complexes which are formed between one iron and two or three 
quercetin molecules (see Figure 1–11; Ren et al., 2008). In addition, it is estimated 
that quercetin, like most other flavonoids, forms a complex with Fe
3+
 with a greater 
stability than Fe
2+
. Even though when quercetin initially forms a complex with Fe
2+
, 
Fe
2+
 will autooxidise to Fe
3+
 (Perron and Brumaghim, 2009).  
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Figure 1–11 Structures of complexes between Fe3+ and quercetin 
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Considering that quercetin is a powerful chelator of iron, a couple of ways of how it 
can modulate iron homeostasis come to mind. Namely, intracellularly it could lower 
free iron and thus change the influence of the IRE/IRP regulatory system in iron 
homeostasis. Bearing in mind that many proteins that have a pivotal role in iron 
homeostasis, such as FPN, ferritin, DMT1, TfR1 and Hif–2α, are regulated by the 
IRE/IRP system (described in detail in1.4.1), the quercetin effect becomes even more 
important. Additionally, quercetin could inhibit iron absorption and redistribution 
during iron overload by chelating it and thus affecting iron status. Over 30 years ago 
it was shown that consumption of tea is in accordance with low non-haem iron 
bioavailability (Disler et al., 1975; Rossander et al., 1979). Consequently, flavonoids, 
or polyphenols, from the tea were recognized as the main cause for low non-haem 
iron absorption. Today, flavonoids, among them quercetin, are considered as one of 
the main dietary inhibitors of iron absorption in the duodenum. Even though the 
exact mechanism of how flavonoids inhibit non-haem iron absorption is still not fully 
elucidated, it is strongly believed that its power to chelate iron is mainly responsible 
for this action (Petry, 2014). In contrast, it was shown that quercetin may operate as a 
substrate for DcytB by increasing its reduction potential and providing more Fe
2+
 for 
cellular uptake by DMT1 (Vlachodimitropoulou et al., 2010). Furthermore, it has 
been proven in cells that quercetin is able to activate Nrf2 pathway by supporting its 
nuclear translocation and transcriptional activity (Granado–Serrano et al., 2012). In 
view of the fact that levels of FPN and H and L ferritin are also known to be 
transcriptionaly up regulated by Nrf2 pathway (described in detail in1.4.3), quercetin 
could affect iron homeostasis and help cells defending against oxidative stress. 
In diseases connected with an imbalance in iron homeostasis (described in detail in 
Section 1.4.4) organ-specific iron accumulation is present, even under conditions of 
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anaemia. In order to bring iron levels back into balance, chelato therapeutics are 
applied. Potent chelato therapeutics should be able to go through iron-overloaded 
tissues, complex iron by forming stable and redox-inactive iron and transfer it to 
transferrin in the circulation. Known chelato therapeutic drugs fulfill more or less 
listed requirements (Poggiali et al., 2012; described in detail Section 1.4.4). However, 
it has been proven in vitro that quercetin is able to decrease intracellular iron and to 
transfer it to transferrin. These significant findings suggest that quercetin could be a 
valuable representative of chelato therapeutics for iron-redistribution therapy. Yet, 
this fact still needs to be proven with in vivo studies (Baccan et al., 2012). On the 
other hand, it is clear that quercetin should be avoided in IDA, especially during oral 
consumption of iron either as a natural constituent of the diet or as a food 
supplement. 
All of the above mentioned possible impacts of quercetin on iron homeostasis 
become even more significant in view of the fact that quercetin is consumed 
regularly in considerable amounts (see Table 1–4) and that nowadays its 
supplementation is supported due to numerous health benefits. On the other hand, as 
imbalance in iron homeostasis is connected with many diseases, flavonoids may have 
important applications in their treatment. Hence it is of great importance to fully 
understand how dietary flavonoids interact with intake and homeostasis of iron. The 
main body of this thesis will try, at least partially, to address this issue. 
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1.7 Aims of study 
The main aim of this thesis was to elucidate the mechanisms underlying the effects 
of polyphenols, mainly quercetin, on iron homeostasis in vivo. 
The specific aim of each Chapter of this thesis was: 
1. To investigate the effect of oral quercetin on iron metabolism, mainly iron 
absorption in duodenum, in an in vivo rat model (Chapter 3). 
2. To investigate the chelation effect of polyphenols on non-haem iron absorption in 
duodenum applying an in vivo uptake method in rats (Chapter 4). 
3. To investigate the effect of intraperitoneal (IP) quercetin on iron metabolism, 
mainly systemic iron homeostasis, in an in vivo rat model (Chapter 5).  
4. To elucidate the effects of different polyphenols on iron-related genes expression 
in HepG2 cells, an in vitro hepatic model (Chapter 6). 
5. To elucidate changes in iron-related and inflammation-related gene expression 
induced by different polyphenols in THP1 cells, a macrophage iron-recycling in 
vitro model (Chapter 7). 
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2. GENERAL MATERIALS AND METHODS 
2.1 Chemicals and standards 
chemical or standard supplier 
catalogue 
number 
3,4’–dimethoxy–5,7,3’–
trihydroxyflavone  
(3,4’–dimethylquercetin) 
abcr GmbH, Germany AB151842 
3’,4’,5,7–tetrahydroxy–3–
methoxyflavone  
(3–O–methylquercetin) 
Extrasynthese, France 1342 
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Fe PerkinElmer, USA NEZ 043 
59
Fe PerkinElmer NEZ 037 
acetic acid (CH3COOH) Sigma–Aldrich, UK ARK2183 
acetone Sigma–Aldrich 270725 
Antibiotic/Antimycotic solution Sigma–Aldrich A5955 
ascorbic acid Sigma–Aldrich 95210 
bathophenanthrolinedisulfonic acid 
disodium salt hydrate 
Sigma–Aldrich B1375 
carbonyl iron Sigma–Aldrich C3518 
chloroform Sigma–Aldrich C2432 
diethyl pyrocarbonate (DEPC) treated 
water 
Life Technologies Ltd., 
Ambion 
AM9916 
dimethyl sulfoxide (DMSO) Sigma–Aldrich D8418 
DNase I 
Life Technologies Ltd., 
Invitrogen 
AM2222 
DNase I Buffer 
Life Technologies Ltd., 
Ambion 
AM8170G 
Dulbecco’s phosphate–buffered saline 
(PBS; 1×) without Ca2+ and Mg2+ 
PAA Laboratories Ltd., 
UK 
H15–002 
epicatechin Extrasynthese 0977 S 
ethanol VWR, USA 20821.330 
Foetal Bovine Serum (FBS) 
Life Technologies Ltd., 
Gibco, USA 
10270–106 
FBS, heat inactivated 
Life Technologies Ltd., 
Gibco 
10500–064 
formic acid (HCOOH) Sigma–Aldrich 56302–50ML–F 
genistein Sigma–Aldrich 92136 
GlutaMAX™–I 
Life Technologies Ltd., 
Gibco 
35050–038 
HEPES sodium salt 
(Na–HEPES) 
Sigma–Aldrich H8651 
hydrochloric acid (HCl) Sigma–Aldrich H1758 
iron (III) chloride hexahydrate 
(FeCl3 × 6H2O) 
Sigma–Aldrich F2877 
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iron-deficient diet Special Diet Service, UK  
isopropyl alcohol Sigma–Aldrich I9516 
isorhamnetin Extrasynthese 1120 S 
isorhamnetin–3–O–glucoside Extrasynthese 1228 
LPS 
Enzo Life Sciences Inc., 
UK 
ALX–581–008–
L002 
methanol Sigma–Aldrich 34860 
pentobarbitone sodium 
Pentoject – obtained from 
Animalcare Ltd., UK 
/ 
phorbol 12–myristate 13–acetate (PMA) Sigma–Aldrich P1585 
potassium chloride (KCl) VWR BDH9258 
quercetin Sigma–Aldrich Q4951 
quercetin–3,3’,4’,7–tetramethylether  
(tetra–methylquercetin) 
Extrasynthese 1074 
quercetin–3,4’–di– 
O–glucoside 
Extrasynthese 1347 S 
quercetin–3,5,7,3’,4’–pentamethylether  
(penta–methylquercetin) 
Extrasynthese 1285 
quercetin–3–O–glucuronide Extrasynthese 1315 
resveratrol Extrasynthese 4963 S 
RM1 diet Special Diet Service, UK  
RPMI–1640 Medium Sigma–Aldrich R8758 
sodium acetate (CH3COONa) Sigma–Aldrich W302406 
sodium chloride (NaCl) VWR 27810.295 
Solvable™ PerkinElmer 6NE9100 
tamarixetin  
(4’–O–methylquercetin) 
Extrasynthese 1140 S 
thioglycolic acid Sigma–Aldrich T3758 
trichloroacetic acid  
(CCl3COOH) 
Sigma–Aldrich T4885 
TRIzol
®
 reagent 
Life Technologies Ltd., 
Ambion 
10296–028 
Trypsin EDTA (1×) 0.05%/0.02% in 
Dulbecco’s phosphate–buffered saline 
PAA Laboratories Ltd. L11–004 
William’s E Medium, without phenol 
red, without L–Glutamine 
PAA Laboratories Ltd. E15–073 
2.2 Animal care and treatments 
Rats were supplied by the Comparative Biology Unit, Royal Free Campus, UCL 
Medical School, London, UK. All experimental procedures were approved by the 
University College London local animal ethics committee and were conducted in 
accordance with the UK Animals (Scientific Procedures) Act, 1986. In all 
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experiments male Sprague Dawley (SD) rats were used. After weaning (three weeks 
old) SD rats were placed on a low iron (25 ppm iron) diet or a regular (RM1, 156 
ppm iron) diet for two weeks and allowed free access to water throughout. 
Subsequently, animals were subject to different gavage or IP treatments with 
quercetin or 10% DMSO. Additionally, separate groups of animals had no specified 
treatments prior to uptake studies (described in detail in Section 2.3). In Figure 2–1 
time line of performed treatments and in Table 2–1 and Table 2–2 a detailed 
description of performed treatments is given. At the end of the experimental 
procedure animals were killed by administering a terminal dose of pentobarbitone 
sodium (120 mg/kg body weight, IP) and blood samples were removed via cardiac 
puncture. Subsequently, serum was separated from clotted blood sample after 
centrifugation for 10 minutes at 5000g, rapidly frozen in liquid nitrogen before being 
stored at -80ºC and afterwards used for serum iron and transferrin saturation 
measurements (described in detail in Section 2.4). Additionally, duodenum, liver, 
spleen and kidney were removed and rapidly frozen in liquid nitrogen before being 
stored at -80ºC and subsequently used for tissue non-haem iron measurements 
(described in detail in Section 2.5) and gene expression levels determination 
(described in detail in Section 2.5). However, animal groups 5 and 6 (see Table 2–1) 
and 11 and 12 (see Table 2–2) were the subject of uptake studies (described in detail 
in Section 2.3) and were neither killed by the specified procedure nor blood or tissue 
samples were collected as detailed above. 
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Figure 2–1 Time line of performed treatments 
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Table 2–1 Detailed description of performed gavage treatments 
group type of treatment time of treatment 
number of 
animals 
per group 
type of diet 
corresponding  
treatment from 
Figure 2–1 
1 
control 
a
d
m
in
is
tr
a
ti
o
n
 b
y
 g
a
v
a
g
e
 
10% DMSO 
5 hours prior to dissection 
5 
iron-deficient diet A 
treated quercetin 50 mg/kg 5 
2 
control 10% DMSO 
18 hours prior to dissection 
4 
iron-deficient diet A 
treated quercetin 50 mg/kg 4 
3 
control 10% DMSO 
18 hours prior to dissection 
3 
RM1 diet A 
treated quercetin 50 mg/kg 3 
4 
control 10% DMSO 10 days in the row; 
the 10
th
 day treatment was performed 
4 hours prior to dissection 
5 
iron-deficient diet A 
treated quercetin 50 mg/kg 5 
5
*
 
control 10% DMSO 
5 hours prior to uptake experiment 
5 
iron-deficient diet C 
treated quercetin 50 mg/kg 5 
6
*
 
control 10% DMSO 18 hours and 5 hours prior to uptake 
experiment 
5 
iron-deficient diet B 
treated quercetin 50 mg/kg 5 
*
animals were subject to uptake studies (described in detail in Section 2.3) 
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Table 2–2 Detailed description of performed IP treatments 
group type of treatment time of treatment 
number of 
animals 
per group 
type of diet 
corresponding 
treatment from 
Figure 2–1 
7 
treated 
a
d
m
in
is
tr
a
ti
o
n
 b
y
 I
P
 
quercetin 50 mg/kg 
0 hours prior to dissection 4 
iron-deficient diet D 
treated 2 hours prior to dissection 4 
treated 5 hours prior to dissection 4 
treated 12 hours prior to dissection 4 
treated 18 hours prior to dissection 4 
8 
control 10% DMSO 18 hours and 5 hours prior to 
dissection 
5 
iron-deficient diet B 
treated quercetin 50 mg/kg 5 
9 
control 10% DMSO 18 hours and 5 hours prior to 
dissection 
4 
RM1 diet B 
treated quercetin 50 mg/kg 4 
10 
control 10% DMSO 
5 hours prior to dissection 
4 
iron-deficient diet A 
treated quercetin 2 mg/kg 4 
treated quercetin 5 mg/kg 4 
treated quercetin 10 mg/kg 4 
treated quercetin 20 mg/kg 4 
11
*
 
control 10% DMSO 
5 hours prior to uptake experiment 
5 
iron-deficient diet A 
treated quercetin 50 mg/kg 5 
12
*
 
control 10% DMSO 18 hours and 5 hours prior to uptake 
experiment 
5 
iron-deficient diet B 
treated quercetin 50 mg/kg 5 
*
animals were subject to uptake studies (described in detail in Section 2.3) 
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2.3 In vivo iron uptake 
After the animal care procedure and treatments (described in detail in Section 2.2), 
groups of SD rats were subjected to uptake studies. Namely, SD rats were 
anesthetized with 60 mg/kg pentobarbitone sodium IP and 10 cm long segments of 
duodenum (starting 1 cm distal to the pylorus) were cannulated and rinsed free of 
their contents with warm saline (0.9% w/v of NaCl), followed by air. Uptake buffer 
(200 µL), containing Na–HEPES (14.6 mmol/L), NaCl (127.4 mmol/L), KCl (3.2 
mmol/L), ascorbic acid (4.0 mmol/L) and 
59
Fe
2+
 (
55
Fe; 0.2 mmol/L) was instilled into 
the duodenal segment, which was then tied off. However, in experiments with SD 
rats that were not treated prior to uptake studies, 1 mmol/L of either quercetin or 3–
O–methylquercetin or 4’–O–methylquercetin or 3,4’–dimethylquercetin or penta–
methylquercetin or resveratrol (stock solutions prepared in DMSO:ethanol [1:1]) was 
added to uptake buffer. In the corresponding control groups, DMSO:ethanol (1:1) 
was added to buffer instead of the polyphenols. The effect of each polyphenol on 
iron absorption was investigated in a group of five SD rats. In uptake studies with 
quercetin, 3–O–methylquercetin, 4’–O–methylquercetin, 3,4’–dimethylquercetin and 
penta–methylquercetin 59Fe was used. However, due to a change in regulations at the 
time when the experiment with resveratrol was performed instead of 
59
Fe,
 55
Fe was 
used. 
During the experiment rat body temperature was maintained at 37°C using a 
thermostatically controlled heating blanket. After 30 minutes, blood samples (≤2 
mL) were collected via cardiac puncture and put in pre-weighed tubes, and blood 
weight was determined afterwards. In the experiment where 
55
Fe was used, after 30 
minutes 1 mL blood was also removed via cardiac puncture and but placed in tubes 
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containing anticoagulant. The segment of duodenum was removed and washed with 
approximately 40 mL of solution containing 154 mmol/L NaCl, 0.1 mmol/L ascorbic 
acid, 0.01 mmol/L FeCl3 to displace any 
59
Fe or 
55
Fe bound to the mucosal surface. 
The duodenal segment was cut longitudinally to form a flat sheet, and the mucosa 
was removed by scraping, placed into a pre-weighed tube, and its weight determined. 
Appropriate blood and mucosa samples were gamma counted (Wallac 1282 
Compugamma Counter Model 1283) for the determination of 
59
Fe activity. However, 
in the experiment where 
55Fe was used mucosa was digested in 2 mL Solvable™ and 
a 50 µL sample of the digestant was counted on the liquid scintillation counter 
(Packard Scintillation Counter Model 2900) in duplicate for the determination of 
55
Fe 
activity. In the corresponding animal group blood was centrifuged and a 50 µL 
aliquot of plasma was counted in duplicate to determine 
55
Fe activity. Results were 
expressed as a percentage of absorbed radioactive iron retained in duodenal mucosa 
or transferred to blood. Namely, it was considered that absorbed radioactive iron is 
distributed between mucosa of cannulated duodenum and total body blood, and that 
sum of their counts is 100%. The percentage of 
59
Fe or 
55
Fe transferred to the entire 
blood volume of the animal was calculated using the equation: total blood volume = 
(body weight*0.06) +0.77 (Lee and Blaufox, 1985). In Figure 2–2 the experimental 
procedure is presented schematically.  
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Figure 2–2 Time line of uptake experiment 
2.4 Serum iron and transferrin saturation measurements 
Serum iron and transferrin saturation were measured by using a commercial kit 
(Pointe Scientific Inc., USA cat. no. I7504) as instructed by the manufacturer and 
described below. 
2.4.1 Measurement of serum iron 
All samples, blank and standard probes were prepared for spectrophotometric 
measurements in duplicate in 96-well plate. Forty microliters of each standard, serum 
sample and water was added into standard, sample and blank wells. Iron buffer 
reagent (200 μL) was added to each well and the absorbance reading (A1) was taken 
at 560 nm by a plate reader (Thermo/LabSystems 352 Multiskan MS Microplate 
Reader) after mixing. Iron colour reagent (4 μL) was added to each well and plate 
was incubated at 37ºC for 10 minutes. Again the absorbance was measured at 560 
nm named A2 and the serum iron was calculated with the following equation: 
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(A2 sample - A1 sample)/(A2 standard - A1 standard) × 500 = serum iron (μg/dL) 
2.4.2 Determination of transferrin saturation levels 
All samples, blank and standard probes were prepared for spectrophotometric 
measurements in duplicate in 96-well plates. Forty microliters of each standard and 
sample was added to standard and sample wells. Eighty microliters of water was 
added to the blank well and 40 μL of water was added to standard well. 40 μL of iron 
standard was added to the sample wells. Unsaturated iron binding capacity (UIBC) 
reagent (160 μL) was added to each well and after mixing the absorbance reading 
(A1) was measured at 560 nm. Iron colour reagent (4 μL) was added to each well and 
plate was incubated at 37ºC for 10 minutes. Again the absorbance was measured at 
560 nm named A2. UIBC, total iron binding capacity (TIBC), and transferrin 
saturation were measured by using the following equations: 
500 - (A2 sample - A1 sample)/(A2 standard - A1 standard) × 500 = UIBC (μg/dL) 
serum iron + UIBC = TIBC (μg/dL) 
serum iron/TIBC × 100 = transferrin saturation (%) 
2.5 Tissue non-haem iron determination 
The tissue non-haem iron content was determined by using a modified method of a 
method firstly reported by Torrance and Bothwell (1980). Namely, tissues 
(duodenum, liver, spleen) were oven dried at 50ºC for 72 hours and subsequently 
weighed. The dried tissues were digested in 1 mL of acid mixture (30% HCl and 
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10% CCl3COOH) at 65°C over 20 hours. Blanks were prepared in the same way, but 
without tissue. After cooling, samples, blank and standard probes were prepared for 
spectrophotometric measurements in triplicate in plastic cuvettes as presented in 
Table 2–3 Preparations of samples for tissue non-haem iron determination. 
Table 2–3 Preparations of samples for tissue non-haem iron determination 
 
sample/blank 
μL 
working chromogen 
reagent  
(mL) 
dH2O 
μL 
working iron 
solution 
(μL) 
sample 25 sample 1 225 0 
standard 25 blank 1 100 125 
blank 25 blank 1 225 0 
All samples were incubated at 37°C for 10 minutes, after which measurements of 
absorbance (A) were made at 535 nm using a spectrophotometer (Cary 100, Agilent 
Technologies) and non-haem levels in tissues were calculated using the following 
equation: 
[(A sample - A blank)/(A standard - A blank)]×[11.169/dry weigh (dw; g)] × 
[(2500/150)/(2500/250)] = tissue non-haem iron (μg/g dw) 
The working chromogen reagent and working iron solution were freshly prepared 
just before the assay. The composition of the reagents was as follows: 
Chromogen reagent was prepared by mixing 50 mg bathophenanthrolinedisulfonic 
acid disodium salt hydrate and 500 μL of thioglycolic acid and afterwards made up to 
50 mL of dH2O (stable for 1 month in dark bottle). 
Working chromogen reagent was prepared on the day of experiment by mixing one 
volume of previously described chromogen reagent, five volumes of saturated 
solution of CH3COONa and five volumes of dH2O. 
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Stock iron standard solution was prepared by mixing 22.3 mg of carbonyl iron 
powder with 1096 μL HCl. Afterwards, solution was left to stand overnight and 
made up to 20 mL with dH2O (stable indefinitely when stored tightly sealed). 
Working iron solution was prepared on the day of experiment by mixing 50 μL of 
stock iron standard solution, 27 μL of HCl and 423 μL dH2O. 
2.6 Cell culture 
2.6.1 HepG2 cells 
HepG2 cells were cultured in William’s E medium without phenol red and L–
glutamine. The medium was supplemented with 10% (v/v) FBS, 2 mM L–glutamine 
(1% v/v GlutaMAX™–I) 100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 
µg/mL amphotericin B (1% v/v Antibiotic/Antimycotic solution). All supplements 
were filtered through a 0.2 μm pore size filter (Merck Millipore, USA, Cat no. 
SLGS033SB). The cell were seeded onto 75 cm
2
 cell plastic culture flasks with vent 
cap (Corning, USA, cat. no. 430641) and grown in an incubator at 37ºC with 5% 
CO2 until they were 70–75% confluent. The culture medium was changed every two 
days. To subculture the HepG2 cells the culture medium was carefully removed and 
the adherent cells were washed three times with 10 mL PBS without Ca
2+
 and Mg
2+
. 
To release the cells from the flask 10 mL of 0.05% Trypsin–EDTA was added for 10 
minutes. Detached cells were transferred into a 50 ml sterile tube (Thermo Fisher 
Scientific Inc., USA, Cat. no. 352070) containing 10 mL of culture medium in order 
to deactivate trypsin activity and pelleted by centrifugation (1400g for 3 minutes). 
The supernatant was removed and the cell pellet was re–suspended in 10 mL of fresh 
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culture medium. To disperse the cells further, the cell suspension was filtered 
through a 40µm sterile cell strainer (Corning, USA, cat. no. 352340) on top of a 50 
mL sterile tube. Cell numbers and percentage of viable cells were determined by 
using the haemocytometer and the trypan blue exclusion test.  
2.6.1.1 Treatment of HepG2 cells 
Prior to treatments cells were plated in 6-well plates (Greiner Bio–One, USA, cat no. 
657160) with seeding density 5 × 105 (viable cells/well). HepG2 cells were treated 
with polyphenols at 90% confluence. Polyphenols, epicatechin, 3–O–
methylquercetin, isorhamnetin, tamarixetin, 3,4’–dimethylquercetin, penta–
methylquercetin, quercetin–3–O–glucuronide, resveratrol and quercetin were 
dissolved in serum–free culture medium in concentration of 100 µM, and were added 
to the cell plates for 5 hours. In control wells for 3–O–methylquercetin and 
resveratrol an equal volume of ethanol was added instead of the compound (final 
concentration 0.1%); for epicatechin, isorhamnetin, tamarixetin, 3,4’–
dimethylquercetin, quercetin–3–O–glucuronide, quercetin an equal volume of 
DMSO was added instead of the compound (final concentration 0.125%); for penta–
methylquercetin equal volume of ethanol:DMSO was added instead of compound 
(final concentration 0.09% ethanol/0.09% DMSO). All probes were done in 
triplicate. After treatment cells were washed 3 times in PBS and were subject to 
RNA isolation and gene expression (hepcidin, FPN and HO–1) analysis (described in 
detail in Section 2.7). 
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2.6.2 THP1 cells 
The THP1 cells were cultured in RPMI–1640 with L–Glutamine and NaHCO3. The 
medium was supplemented with 10% (v/v) heat inactivated FBS, 100 U/mL 
penicillin, 100 µg/mL streptomycin and 0.25 µg/mL amphotericin B. All 
supplements were filtered through a 0.2 μm pore size filter. The cells were seeded 
onto 75 cm
2
 straight neck vented tissue culture flasks (Thermo Scientific, Nunc, 
USA, cat. no. 153732) and grown in an incubator at 37ºC with 5% CO2. The THP1 
cells remained in cell suspension and were maintained between 2–9 x 105 cells/mL. 
To subculture the cells, the cell suspension was collected in a 50 mL sterile tube and 
pelleted by centrifugation (1400g for 3 minutes). The supernatant was removed and 
the pellet was re-suspended in 5 mL of culture medium. Cell numbers and percentage 
of viable cells were determined by using the haemocytometer and the trypan blue 
exclusion test. 
2.6.2.1 Treatment of THP1 cells 
Prior to treatments cells were plated in 6-well plates for 24 hours (Greiner Bio–One, 
USA, cat no. 657160) with seeding density 1 × 106 (cells/well). 100 nM PMA in 
DMSO was added for a further 24 hours to promote differentiation of monocytes into 
macrophages. The PMA-containing medium was removed and replaced with serum–
free medium for 24 hours before treatment.  
THP1 cells were treated with quercetin, quercetin–3–O–glucuronide and tamarixetin 
(30 µM) for 0, 5 and 18 hours. In control wells an equal volume of DMSO was 
added instead of the compound (final concentration 0.04%). All probes were done in 
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triplicate. After treatment, cells were subject to RNA isolation and gene expression 
(hepcidin and FPN) of analysis (described in detail in Section 2.7). 
Other batches of THP1 cells were treated with LPS in the presence or absence of 
quercetin, isorhamnetin and quercetin–3–O–glucuronide (30 µM). Namely, LPS (500 
ng/mL, dissolved in medium) was added to cells 2 hours after polyphenols. Cells 
were treated with LPS for 18 hours. In control wells an equal volume of DMSO was 
added instead of the compound (final concentration 0.04%). All probes were done in 
triplicate. After treatment cells were subject to RNA isolation and gene expression 
(IL–6, IL–1β, TNF–α, inducible nitric oxide synthase (iNOS) and cyclooxygenase–2 
(COX–2)) analysis (described in detail in Section 2.7). 
2.7 Gene expression levels by Real–Time Polymerase Chain 
Reaction (RT–PCR) 
2.7.1 RNA extraction by TRIzol® reagent 
Precautions were taken against contamination of samples with RNAses. The bench 
working area was cleaned with RNaseZAP (Life Technologies Ltd., Ambion, USA 
AM9780 and AM9784), disposal gloves were worn at all times, and sterile 
disposable plasticware and pipettes for RNA work only were used. 
RNA extraction was carried out using TRIzol
®
/chloroform extraction and isopropyl 
alcohol precipitation according to the manufacturer’s instructions (Chomczynski and 
Sacchi, 1987). TRIzol
®
 reagent was added to the cells or frozen tissue (1 mL was 
used per well of six well plate or 100 mg tissue) in sterile 1.5 mL micro centrifuge 
tube. Cell samples were homogenized by repeatedly passing the cell suspension 
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through a syringe and needle (BD, UK, Cat no. 300600, 25 G (orange)). Tissue 
samples were homogenized by pellet pestles (Sigma–Aldrich, UK, Cat no. Z359971 
and Z359947). Samples were then incubated at room temperature for 5 minutes for 
complete dissociation of nucleotide/protein complexes. Chloroform (200 µL) was 
added to the samples and samples were shaken vigorously by hand for 15 seconds. 
Tubes were incubated at room temperature for 3 minutes and then centrifuged at 12 
000g for 15 minutes at 4ºC. The mixture separated into a lower red, phenol-
chloroform phase, which contained DNA and protein, and a colourless upper 
aqueous phase containing the RNA. The aqueous phase was carefully removed with 
a pipette and transferred to a clean 1.5 mL tube and the lower organic phase was 
discarded.  
The RNA was precipitated form the aqueous phase with isopropyl alcohol (500 µL) 
by inverting the tubes. Samples were incubated at room temperature for 10 minutes 
and then centrifuged at 12000g for 15 minutes at 4ºC. The supernatant was discarded 
and the RNA pellet was washed with 1.2 mL 70% ethanol by vortexing followed by 
centrifugation at 7500g for 5 minutes at 4ºC. Ethanol was discarded and the final 
RNA pellet air–dried. RNA pellet was resuspended in DEPC-treated water 
(approximately 50 µL for cell sample and 500 µL for tissue sample) and kept at 60ºC 
for 10 minutes. After this, RNA samples were kept on ice at all times. 
The concentration of extracted RNA was measured using a NanoDrop 2000c UV–
VIS spectrophotometer, Thermo Scientific. RNA quality was assessed by using the 
A260/280 ratio. RNA with a ratio between 1.8 and 2.00 indicates RNA free of 
protein contamination. The RNA samples were kept at -80ºC until required. 
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2.7.2 Complementary DNA (cDNA) synthesis 
In order to prevent DNA contamination, firstly RNA samples were incubated in a 
thermal cycler (MJ Research PTC–200) with DNase I (RNase-free) enzyme for 30 
minutes and an additional 10 minutes at 37ºC and 70ºC, respectively. A total reaction 
mixture consisted of 1 µg of RNA, 1 µL DNase I Buffer, 0.5 µL DNase I and made 
up by DEPC treated water to 11 µL for each sample. As soon as treatment was 
finished samples were placed at 4ºC until required. 
After DNase I treatment cDNA synthesis was performed using a VersoTM cDNA kit 
(Thermo Scientific, Cat no. AB–1453/B). The following components were added 
into each tube: 4 µL 5 × cDNA synthesis buffer, 2 µL dNTP mix, 1 µL anchored 
Oligo dT, 1 µL RT enhancer and 1 µL Verso enzyme mix. The tubes were places 
back into the thermal cycler for further 60 and 2 minutes incubation periods at 42ºC 
and 95ºC, respectively. Samples were kept at 4ºC for immediate use or at -20ºC to be 
used later. 
2.7.3 Real-Time PCR amplification 
Real-time quantitative gene analysis was performed using a LightCycler® 480 
System (Roche Diagnostics GmbH, Germany) and a LightCycler 480 SYBR Green I 
Master kit (Roche Diagnostics, Cat no. 04707516001). SYBR green is a fluorescent 
dye that binds to the minor groove of DNA and fluoresces only when bound to 
double stranded DNA, but not single stranded DNA. SYBR green is excited at 494 
nm and emits light at 521 nm. Monitoring the emission at 521 nm allows indirect 
quantification of double stranded DNA in the reaction tube. Fluorescence was 
measured at 521 nm within each reaction tube of a 96-well plate following 
completion of every PCR extension step. The PCR cycle at which the fluorescence 
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reaches the threshold value is used as a measure of relative template concentration. 
The second derivative maximal method was used to determine threshold values of 
fluorescence. Cycle threshold (Ct) values were obtained for each gene of interest and 
the glyceraldehyde 3–phosphate dehydrogenase (GAPDH) internal standard. Gene 
expression was normalized to GAPDH and represented as ΔCt values. For each 
sample the mean of the ΔCt values was calculated. Relative gene expression was 
normalized to 1.0 (100%) of controls. Each PCR reaction contained 0.3 µM of each 
specific primer, forward and reverse, 6 µL of SYBR Green I Master, 1 µL of cDNA 
made up by DEPC treated water to 11 µL for each sample. Samples without cDNA 
were included as negative controls. The primers for genes of interest were 
synthesized by Sigma Aldrich. The primers for the internal standard gene GAPDH 
was obtained from Primer Design, UK (Cat no. HK–SY–ra–600). For the primers’ 
sequences see  
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Table 2–4 Primer sequences used in this study. qPCR plates were centrifuged and 
placed in a LightCycler® 480 System real-time cycler with the following 
programme: 
step temperature time cycles 
initial denaturation 95ºC 10 minutes 1 
denaturation 95ºC 10 seconds 
50 annealing 60ºC 10 seconds 
extension 72ºC 10 seconds 
metltcurve 95ºC 5 seconds 1 
cooldown 65ºC 1 minute 1 
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Table 2–4 Primer sequences used in this study 
gene 
forward 
(5’→3’) 
reverse 
(5’→3’) 
Dcytb 
(rat) 
TCCTGAGAGCGATTGTGTTG TTAATGGGGCATAGCCAGAG 
DMT1 
(rat) 
GCTGAGCGAAGATACCAGCG TGTGCAACGGCACATACTTG 
ferritin 
(rat) 
CACTCTTCCAGGATGTGCAG ACAGAGGTGAGGGTCTGTGC 
FPN 
(rat) 
TTCCGCACTTTTCGAGATGG TACAGTCGAAGCCCAGGAC 
GST 
(rat) 
AGACATCCACCTGCTGGAAC GGCTGCAGGAACTTCTTCAC 
hepcidin 
(rat) 
AGACACCAACTTCCCCATATG ACAGAGACCACAGGAGGAATTCT 
Hif–1α 
(rat) 
TGCTTGGTGCTGATTTGTGA GGTCAGATGATCAGAGTCCA 
Hif–2α 
(rat) 
CCCCAGGGGATGCTATTATT GGCGAAGAGCTTCTCGATTA 
OH–1 
(rat) 
TGCTCGCATGAACACTCTG TCCTCTGTCAGCAGTGCC 
QR 
(rat) 
GCTTTCAGTTTTCGCCTTTG GAGGCCCCTAATCTGACCTC 
COX–2 
(human) 
CAGCACTTCACGCATCAGTT CGCAGTTTACGCTGTCTAGC 
FPN 
(human) 
CAGTTAACCAACATCTTAGC AAGCTCATGGATGTTAGAG 
GAPDH 
(human) 
TGGTATCGTGGAAGGACTC AGTAGAGGCAGGGATGATG 
hepcidin 
(human) 
CTGCAACCCCAGGACAGAG GGAATAAATAAGGAAGGGAGG 
IL–1β 
(human) 
TGAGCTCGCCAGTGAAATGA CATGGCCACAACAACTGACG 
IL–6 
(human) 
AGTACCCCCAGGAGAAGATTCC TGAAGAGGTGAGTGGCTGTCTGT 
iNOS 
(human) 
AAAGACCAGGCTGTCGTTGA ACGGGACCGGTATTCATTCT 
OH–1 
(human) 
GTTGGCACCATGGAGCGTCCG AGCCGTCTCGGGTCACCTGG 
TNF–α 
(human) 
TGGCGTGGAGCTGAGAGATA TGGGTGAGGAGTACATGGGT 
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2.8 LC–MS/MS analysis of quercetin and selected quercetin 
metabolites in rat serum  
2.8.1 Preparation of serum 
In order to remove proteins from serum prior to LC–MS/MS analysis, acetone (50 
µL) and CH3COOH (2 µL) were vigorously mixed with serum (50 µL). Additionally, 
1 µL genistein (1 µg/mL in methanol) was added to the mixture as an internal 
standard. The mixture was centrifuged at 7000g for 15 minutes; the supernatant was 
removed and was subject to further LC–MS/MS analysis. 
2.8.2 LC–MS/MS analysis 
Analysis was performed on an Agilent Technologies 1200 Series high–performance 
liquid chromatograph coupled with Agilent Technologies 6410A Triple Quad tandem 
mass spectrometer with electrospray ion source, and controlled by Agilent 
Technologies MassHunter Workstation software – Data Acquisition (ver. B.03.01). 
Separation was carried out using a Zorbax Eclipse XDB–C18 analytical column (4.6 
× 50 mm, 1.8 μm particle size). The column was maintained at 50ºC and a binary 
gradient separation was performed using a flow rate of 1 mL/min. The mobile phase 
consisted of 0.05% HCOOH in water (A) and 100% methanol (B). The gradient 
profile started at 30% B, reaching 70% B in 6.00 minutes, then 100% B at 9.00 
minutes, holding 100% B until 12.00 minutes, with a post-time of 3 minutes. The 
injection volume was 10 μL and the autosampler needle was washed with acetonitrile 
between injections to eliminate carryover. Eluted components were detected by MS, 
using the ion source parameters as follows: nebulization gas (N2) pressure 60 psi, 
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drying gas (N2) flow 11 L/min and temperature 350ºC, capillary voltage 4 kV. All 
compounds were quantified in selected reaction monitoring mode. Compound–
specific, optimized MS/MS parameters are given in Table 2–5. For all the 
compounds, peak areas were determined using the Agilent MassHunter Workstation 
Software – Qualitative Analysis (ver. B.03.01). Calibration curves were plotted and 
samples’ concentrations calculated using OriginLab’s Origin Pro (ver. 8.0) software. 
Table 2–5 Optimized LC–MS/MS parameters 
compound 
retention 
time 
(min) 
ionisation 
mode 
fragmentor 
voltage 
(V) 
precursor 
ion 
(m/z) 
product 
ion 
(m/z)* 
collision 
energy 
(V)* 
quercetin–3,4’–di–O–
glucoside 
1.46 ni 200 625 463, 301 15, 35 
quercetin–3–O–
glucuronide 
2.11 ni 145 477 301, 151 20, 20 
isorhamnetin–3–O–
glucoside 
2.94 ni 180 477 314, 243 30, 45 
quercetin 3.65 ni 130 301 151 20 
genistein 4.09 ni 145 269 133 30 
tamarixetin/isorhamnetin 4.76 ni 150 315 300 20 
penta–methylquercetin 6.17 pi 175 373 312, 357 25, 30 
 
ni – negative ionization 
pi – positive ionization 
*second number represents qualifier ion parameter 
2.9 Statistical analysis 
All quantitative data are presented as mean ± standard error of the mean (SEM) of at 
least three different independant trials. Statistical significant difference between two 
groups through all study was determined using the Student’s two-tailed unpaired t-
test. Statistical significance was set at p≤0.05. Charts were drawn using Microsoft 
Office Excel 2007. Graphs were drawn using Origin software version 8.0. 
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3. EFFECT OF ORAL QUERCETIN ON IRON 
HOMEOSTASIS 
3.1 Introduction 
In mammals iron excretion is not regulated, therefore regulation of iron homeostasis 
is tightly controlled by intestinal iron absorption, so it matches daily obligatory loses. 
This is particularly important throughout periods of high iron demand, such as 
growth of infants, children and adolescents and the reproductive period for women, 
particularly in pregnancy, during which poor iron absorption can lead to impairment 
of health, in both mother and child (Papanikolaoua and Pantopoulos, 2005; 
Abbaspour et al., 2014). It is important that systemic levels of iron must be balanced 
within a narrow range, as both iron overload and iron deficiency are detrimental to 
human health leading to metabolic, neurodegenerative and haematological disorders. 
There are two forms of iron, haem and non-haem iron. Non-haem iron availability in 
duodenum is regulated by a number of dietary factors, which either enhance or 
inhibit absorption in the duodenum. Non-haem iron is mainly present as the Fe
3+
 
form which is very poorly bioavailable. In order for this to be available/absorbed, 
Fe
3+
 iron must be reduced to Fe
2+
 form. This is achieved by the combined action of 
Dcytb, a ferrireductase that is present on the apical membrane of the duodenal 
enterocyte or dietary reducing agent, such as dietary ascorbic acid. Reduced iron in 
the Fe
2+
 form is then transported across the apical iron symporter, DMT1. Fe
2+
 is 
then transferred across the basolateral membrane via an iron exporter, FPN, 
reoxidised by a membrane-attached ferroxidase, Heph, and loaded on to Tf. 
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In addition to dietary enhancers there are number of components in our diet which 
have an inhibitory effect on non-haem iron absorption in duodenum, included 
amongst these are phytic acid and polyphenols. This property of polyphenols is 
mostly attributed to their ability to chelate iron. The inhibitory effect of polyphenols 
has been demonstrated in single meal studies in human volunteers and acute in vitro 
studies. The long term effect of consuming elevated levels of polyphenols on iron 
status and mechanism of action is not clear (Disler et al., 1975; Rossander et al., 
1979; Hurrell et al., 1999; Hurrell and Egli, 2010; Petry, 2014). 
The flavonol quercetin is the most abundant flavonoid in our diet and is especially 
enriched in onions, tea and apples. 
The aims of this study were to investigate the acute and long term effect of oral 
quercetin on iron metabolism in vivo (in rats) and to determine the mechanism of 
how quercetin influences iron absorption in rats. 
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3.2 Results 
3.2.1 Acute effect of quercetin on iron metabolism in vivo 
The acute effect of quercetin on iron methabolism was studied in vivo in rats 5 hours 
after oral administration of quercetin (50 mg/kg body weight) or 10% DMSO 
(control). After weaning rats were placed on low iron diet for two weeks. At the end 
of the experimental procedure animals were whether killed by administering a 
terminal dose of pentobarbitone sodium and blood samples were removed via cardiac 
puncture or were subject to uptake studies. Regarding first animal group, serum was 
separated and used for serum iron and transferrin saturation measurements using 
stadard spectrophotometric methods. Additionally, duodenum, liver and spleen were 
removed and subsequently used for tissue non-haem iron spectrophotometric 
measurements and gene expression levels determination. Uptake studies comprised 
of instaling 
59
Fe
2+
 inside the cannulated duodenum for 30 minutes while rats were 
anesthetized. After 30 minutes, blood samples were collected via cardiac puncture 
and duodenal mucosa was scraped away and subsequently gamma counted for 
determination of 
59
Fe activity. 
3.2.1.1 Acute effect of quercetin on serum iron and transferrin 
saturation 
Serum iron and transferrin saturation levels were significantly decreased in rats 
treated with a single dose of quercetin (50 mg/kg) by gavage five hours before being 
used for experiments (see Figure 3–1). 
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Figure 3–1 Acute effect of orally administered quercetin on serum iron and 
transferrin saturation in rats. 
The acute effect of quercetin on serum iron and transferrin saturation were measured 
5 hours after oral administration of quercetin (50 mg/kg body weight) or 10% DMSO 
(control) to rats. Data are mean ± SEM; n=5 rats per group; *denotes significant 
difference from the 10% DMSO control group (p<0.05). 
3.2.1.2 Acute effect of quercetin on duodenal iron transporters and 
Dcytb gene expression and iron content 
Five hours after oral administration of a single dose of quercetin, quantitative RT–
PCR analysis of rat duodenal iron transporters and Dcytb revealed a significant up-
regulation of DMT1. But no change in expression in any of the other genes was 
observed (see Figure 3–2). In addition, no significant difference was observed in 
duodenal iron levels between the treated and control groups (see Figure 3–3). 
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Figure 3–2 Acute effect of orally administered quercetin on duodenal iron 
transporters and Dcytb gene expression in rats. 
Rats were given a single gavage containing quercetin (50 mg/kg body weight) or 
DMSO 10% (control). After 5 hours, RNA was isolated from duodenal tissue to 
measure changes in iron transporters and Dcytb mRNA levels. Data are mean ± 
SEM; n=5 rats per group; *denotes significant difference from the 10% DMSO 
control group (p<0.05). 
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Figure 3–3 Acute effect of orally administered quercetin on duodenal iron 
content in rats. 
The acute effect of quercetin on duodenal iron content was measured 5 hours after 
oral administration of quercetin (50 mg/kg body weight) or 10% DMSO (control) to 
rats. Data are mean ± SEM; n=5 rats per group. 
3.2.1.3 Acute effect of quercetin on liver hepcidin, FPN and HO–1 
gene expression and iron content 
Analysis of hepcidin, FPN and HO–1 gene expression in liver of rats sacrificed five 
hours after oral treatment with quercetin, showed a significant, more then double, 
reduction in hepcidin mRNA levels (see Figure 3–4). However, expression of FPN 
and HO–1 mRNA stayed the same after the same treatment (see Figure 3–4). In 
addition, no difference was observed in liver iron levels between the treated and 
control groups (see Figure 3–5). 
100 
 
Figure 3–4 Acute effect of orally administered quercetin on liver hepcidin, FPN 
and HO–1 gene expression in rats. 
Rats were given a single gavage containing quercetin (50 mg/kg body weight) or 
DMSO 10% (control). After 5 hours RNA was isolated from liver tissue to measure 
changes in corresponding mRNA levels. Data are mean ± SEM; n=5 rats per group; 
*denotes significant difference from the 10% DMSO control group (p<0.05). 
 
 
Figure 3–5 Acute effect of orally administered quercetin on liver iron content in 
rats. 
The acute effect of quercetin on liver iron content was measured 5 hours after oral 
administration of quercetin (50 mg/kg body weight) or 10% DMSO (control) to rats. 
Data are mean ± SEM; n=5 rats per group. 
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3.2.1.4 Acute effect of quercetin on spleen hepcidin and FPN gene 
expression and iron content 
Five hours after oral treatment with quercetin rats were sacrificed and estimation of 
hepcidin and FPN mRNA levels was done. Analysis showed a significant increase in 
both hepcidin and mRNA levels (see Figure 3–6). Additionally, the spleen iron level 
was significantly greater in the treated animal group compared with the control group 
(see Figure 3–7). 
 
Figure 3–6 Acute effect of orally administered quercetin on spleen hepcidin and 
FPN gene expression in rats. 
Rats were given a single gavage containing quercetin (50 mg/kg body weight) or 
DMSO 10% (control). After 5 hours RNA was isolated from spleen tissue to measure 
changes in corresponding mRNA levels. Data are mean ± SEM; n=5 rats per group; 
*denotes significant difference from the 10% DMSO control group (p<0.05). 
 
102 
 
Figure 3–7 Acute effect of orally administered quercetin on spleen iron content 
in rats. 
The acute effect of quercetin on spleen iron content was measured 5 hours after oral 
administration of quercetin (50 mg/kg body weight) or 10% DMSO (control) to rats. 
Data are mean ± SEM; n=5 rats per group; *denotes significant difference from the 
10% DMSO control group (p<0.05). 
3.2.1.5 Acute effect of quercetin on iron absorption in duodenum 
Mucosal 
59
Fe uptake in rat duodenum was significantly increased five hours after a 
single dose of quercetin given orally by gavage (50 mg/kg; see Figure 3–8). In 
contrast, in the same group of animals, mucosal 
59
Fe transfer was significantly 
decreased after the same treatment (see Figure 3–8). 
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Figure 3–8 Acute effect of orally administered quercetin on iron absorption in 
duodenum in rats. 
Rats were given a single gavage containing quercetin (50 mg/kg body weight) or 
DMSO 10% (control). After 5 hours mucosal 
59
Fe uptake and 
59
Fe transfer were 
measured. Data are mean ± SEM; n=5 rats per group; *denotes significant difference 
from the 10% DMSO control group (p<0.05). 
3.2.2 Longer-term effect of quercetin on iron metabolism in vivo 
The longer-term effect of quercetin on iron methabolism was studied in vivo in rats 
18 hours after oral administration of quercetin (50 mg/kg body weight) or 10% 
DMSO (control). After weaning rats were placed on low iron diet or regular diet for 
two weeks. At the end of the experimental procedure animals were killed by 
administering a terminal dose of pentobarbitone sodium and blood samples were 
removed via cardiac puncture. Subsequentlly, serum was separated and used for 
serum iron and transferrin saturation measurements using stadard spectrophotometric 
methods. Additionally, duodenum, liver and spleen were removed and subsequently 
used for tissue non-haem iron spectrophotometric measurements and gene expression 
levels determination. 
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Longer-term effect of quercetin on iron absorption in duodenum was sudied in rats 
treated by a double gavage containing quercetin (50 mg/kg body weight) or 10% 
DMSO, for 18 hours and then 5 hours. Afterwards, uptake studies were performed 
where 
59
Fe
2+
 was put inside the cannulated duodenum for 30 minutes while rats were 
anesthetized. After 30 minutes, blood samples were collected via cardiac puncture 
and duodenal mucosa was scraped away and subsequently gamma counted for 
determination of 
59
Fe activity. 
3.2.2.1 Longer-term effect of quercetin on serum iron and 
transferrin saturation 
Serum iron and transferrin saturation levels were significantly decreased in rats fed 
on iron-deficient diet and treated with a single dose of quercetin (50 mg/kg) by 
gavage eighteen hours before being used for experiment (see Figure 3–9; A). 
However, the oppsite outcome was observed in the same parameters in rats fed on 
RM1 diet and treated with single dose of quercetin (50 mg/kg) by gavage eighteen 
hours before being used for experiment. In the treated group serum iron and 
transferrin saturation levels were significantly increased compared with control (see 
Figure 3–9; B). 
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Figure 3–9 Longer-term effect of orally administered quercetin on serum iron 
and transferrin saturation in rats. 
The longer-term effect of quercetin on serum iron and transferrin saturation was 
measured 18 hours after oral administration of quercetin (50 mg/kg body weight) or 
10% DMSO (control). Data are mean ± SEM; n=4 (A); 3 (B) rats per group; 
*denotes significant difference from the 10% DMSO control group (p<0.05). 
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3.2.2.2 Longer-term effect of quercetin on duodenal iron 
transporters and Dcytb gene expression and iron content 
Analysis of the iron transporters (DMT1 and FPN) and Dcytb mRNA expression in 
duodenum of rats fed an iron-deficient diet and sacrificed eighteen hours after oral 
treatment with quercetin showed a significant reduction in DMT1 and FPN mRNA 
levels. It should be noted, that mRNA levels of DMT1 changed nearly 10-fold, while 
levels of FPN changed nearly 2–fold. Additionally, after the same treatment levels of 
Dcytb mRNA levels stayed the same (see Figure 3–10; A). Furthermore, in the 
duodenum of the same group of animals, levels of HIF–1α and HIF–2α mRNA were 
also examined, but no expression was observed (results not shown). The same 
treatment, but with rats fed on RM1 diet, brought about a significant increment in 
Dcytb and FPN mRNA levels between 2- to 3-fold (see Figure 3–10; B). In the same 
group of animals levels of DMT1 mRNA were also increased but not significant (see 
Figure 3–10; B). Duodenal iron levels increased significantly after single longer-term 
oral quercetin treatment in rats fed on an iron-deficient and a normal diet with 
respect to iron content (Figure 3–11; A and B, respectively). 
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Figure 3–10 Longer-term effect of orally administered quercetin on duodenal 
iron transporters and Dcytb gene expression in rats. 
The longer-term effect of quercetin on duodenal iron transporters and Dcytb gene 
expression was measured 18 hours after oral administration of quercetin (50 mg/kg 
body weight) or 10% DMSO (control). Data are mean ± SEM; n=4 (A); 3 (B) rats 
per group; *denotes significant difference from the 10% DMSO control group 
(p<0.05) 
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Figure 3–11 Longer-term effect of orally administered quercetin on duodenal 
iron content in rats. 
The longer-term effect of quercetin on duodenal iron content was measured 18 hours 
after oral administration of quercetin (50 mg/kg body weight) or 10% DMSO 
(control). Data are mean ± SEM; n=4 (A); 3 (B) rats per group; *denotes significant 
difference from the 10% DMSO control group (p<0.05). 
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3.2.2.3 Longer-term effect of quercetin on liver hepcidin, FPN and 
related gene expression and iron content 
Analysis of hepcidin, FPN and HO–1 mRNA expression in liver of rats fed an iron-
deficient diet and sacrificed eighteen hours after oral treatment with quercetin did not 
show significant changes in their levels compared with controls (see Figure 3–12; A). 
Furthermore, in the liver of the same group of animals levels of GST and QR mRNA 
were also followed, but no significant change was evidenced (results not shown). 
The same treatment, but with rats fed on a RM1 diet, caused a significant increase in 
FPN mRNA levels of nearly 4-fold, while mRNA levels of hepcidin and HO–1 were 
not affected with the applied treatment (see Figure 3–12; B). In the same group of 
animals levels of GST were analyzed, but no significant change occurred (results not 
shown). Liver iron levels increased in both groups of animals, but a significant 
change was only evidenced after single longer-term oral quercetin treatment in rats 
fed on an iron-deficient diet where iron levels increased 1.5-fold (Figure 3–13; A). 
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Figure 3–12 Longer-term effect of orally administered quercetin on liver 
hepcidin, FPN and HO–1 gene expression in rats. 
The longer-term effect of quercetin on liver hepcidin, FPN and HO–1 gene 
expression was measured 18 hours after oral administration of quercetin (50 mg/kg 
body weight) or 10% DMSO (control). Data are mean ± SEM; n=4 (A); 3 (B) rats 
per group; *denotes significant difference from the 10% DMSO control group 
(p<0.05). 
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Figure 3–13 Longer-term effect of orally administered quercetin on liver iron 
content in rats. 
The longer-term effect of quercetin on liver iron content was measured 18 hours after 
oral administration of quercetin (50 mg/kg body weight) or 10% DMSO (control). 
Data are mean ± SEM; n=4 (A); 3 (B) rats per group; *denotes significant difference 
from the 10% DMSO control group (p<0.05). 
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3.2.2.4 Longer-term effect of quercetin on spleen hepcidin and FPN 
gene expression and iron content 
Analysis of hepcidin and FPN mRNA expression in the spleen of rats fed on an iron-
deficient diet and sacrificed eighteen hours after oral treatment with quercetin 
showed a noteworthy decrease in hepcidin mRNA expression. In addition, FPN 
mRNA levels in the same group of animals were lower but not significant (see 
Figure 3–14; A). The same treatment, but in rats fed on a RM1 diet, did not cause a 
significant change in the two examined mRNA levels (see Figure 3–14; B). Spleen 
iron levels significantly increased in the first group of animals (see Figure 3–15; A), 
while in animals where the RM1 diet was applied, no significant change in spleen 
iron levels was observed (Figure 3–15; B). 
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Figure 3–14 Longer-term effect of orally administered quercetin on spleen 
hepcidin and FPN gene expression in rats. 
The longer-term effect of quercetin on splenic hepcidin and FPN gene expression 
was measured 18 hours after oral administration of quercetin (50 mg/kg body 
weight) or 10% DMSO (control). Data are mean ± SEM; n=4 (A); 3 (B) rats per 
group; *denotes significant difference from the 10% DMSO control group (p<0.05). 
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Figure 3–15 Longer-term effect of orally administered quercetin on spleen iron 
content in rats. 
The longer-term effect of quercetin on splenic iron content was measured 18 hours 
after oral administration of quercetin (50 mg/kg body weight) or 10% DMSO 
(control). Data are mean ± SEM; n=4 (A); 3 (B) rats per group; *denotes significant 
difference from the 10% DMSO control group (p<0.05). 
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3.2.2.5 Longer-term effect of quercetin on iron absorption in 
duodenum 
The effect on iron absorption in duodenum after longer-term gavage was similar to 
that following the shorter-term quercetin gavage treatment shown previously (see 
3.2.1.5). Namely, mucosal 
59
Fe uptake was significantly increased after a double 
dose of quercetin (50 mg/kg) given orally by gavage eighteen hours and then five 
hours before the experiment (see Figure 3–16). In contrast, in the same group of 
animals, mucosal 
59
Fe transfer was significantly decreased after the same treatment 
(see Figure 3–16). 
 
Figure 3–16 Longer-term effect of orally administered quercetin on iron 
absorption in duodenum in rats. 
Rats were given a double gavage containing quercetin (50 mg/kg body weight) or 
10% DMSO, for 18 hours and then 5 hours, after which mucosal 
59
Fe uptake and 
59
Fe transfer were measured. Data are mean ± SEM; n=5 rats per group; *denotes 
significant difference from the 10% DMSO control group (p<0.05). 
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3.2.3 Chronic effect of quercetin on iron metabolism in vivo 
The chronic effect of quercetin on iron methabolism was studied in vivo in rats after 
oral administration of quercetin (50 mg/kg body weight) or 10% DMSO (control), 
where quercetin tretement was applied once per day during 10 days. Afterwards, 
animals were killed by administering a terminal dose of pentobarbitone sodium and 
blood samples were removed via cardiac puncture. Subsequentlly, serum was 
separated and used for serum iron and transferrin saturation measurements using 
stadard spectrophotometric methods. Additionally, duodenum, liver and spleen were 
removed and subsequently used for tissue non-haem iron spectrophotometric 
measurements and gene expression levels determination. 
3.2.3.1 Chronic effect of quercetin on serum iron and transferrin 
saturation 
Serum iron and transferrin saturation levels were unchanged in rats after ten days 
oral quercetin treatment (50 mg/kg each day) compared with controls (see Figure 3–
17). 
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Figure 3–17 Chronic effect of orally administered quercetin on serum iron and 
transferrin saturation in rats.  
The chronic effect of quercetin on serum iron and transferrin saturation were 
measured after oral administration of quercetin (50 mg/kg body weight) or 10% 
DMSO (control), during 10 days, single per day. Data are mean ± SEM; n=5 rats per 
group. 
3.2.3.2 Chronic effect of quercetin on duodenal iron transporters 
and Dcytb gene expression and iron content 
Analysis of iron transporters (DMT1 and FPN) and Dcytb mRNA expression in 
duodenum of rats day–to–day treated with quercetin during ten days showed a 
significant decrease in DMT1, Dcytb and FPN mRNA levels (2.2, 1.6 and 1.8 fold, 
respectively; see Figure 3–18). Furthermore, in the duodenum of the same group of 
animals levels of HIF–1α and HIF–2α mRNA were also followed. However there 
was no change in HIF–1α levels, while there was no expression of HIF–2α mRNA 
levels (results not shown). In addition, no difference was observed in duodenal iron 
levels between the treated and control groups (see Figure 3–19). 
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Figure 3–18 Chronic effect orally administered quercetin on duodenal iron 
transporters and Dcytb gene expression in rats. 
The chronic effect of quercetin on duodenal iron transporters and Dcytb gene 
expression was measured after oral administration of quercetin (50 mg/kg body 
weight) or 10% DMSO (control), during 10 days, single per day. Data are mean ± 
SEM; n=5 rats per group; *denotes significant difference from the 10% DMSO 
control group (p<0.05). 
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Figure 3–19 Chronic effect of orally administered quercetin on duodenal iron 
content in rats. 
The chronic effect of quercetin on duodenal iron content was measured after oral 
administration of quercetin (50 mg/kg body weight) or 10% DMSO (control), during 
10 days, single per day. Data are mean ± SEM; n=5 rats per group. 
3.2.3.3 Chronic effect of quercetin on hepcidin, FPN and HO–1 gene 
expression and iron content 
Analysis of hepcidin, FPN and HO–1 mRNA expression in liver of rats fed on an 
iron-deficient diet and treated daily with quercetin for ten days showed a noteworthy 
increased in HO–1 levels (see Figure 3–20). However, other mRNA levels (hepcidin 
and FPN) were unchanged after chronic treatment with quercetin compared with 
control (see Figure 3–20). In addition, liver iron levels decreased significantly after 
the same treatment compared with the control (see Figure 3–21). 
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Figure 3–20 Chronic effect of orally administered quercetin on liver hepcidin, 
FPN and HO–1 gene expression in rats. 
The chronic effect of quercetin on liver hepcidin, FPN and HO–1 gene expression 
was measured after oral administration of quercetin (50 mg/kg body weight) or 10% 
DMSO (control), during 10 days, single per day. Data are mean ± SEM; n=5 rats per 
group. Data are mean ± SEM; n=5 rats per group; *denotes significant difference 
from the 10% DMSO control group (p<0.05). 
 
Figure 3–21 Chronic effect of orally administered quercetin on liver iron 
content in rats. 
The chronic effect of quercetin on liver iron content was measured after oral 
administration of quercetin (50 mg/kg body weight) or 10% DMSO (control), during 
10 days, single per day. Data are mean ± SEM; n=5 rats per group; *denotes 
significant difference from the 10% DMSO control group (p<0.05). 
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3.2.3.4 Chronic effect of quercetin on spleen hepcidin and FPN gene 
expression and iron content 
Analysis of hepcidin and FPN mRNA expression in spleen of rats fed on an iron-
deficient diet and treated daily with quercetin for ten days showed no significant 
change between treated and control animal group (see Figure 3–22). However, spleen 
iron levels decreased significantly after the same treatment compared with the 
control group (see Figure 3–23). 
 
Figure 3–22 Chronic effect of orally administered quercetin on spleen hepcidin 
and FPN gene expression in rats. 
The chronic effect of quercetin on spleen hepcidin and FPN gene expression was 
measured after oral administration of quercetin (50 mg/kg body weight) or 10% 
DMSO (control), during 10 days, single per day. Data are mean ± SEM; n=5 rats per 
group. 
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Figure 3–23 Chronic effect of orally administered quercetin on spleen iron 
content in rats. 
The chronic effect of quercetin on splenic iron content was measured after oral 
administration of quercetin (50 mg/kg body weight) or 10% DMSO (control), during 
10 days, single per day. Data are mean ± SEM; n=5 rats per group; *denotes 
significant difference from the 10% DMSO control group (p<0.05). 
3.2.3.5 Distribution of quercetin metabolites in serum after oral 
guercetin administration 
Quantitative analysis of quercetin and five selected quercetin metabolites in rat 
serum, after short-term, longer-term and chronic oral quercetin treatment, was 
performed using the LC–MS/MS technique. The contents of the determined 
compounds are presented in Table 3–2. Only quercetin–3–O–glucuronide was 
detected in the serum of the rats treated short-term or longer-term with quercetin, 
while no other examined compounds were identified. After short-term oral quercetin 
treatment (rats were treated with single dose of quercetin (50 mg/kg) given by 
gavage five hours before being used for experiment) the concentration of quercetin–
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3–O–glucuronide was 12.65 ng/mL of serum. The lower concentration of quercetin–
3–O–glucuronide (0.37 ng/mL of serum) was determined in rats fed a RM1 diet and 
treated with a single dose of quercetin (50 mg/kg) by gavage eighteen hours before 
the experiment. After chronic oral quercetin treatment neither quercetin nor the five 
selected metaboplites were detected. 
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Table 3–1 Concentrations of quercetin and selected quercetin metabolites in rat serum after acute, longer-term and chronic oral 
quercetin treatment determined by LC–MS/MS technique 
treatment* 
content of quercetin and selected quercetin metabolites 
(ng/mL serum) 
quercetin–3,4’–di– 
O–glucoside 
quercetin–3– 
O–glucuronide 
isorhamnetin–3– 
O–glucoside 
quercetin isorhamnetin 
quercetin–3,5,7,3’,4’–
penthamethylether 
acute treatment 
(5 hours before 
experiment; 
iron-deficient diet) 
10% DMSO (control) nd nd nd nd nd nd 
quercetin (50 mg/kg) nd 12.65 ± 0.99 nd nd nd nd 
longer–term treatment 
(18 hours before 
experiment; RM1 diet) 
10% DMSO (control) nd nd nd nd nd nd 
quercetin (50 mg/kg) nd 0.37 ± 0.023 nd nd nd nd 
chronic treatment 
(single day-to-day during 
ten days; 
iron-deficient diet) 
10% DMSO (control) nd nd nd nd nd nd 
quercetin (50 mg/kg) nd nd nd nd nd nd 
nd – not detected 
*serum from rats treated with quercetin 18 hours before experiment and fed on an iron-deficient diet are not included in the study due to the lack of serum 
 
125 
3.3 Discussion 
In this chapter short–term, longer–term and chronic effects of quercetin administered 
orally by gavage on iron homeostasis in rats were investigated. All the results are 
summarised in Table 3–2. The results indicate that the period of gavage with 
quercetin had significant, but somewhat different, effects on iron homeostasis and 
gene expression. To be more precise, in the shor-term, longer-term and chronic 
setting quercetin generally caused iron deficiency in rats that were fed on an iron-
deficient diet prior to the experiment. Iron deficiency was evident from the 
significant reduction in liver and spleen iron pools, as well as the reduction in serum 
iron and transferrin saturation levels. However, these results came as no surprise 
because many authors previously have shown that consumption of a diet rich in 
polyphenols caused iron deficiency in vivo. For example, thirty years ago Merhav et 
al. (1985) recognized that the main cause of IDA in infants in Israel was regular tea 
drinking, while Hamdaoui et al. (2005) and Marouani et al. (2007) provided evidence 
for iron deficiency after tea consumption in rats. My results indicate that oral 
quercetin treatment generally induced iron deficiency in all treated groups. However, 
there is a great difference in the change of gene expression of the monitored mRNA 
levels and tissue iron levels in duodenum, liver and spleen, between the different 
treated groups. 
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Table 3–2 Summary of the effect of oral quercetin on iron homeostasis 
treatment obtained results 
acute treatment 
(5 hours before experiment; 
iron-deficient diet) 
10% DMSO (control) Serum: Iron↓*, transferrin saturation↓* 
Duodenum: DMT1↑*, Dcytb↑, GLUT1↑, SGLT1=, FPN↑, Iron= 
Liver: Hepcidin↓*, FPN=, HO–1↑, Iron= 
Spleen: Hepcidin↑*, FPN↑*, Iron↑* quercetin (50 mg/kg) 
longer-
term 
treatment 
(18 hours before 
experiment; iron-
deficient diet) 
10% DMSO (control) 
Serum: Iron↓*, transferrin saturation↓* 
Duodenum: DMT1↓*, Dcytb↓, GLUT1=, SGLT1↑*, FPN↓*, HIF–1α (no expression), HIF–2α (no 
expression), Iron↑* 
Liver: Hepcidin↓, FPN=, HO–1=,GST↑, QR↓, Iron↑* 
Spleen: Hepcidin ↓*, FPN↓ Iron↑* 
quercetin (50 mg/kg) 
(18 hours before 
experiment; RM1 
diet) 
10% DMSO (control) Serum: Iron↑*, transferrin saturation↑* 
Duodenum: DMT1↑, Dcytb↑*, GLUT1 no expression, SGLT1↑*, FPN↑*, Iron↑* 
Liver: Hepcidin↑, FPN↑*, HO–1↑, GST=, Iron↑ 
Spleen: Hepcidin=, FPN=, Iron= quercetin (50 mg/kg) 
chronic treatment 
(single day-to-day during ten 
days; 
iron-deficient diet) 
10% DMSO (control) Serum: Iron=, transferrin saturation= 
Duodenum: DMT1↓*, Dcytb↓*, GLUT1↓, SGLT1↓*, FPN↓*, HIF–1α↓, HIF–2α no expression, Iron↑ 
Liver: Hepcidin=, FPN↓, HO–1↑*, Iron↓* 
Spleen: Hepcidin↑, FPN=, Iron↓* 
quercetin (50 mg/kg) 
results in red and marked with * indicate that parameter significantly differ from treated and corresponding control group 
↑ indicate that parameter increased, but not significantly, between treated and corresponding control group 
↓ indicate that parameter decreased, but not significantly, between treated and corresponding control group 
= indicate that parameter did not change in treated group compared with corresponding control group 
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Specifically, short-term oral quercetin treatment, caused a significant up-regulation 
of mRNA for the iron transporter DMT1 mRNA in enterocytes. This result seems 
logical as an organism during iron deficiency makes every effort to boost iron 
uptake. This outcome was also confirmed previously in duodenal biopsy specimens 
of iron-deficient patients. Zoller et al., (2001) showed that both mRNA and protein 
levels of DMT1 and FPN were significantly up-regulated in iron-deficient patients 
compared with healthy subjects. Similarly, up-regulation of DMT1, Dcytb and FPN 
mRNA levels was reported in the duodenum of four iron-deficient mice strains 
(Dupic et al., 2002), while McKie et al. (2001) confirmed an increase in Dcytb 
mRNA and protein levels in the duodenum of iron-deficient mice. However, in this 
thesis, Dcytb and FPN mRNA levels were increased but not significantly, regardless 
of iron deficiency. However, it is not clear whether changes in mRNA levels of 
proteins that are involved in iron uptake are due to iron deficiency caused by 
quercetin or directly by quercetin itself. There is no evidence in the literature that 
polyphenols, or specifically quercetin, affect duodenal gene expression in this 
manner in vivo, apart from a recent study where following polyphenol-rich bean 
consumption for six weeks by chickens, levels of DMT1, Dcytb and FPN mRNA did 
not show any significant difference (Tako et al., 2014). An in vitro experiment with 
Caco–2 cells treated with quercetin for 24 hours did not show a significant change in 
DMT1 or Dcytb, while FPN mRNA levels were decreased (Hoque and Sharp, 2010), 
whereas treatment with flavonoid-rich berry extract for 16 hours decreased DMT1 
mRNA levels in the same cells (Alzaid et al., 2010). 
Furthermore, in our study quercetin administered orally short-term to rats caused a 
decrease in liver hepcidin mRNA expression. This is likely to reflect the low 
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transferrin saturation and low iron in the serum of rats treated with quercetin for 5 
hours. A decreased expression of liver hepcidin has been shown to be associated with 
iron deficiency and induction of DMT1 mRNA (Frazer et al., 2004; Papanikolaou et 
al., 2005). In contrast to liver hepcidin, in the same group of rats, spleen hepcidin 
mRNA levels were significantly up-regulated. One possible explanation for this is 
that polyphenols increase hepcidin expression in both tissues, but only the liver 
hepcidin expression is sensitive to serum iron levels and this is the dominant factor in 
the repression of hepcidin expression. The other possible explanation is that hepcidin 
expression is regulated in a tissue-specific manner in response to quercetin 
administration. Independent of the mechanism of increased hepcidin expression in 
spleen, it is tempting to suggest that the increased hepcidin in the spleen binds to 
spleen FPN, leading to its internalization which leads to a decreased iron efflux 
thereby causing an increased spleen iron and decreased serum iron and transferrin 
saturation as observed in this study. However, this view should be confirmed with an 
increase in FPN protein levels, not just with mRNA. Furthermore, decreased serum 
iron will also be contributed by a decreased efflux of iron from the duodenum in 
quercetin-treated rats as shown in this study with uptake experiments. The effect of 
quercetin on iron efflux is likely to be independent of hepcidin as liver hepcidin 
expression levels, the major contributor to serum iron, are significantly decreased 
after quercetin treatment. However, increased spleen FPN expression in quercetin 
treated rats is in agreement with previous studies which have shown that polyphenols 
increase FPN expression by promoting its expression by increasing Nrf2 levels 
which then bind to an ARE in the promoter of FPN (Marro et al., 2010). Also it 
could be proposed that the increased spleen FPN expression is a direct consequence 
of a decrease in hepatic hepcidin levels, which leads to splenic FPN re-expression on 
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the membrane. Also, these results support the view that internalization of FPN as a 
response to hepcidin is tissue- and cell-specific. Namely, it was shown that 
macrophages respond more acutely to a hepcidin challenge, while the duodenum 
appears to be less sensitive to a rise in hepcidin levels (Chaston et al., 2008; 
Masaratana et al., 2011). Moreover, FPN levels in spleen might be under post-
transcriptional IRE/IRP control, which when iron levels in tissue are high, expression 
of FPN is up-regulated (Muckenthaler et al., 2008). 
However, uptake studies after short–term, as well as after longer-term, quercetin 
treatment caused a significant increase of mucosal iron uptake, while there was a 
significant decrease in iron efflux from enterocytes. These results solidly confirm 
that quercetin plays an important role in the bioavailability of non-haem iron in the 
duodenum. In particular, decreased iron transfer is probably due to chelation of iron 
by quercetin which increases apical uptake of iron, but prevents basolateral transport. 
This explanation can be applied to all polyphenols that have a noticeable capacity to 
chelate iron, particularly those which are abundant in the diet. These results were 
only preliminary to a further, more detailed, study of the chelation property of 
quercetin and its effect on iron absorption in duodenum, which is presented in 
Chapter 4. 
Furthermore, the possibility cannot be discarded that quercetin, or its metabolites, 
have direct effects on the expression of proteins involved in iron absorption and 
systemic homeostasis, and that together with chelation this modifies iron 
metabolism. This fact is even more important bearing in mind that uptake studies 
after longer-term quercetin treatment showed a decrease in iron uptake. Eighteen 
hours is a long period for quercetin to remain in lumen or inside the enterocyte, thus, 
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it is more likely that after 18 hours there is no quercetin in place to form a complex 
with iron, and the only explanation of its effect is to cause changes in expression of 
proteins involved in iron metabolism. 
It was pointed out previously that longer-term oral quercetin treatment caused iron 
deficiency in animals fed an iron-deficient diet. Namely, 18 hours after quercetin 
treatment serum iron and transferrin saturation levels were reduced significantly. 
This result is the same as after short-term oral quercetin treatment. Surprisingly, 
levels of iron in spleen and liver were significantly higher, which is not in 
accordance with the iron-deficient status. This occurrence was previously shown for 
spleen after short-term oral quercetin treatment. At this moment is it hard to explain 
this results. Additionally, in the same group of animals, duodenal iron was increased 
which confirms previously explained hypotheses that quercetin supports iron uptake, 
but not iron transfer across mucosa. Iron retention in the duodenum probably down-
regulated DMT1 mRNA levels, as shown in this thesis, through the IRE/IRP control 
mechanism, such that when iron levels in tissue are high, expression of DMT1 is 
supressed (Muckenthaler et al., 2008). Though the same control mechanism should 
increase FPN levels in the duodenum, FPN mRNA levels decreased. However, it was 
proven that duodenal enterocytes express a FPN transcript, FPN1B, which lacks the 
IRE and thus is not affected by iron-excessive conditions (Zhang et al., 2009). Thus, 
the FPN -IRE form could mostly contribute to FPN down-regulation in the intestine 
under overall iron-deficient conditions. However, this is just an assumption as the 
mechanism of this action is hard to explain with the current limited data. Splenic 
hepcidin mRNA also decreased, however this occurrence is also hard to explain. 
However following results discussed previously, this data supports the hypothesis of 
different tissue-specific hepcidin isoforms. Namely, proven effects that lower 
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hepcidin should increase DMT1 levels in the duodenum was absent, as well as up-
regulation of FPN. 
After chronic ten-day-long treatment with quercetin, animals became iron-deficient, 
as both spleen and liver iron pools decreased. This was observed previously in vivo. 
Namely, quercetin reduced the liver iron content after an induced tissue iron-
overload. This effect was attributed to the ability of quercetin to combine with non-
haem iron in tissue, transport it to the bloodstream and excrete it from the body, 
which supported the use of quercetin and other polyphenols as medicines in iron-
related disorders (Zhang et al., 2011). This issue was also confirmed in this study for 
both liver and spleen. This also supports the need for further research of polyphenols 
as potential new chelating drugs. Furthermore, the observed reduction in iron pools 
was most probably due to the tendency of to keep serum iron levels in balance. 
Surprisingly, at the same time, levels of the duodenal iron transporters decreased. 
Specifically, mRNA levels of DMT1, Dcytb and FPN were significantly down 
regulated. Additionally, in the same group of animals duodenal iron was slightly 
increased, which could partly explain this outcome. Namely, it is discussed 
previously that quercetin supports iron uptake, but not iron transfer, across mucosa. 
Thus, iron retention in the duodenum could down-regulate DMT1 mRNA levels 
through the IRE/IRP control system. However, down-regulation of Dcytb and FPN 
during iron deficiency is difficult to explain, particularly in the light of data showing 
up-regulation of the examined genes after longer-term quercetin treatment. Also, 
HO–1 mRNA levels were up-regulated in the liver of the same animals, which is in 
accordance with the established observation fact that polyphenols, particularly 
quercetin, increase the levels of antioxidant enzymes (Liu et al., 2012b). 
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Results from the group of animals that was kept on a normal diet and treated with 
quercetin for 18 hours, differ considerably from previous results. Namely, animals 
were not iron-deficient. Furthermore, levels of serum iron and transferrin saturation 
increased. Additionally, mRNA levels of Dcytb and FPN in the duodenum and FPN 
in the liver increased significantly. Up-regulation of these genes corresponds to a 
iron-deficient state, as was discussed earlier. Also, duodenal iron levels increased, 
which confirms that quercetin promotes duodenal iron uptake. The complexity of 
changes in parameters could be the result of an initial iron-deficient state, while after 
eighteen hours the animal has regained normal iron balance. By comparing results 
from animals fed an iron-deficient and normal diet, it is evident that the iron content 
of the diet greatly affects the investigated parameters of iron metabolism. In the 
literature it is known that differences in dietary iron content greatly affects 
expression of iron metabolism-related genes (Li et al., 2013). However, it looks like 
those animals that are kept on an iron-deficient diet are more suitable models for 
research in the field of iron metabolism, because they are more sensitive to applied 
treatments and the results are more pronounced. 
Furthermore, it was proven in vivo that HIF–2α is a main transcriptional factor which 
regulates the expression of genes involved in iron uptake and is critical for 
compensating iron deficiency by increasing iron absorption. Namely, it was shown 
that HIF–2α expression is significantly induced by iron deficiency in the duodenum 
and that it is followed by increase in DMT1 and Dcytb levels (Shah et al., 2009). 
However, this view was not confirmed in this study. Specifically, there was no 
expression of HIF–2α mRNA in the duodenum of treated rats, regardless of iron 
deficiency and changes in DMT1 and Dcytb mRNA levels. 
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Analysis of quercetin and selected quercetin metabolites concentrations in rat serum 
after short-term, longer-term and chronic oral quercetin treatment by LC–MS/MS 
technique aimed to assess which metabolites are present in the serum and at what 
concentration. This was important for subsequent experiments in which THP1 cells 
and HepG2 cells were treated with metabolites in order to investigate their potential 
role in expression of iron metabolism-related genes. The result of qualitative and 
quantitative studies in this thesis are in agreement with previous data where one of 
the dominant quercetin metabolites in serum was also quercetin-glucuronide, present 
in similar concentrations to those shown here. Additionally, results confirmed that 
quercetin has a short half–life as it was not detected in serum more than 5 hours after 
oral treatment (Gee et al., 2004; Justino et al., 2004; Moon et al., 2008). 
3.4 Conclusions 
In conclusion, short-term, longer-term and chronic oral administration of quercetin 
caused iron deficiency in rats. Furthermore, after different time of treatments, single 
or double dose and different concentrations of quercetin, the disturbance in iron 
balance was compensated by different mechanisms. However, the main mechanism 
seems to be an increase of iron absorption and release of iron from liver and splenic 
pools. 
Additionally, data confirms that quercetin increases mucosal iron uptake and inhibits 
iron efflux from duodenal mucosa. Still it is not clear if this effect is only due to 
chelation of iron by quercetin or whether quercetin, or its metabolites, has a direct 
effect on the expression of proteins involved in iron absorption and systemic 
homeostasis. Specifically, oral quercetin treatment mostly affected mRNA levels of 
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duodenal DMT1, Dcytb and FPN. These results also indicate that oral quercetin has a 
great effect on iron absorption and a minor effect on systemic iron regulation. 
However, the exact mechanism of the action of quercetin on iron metabolism 
remains to be fully elucidated. 
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4. MECHANISM OF THE DIRECT EFFECT OF 
QUERCETIN ON INTESTINAL IRON ABSORPTION 
IN THE DUODENUM 
4.1 Introduction 
Balancing systemic iron levels within narrow limits is critical for human health, as 
both iron deficiency and iron overload leads to serious haematological, metabolic 
and neurodegenerative disorders. In mammals there are no known pathways to 
eliminate excess iron from the body and therefore iron homeostasis is maintained by 
its absorption, recycling and its loss (Yehuda and Mostofsky, 2010). Therefore to 
maintain iron balance, especially during the growth period and pregnancy when extra 
iron is needed, essential iron must be provided by the food. 
Nutritional iron absorption occurs primarily in the duodenum, on the apical (luminal) 
membrane of the enterocytes, and is tightly regulated by bioavailable iron, iron 
stores, erythropoietic drive and inflammation. From a common diet, average iron 
bioavailability rate is low. Namely, approximately 10–20 mg of iron is consumed 
daily by diet, from which 10% is absorbed. This amount of absorbed iron fulfils daily 
needs, but it can be easily reduced eventually leading to IDA. There are two types of 
dietary iron: non-haem iron, which is present in food from both animal or plant 
origin, and haem iron, which is present only in food of animal origin. Haem iron 
makes up only 10–15% of the total iron from the diet in meat-eating populations, but, 
it is estimated to contribute more then 40% of total absorbed iron. Despite its great 
occurrence in general diet, rate of non-haem iron absorption is much lower than it is 
the case with haem iron (Hurrell and Egli, 2010).  
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Low bioavailability of non-haem iron contributes greatly to IDA, which is the most 
prevalent nutritional deficiency worldwide, estimated to affect two billion people 
(World Health Organisation, 2007), especially in low-income countries where 
people’s diets are based on plants and where consumption of meat is low, and 
consequently, availability of haem iron is minimal. On the other hand, the same 
problem occurs in groups eating mostly or strictly plant based diet, such as 
vegetarians and vegans whose popularity is rising in modern societies, or in groups 
which do not consume meat due to religious issues. 
It is generally believed that bioavailability of non-haem iron highly depends on 
presence of promoters or inhibitors of dietary iron absorption. On the other hand, it is 
supposed that dietary factors have little effect on haem iron absorption. Among 
inhibitors of iron absorption, dietary polyphenols are marked as one of the most 
potent. Polyphenols are a group of plant secondary metabolites which include vast 
number of structurally diverse compounds. From a chemical point of view, they are 
compounds which contain one or more aromatic rings, bearing one or more hydroxyl 
groups, which can be esterified, etherified or glycosylated. Polyphenols are present 
in nearly all edible fruits, vegetables and other food of plant origin, as well as in 
beverages. Generally, human population consumes notable amounts of polyphenols 
on a daily basis, approximately 1 g and even more in the regions where diet is mainly 
based on plant sources, such as in developing countries. Dietary polyphenols are 
receiving increasing attention worldwide due to their proven health benefits for a 
variety of disorders (Havsteen, 2002). However, the negative impact of dietary 
polyphenols on non-haem iron absorption in duodenum has been highlighted 
previously (Cook et al., 1995; Hurrell et al., 1999; Samman et al., 2001; Kim et al., 
2008; Petry et al., 2010). The exact mechanism of how polyphenols reduce 
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bioavailability of non-haem iron is not fully understood, but it is proposed that 
polyphenols have this effect as a result of their ability to chelate iron (Petry et al., 
2010; Kim et al., 2011). 
Bearing in mind that IDA is the most prevalent nutritional deficiency worldwide 
(World Health Organisation, 2007) and dietary polyphenols are consumed in 
increasing levels due to their health benefits, it is important to elucidate the exact 
mechanism by which dietary polyphenols suppress non-haem iron absorption in the 
duodenum. By elucidating the mechanism, polyphenol consumption could be 
optimised in order to contribute to overall health. 
The polyphenol quercetin, a wel-known iron chelating agent, is ingested daily in 
great amounts (16 mg/day; Olthof et al., 2000) and thus it was considered worthwhile 
to investigate the chelation effect of quercetin, its methylated forms, and resveratrol, 
a polyphenol that do not possess iron chelation ability, on duodenal non-haem iron 
absorption using an in vivo uptake method. 
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4.2 Results 
To investigate the effects of quercetin on duodenal non-haem iron absorption, the in 
situ duodenal loop method was carried out, where either quercetin (aglycone) or 
methylated quercetin isoforms or resveratrol were introduced into the rat duodenum 
together with radioactive iron. Afterwards, radioactive measurements of blood 
samples and duodenal mucosa were preformed in order to estimate mucosal iron 
uptake and mucosal iron transfer. 
In the presence of quercetin, 3–O–methylquercetin, 4’–O–methylquercetin, 3,4’–
dimethylquercetin, but not penta–methylquercetin, there was a significant increase in 
mucosal 
59
Fe uptake compared with the untreated control group (see Figure 4–1). 
The increase in uptake was significantly higher in the presence of quercetin aglycone 
and 4’–O–methylquercetin compared with the other methylated forms (see Figure 4–
1). Additionally, there was no difference in mucosal 
55
Fe uptake when resveratrol 
was introduced compared with the untreated control group (see Figure 4–2).  
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Figure 4–1 Effect of quercetin and its metabolites on mucosal iron uptake in 
rats 
Effects of quercetin and its methylated analogues on iron transport in vivo were 
measured using the in situ duodenal loop method. 
59
Fe and polyphenol were added to 
the lumenal uptake buffer and mucosal iron uptake was measured. Data are mean ± 
SEM; n=5 rats per group; groups with no common letters are significantly different 
from each other (p<0.05). 
 
 
Figure 4–2 Effect of resveratrol on mucosal iron uptake in rats 
Effect of resveratrol on iron transport in vivo was measured using the in situ 
duodenal loop method. 
55
Fe and resveratrol were added to the lumenal uptake buffer 
and mucosal iron uptake was measured. Data are mean ± SEM; n=5 rats per group. 
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Furthermore, 
59
Fe release from the intestinal mucosa into the blood was significantly 
diminished in the presence of quercetin, 3–O–methylquercetin, 4’–O–
methylquercetin, 3,4’–dimethylquercetin, but not penta–methylquercetin, compared 
with the control group (see Figure 4–3). The decrease iron transfer was significantly 
emphasized in the presence of quercetin aglycone and 4’–O–methylquercetin 
compared with the other methylated forms (see Figure 4–3). In contrast, when 
resveratrol was introduced into the duodenum together with 
55
Fe, iron transfer was 
the same as in the control group (see Figure 4–4). 
 
Figure 4–3 Effect of quercetin and its metabolites on mucosal iron transfer in 
rats 
Effects of quercetin and its methylated analogues on iron transport in vivo were 
measured using the in situ duodenal loop method. 
59
Fe and polyphenol were added to 
the lumenal uptake buffer and mucosal iron transfer was measured. Data are mean ± 
SEM; n=5 rats per group; groups with no common letters are significantly different 
from each other (p<0.05). 
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Figure 4–4 Effect of resveratrol on mucosal iron transfer in rats 
Effect of resveratrol on iron transport in vivo was measured using the in situ 
duodenal loop method. 
55
Fe and resveratrol were added to the lumenal uptake buffer 
and mucosal iron transfer was measured. Data are mean ± SEM; n=5 rats per group. 
4.3 Discussion 
In Chapter 3 of this thesis it was shown that quercetin increases iron uptake and 
retention by the duodenal mucosa in vivo. However, it is not clear what is the exact 
mechanism behind this phenomenon, but it is assumed that iron chelation by 
quercetin could play an important role. 
Previously it has been shown that the preferred site for iron chelation by quercetin is 
between the 3–hydroxyl and 4–carbonyl group. However, for complexes containing 
one iron and one quercetin molecule, the binding strength of chelation site has an 
order 3–4 > 4–5 > 3ʼ–4ʼ (see Figure 4–5; Ren et al., 2008). Moreover, the 3–4 
chelation site is also preferred for complexes which are formed between one iron and 
two or three quercetin molecules (see Figure 4–5; Ren et al., 2008). 
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Figure 4–5 Structures of complexes between Fe3+ and quercetin 
Therefore, in order to elucidate the importance of iron chelating by quercetin in 
transepithelial iron transport, in vivo uptake experiments were performed with 
quercetin aglycone and the methylated forms of quercetin, as well as resveratrol (see 
Figure 4–6). The main aim of this experiment was to determine whether replacing 
the putative iron-binding groups of quercetin would influence iron transport across 
the intestine. Additionally, an experiment was performed with the polyphenol 
resveratrol, which lacks iron chelating ability. 
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Figure 4–6 Structures of methylated forms of quercetin and resveratrol 
Results in this thesis revealed that when quercetin was introduced into the duodenum 
together with 
59
Fe, 85% of the total absorbed iron stayed in the mucosa, while only 
15% crossed into the circulation. These results were opposite to those in the control 
group where no polyphenol was introduced into duodenum and 89% of total of 
absorbed 
59
Fe was detected in the circulation. Additional uptake studies with the 
methylated quercetin forms showed that the iron chelation power of the investigated 
compounds was in correlation with the decrease of transepithelial iron transport. The 
iron chelation power of the examined compounds decrease in the order quercetin > 
4’–O–methylquercetin > 3–O–methylquercetin ≥ 3,4’–dimethylquercetin > 
pentamethylquercetin. In the same order amount of transepithelial iron transport 
increased. Namely, when each polyphenol, quercetin, 4’–O–methylquercetin, 3–O–
methylquercetin, 3,4’–dimethylquercetin and pentamethylquercetin, was introduced 
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into duodenum 15%, 35%, 73%, 73% and 91% of total of absorbed iron was detected 
in the circulation, respectively. In accordance with that, mucosal uptake decreased in 
same order and when each of listed polyphenols was introduced into duodenum, 
85%, 65%, 27%, 27% and 9% of total of absorbed iron stayed in mucosa, 
respectively). Our data clearly indicate that the greatest increase in transepithelial 
iron transport was observed with compounds where 3–hydroxyl groups were 
methylated (3–O–methylquercetin, 3,4’–dimethylquercetin and 
pentamethylquercetin). In contrast, when the 3–hydroxyl group was present, that is in 
quercetin and 4’–O–methylquercetin, there was a decrease in transepithelial iron 
transport. These results demonstrate that chelation of iron by the 3–hydroxyl group 
of quercetin is an important determinant of iron uptake in the duodenum. In other 
words, transepithelial iron transport increased as the iron chelating power of the 
compounds decreased. 
This is also confirmed with the experiment with resveratrol where inhibition of 
transepithelial iron transport was lacking (i.e. resveratrol does not have structural 
characteristics which are required for iron chelation, such as hydroxyl and carbonyl 
group in near vicinity or galloyl group). Resveratrol was chosen as the polyphenol 
abundant in a plant-based diet, particularly in red wine that is known to decrease iron 
absorption in intestine (Bezwoda et al., 1985; Cook et al., 1995). 
The above results firmly confirm that the decrease in mucosal iron transfer is due to 
chelation of iron by quercetin which increases apical uptake of iron, but prevents 
basolateral transport. This explanation can be applied to all polyphenols that have a 
noticeable capacity to chelate iron, particularly those which are present in the diet 
and thus can directly affect iron absorption. This phenomenon was previously shown 
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for other polyphenols, particularly for (–)–epigallocatechin–3–gallate, but in in vitro 
conditions using Caco–2 cells as a model system (Kim et al., 2008; Kim et al., 2011). 
Kim et al. (2008; 2011) reported their finding as unexpected as it was common to 
think that polyphenols inhibit iron absorption by preventing mainly apical uptake of 
non-haem iron. My findings greatly contribute to a revision of this concept, 
especially by providing the first in vivo results. Further information that supports this 
hypothesis is the fact that the quercetin–Fe complex is considerably stable in 
gastrointestinal conditions. Namely, it was proven in vitro, by mimicking conditions 
that occur in the stomach, that the recovery of quercetin–Fe complex is up to 45%, 
which supports the importance of chelation of iron by quercetin in the human body 
(Escudero et al., 2014). 
However, the precise place of iron chelation by quercetin is still uncertain. It is still 
unknown whether chelation occurs in the duodenal lumen or the cytosol of duodenal 
enterocytes. One explanation could be that iron is chelated by quercetin in the 
duodenal lumen by forming the apical–membrane–permeable quercetin–Fe complex 
that cannot cross the basolateral membrane of enterocyte. Despite its great size, there 
are in vitro reports that support transport of the quercetin–Fe complex across the cell 
membrane in both directions (Baccan et al., 2012). Furthermore, there is evidence 
that quercetin–Fe complex is transported by GLUTs transporters 
(Vlachodimitropolou et al., 2011), which could also be the case in vivo. Furthermore, 
even though it was proven that quercetin can be transported via GLUTs 1, 3 and 4 
transporters, quercetin is lipophilic enough so it can easily cross lipid bilayers 
without interaction with transporters (Strobel et al., 2005; Cunningham et al., 2006; 
Vlachodimitropoulou et al., 2011). A second possibility is that that quercetin could 
influx into the cell and then form a complex with free iron. Additionally, it was 
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shown that quercetin may operate as a substrate for DcytB by increasing its reduction 
potential and providing more Fe
2+
 for cellular uptake by DMT1 
(Vlachodimitropoulou et al. 2010). Knowing this, quercetin could firstly chemically 
reduce non-haem iron and thus increase apical uptake followed by formation of the 
quercetin–Fe complex inside the cell. However, this hypothesis would not affect the 
results in this study, as ascorbic acid was added to the uptake buffer which is likely 
to keep free iron in the Fe
2+
 form. Therefore both luminal and cytosolic iron 
chelation, or their combination, can provoke iron accumulation within duodenal 
mucosa in vivo. However, in both cases the quercetin–Fe complex could remain in 
the enterocyte due to the inhibition of FPN function or simply because the quercetin–
Fe complex would be too bulky to be transported by FPN. Furthermore, the 
quercetin–Fe complex inside the cell could be a negative signal for the IRE/IRP 
system and thus destabilize FPN mRNA. Thus by chelating iron quercetin could 
lower free iron levels inside the cell and thus trigger the post-transcriptional IRE/IRP 
control system, such that when iron levels in tissue are reduced, expression of FPN is 
decreased (Muckenthaler et al., 2008). Furthermore, the possibility that quercetin or 
its metabolites have direct inhibitory effects on the function of FPN should not be 
discounted. Together these mechanisms could account for the increased mucosal iron 
retention observed in the present study. Furthermore, if a quercetin–Fe complex is 
formed inside the cell, it could be proposed that quercetin could affect absorption of 
haem iron too. Namely, quercetin could also prevent export of free iron for the haem 
source, after haem degradation by HO–1 which occurs in the cytosol after its 
absorption. This theory is only an assumption because not sufficient experimental 
work has been carried out to tnvestigate this further. 
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4.4 Conclusions 
In conclusion the presented results are the first evidence that specific polyphenols 
inhibit in vivo non-haem iron absorption in the duodenum through chelation. It was 
shown that quercetin chelates iron within via its 3–hydroxyl group and thus prevents 
transepithelial non-haem iron transport across the enterocyte by increasing apical 
iron uptake and decreasing the basolateral iron release. However, the precise place of 
iron chelation by quercetin, luminal or cytosolic, is still uncertain. The ultimate aim 
of this research is the use of polyphenols in the future as drugs for treating iron 
metabolism disorders. Specifically, quercetin and other polyphenols with chelation 
properties could be used as a part of so-called chelato-therapies, where their ability to 
chelate iron can be used in iron-overload conditions to reduce iron absorption or to 
modify tissue iron distribution. However, it is obvious that the use of quercetin and 
polyphenols should be avoided in iron deficiency, especially during oral 
consumption of iron, either as a natural constituent of the diet or as a food 
supplement. 
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5. SYSTEMIC EFFECTS OF QUERCETIN (IP) ON IRON 
HOMEOSTASIS 
5.1 Introduction 
Polyphenols are well known for their numerous health benefits, which are mostly 
attributed to their ability to scavenge highly reactive free radical species or up-
regulate transcription of cytoprotective enzymes (Williamson et al., 1996; Havsteen, 
2002; Molina et al., 2003; Masella et al., 2005; Sharma, 2014). 
Their antioxidant potential is, at least partially, associated with their ability to chelate 
iron. Despite iron’s essential role in life, excess iron is toxic. Namely, surplus iron 
induces oxidative stress and reactive oxygen species, which in turn causes the 
oxidation of lipids, proteins and nucleic acids (Halliwell and Gutteridge, 2007). The 
introduction of new iron chelating drugs may ultimately improve iron-chelation 
therapy for patients with iron overload diseases, such as -thalassemia and 
haemochromatosis. Research in the light of selecting the most effective and least 
toxic drug, or drug combinations, is evolving (Kontoghiorghes, 2003; Poggiali et al., 
2012). 
Like most other flavonoids, it was also proven  that quercetin possesses a high ability 
to chelate iron (Leopoldini et al, 2006). Furthermore, it has been proven in vivo that 
quercetin is able to decrease intracellular iron, which makes it as valuable 
representative of new chelato therapeutics for iron-redistribution therapy (Zhao et al., 
2005; Zhang et al., 2006; Zhang et al., 2011; Baccan et al., 2012). 
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Polyphenols were shown to up-regulate hepcidin along with up-regulation of 
transcription of a battery of cytoprotective genes, in a preliminary study in our lab 
using in vitro HepG2 culture cell model (personal communication with Henry K. 
Bayele and Sara Balesaria). It was reasoned that the hepcidin gene, as a main iron 
regulatory hormone, might be a member of the battery of genes that are involved in 
coordinating cellular responses to oxidative stress.  
The aims of this study were to investigate the effect of quercetin on systemic iron 
regulation in vivo (in rats) and determine the mechanism of its action. 
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5.2 Results 
5.2.1 Effects of quercetin IP administration on iron metabolism in 
vivo at various times after administration 
The effect of IP quercetin on iron methabolism was studied in vivo in rats 0 or 2, 5, 
12 and 18 hours after a single IP, or duoble IP 18 and then 5 hours before being 
sacrificed containing quercetin (50 mg/kg body weight) or 10% DMSO (control). 
After weaning rats were placed on low iron diet or regular diet for two weeks. At the 
end of the experimental procedure animals were killed by administering a terminal 
dose of pentobarbitone sodium and blood samples were removed via cardiac 
puncture. Subsequentlly, serum was separated and used for serum iron and 
transferrin saturation measurements using stadard spectrophotometric methods. 
Additionally, duodenum, liver, spleen and kidney were removed and subsequently 
used for tissue non-haem iron spectrophotometric measurements and gene expression 
levels determination. 
5.2.1.1 Effect of quercetin on serum iron and transferrin saturation 
Serum iron and transferrin saturation levels were significantly decreased five hours 
after a single IP treatment of quercetin (50 mg/kg) to rats fed on an iron-deficient 
diet, while 12 and 18 hours after the same treatment both serum iron and transferrin 
saturation increased significantly compared with the group that was killed right after 
the quercetin treatment (see Figure 5–1). Furthermore, serum iron and transferrin 
saturation levels decreased significantly in rats fed on an iron-deficient diet and 
treated with double quercetin IP treatment (see Figure 5–2; A). However, serum iron 
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and transferrin saturation in rats fed on normal iron diet and treated with double 
quercetin IP treatment showed no change (see Figure 5–2; B). 
 
 
Figure 5–1 Effects of a single quercetin IP treatment on serum iron and 
transferrin saturation in rats at different times. 
The effects of quercetin on serum iron and transferrin saturation were measured 0 or 
2, 5, 12 and 18 hours after a single IP containing quercetin (50 mg/kg body weight) 
or 10% DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per group; 
groups with no common letters are significantly different from each other (p<0.05). 
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Figure 5–2 Effects of double quercetin IP treatment on serum iron and 
transferrin saturation in rats. 
The effects of quercetin on serum iron and transferrin saturation were measured in 
rats that were IP with quercetin (50 mg/kg body weight) or 10% DMSO (control) 
eighteen and then five hours before being sacrificed. Data are mean ± SEM; n=5 (A); 
4 (B) rats per group; *denotes significant difference from the 10% DMSO control 
group (p<0.05). 
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5.2.1.2 Effect of quercetin on gene expression in duodenum, liver, 
spleen and kidney 
Analysis of iron transporters (DMT1, FPN) and Dcytb mRNA expression in 
duodenum of rats fed on an iron-deficient diet and sacrificed at different times after 
IP treatment with quercetin, generally showed a significant increase of all three 
examined genes. DMT1 mRNA levels increased significantly 12 hours after 
quercetin IP treatment (2.5-fold), while levels of Dcytb and FPN mRNA levels 
increased notably earlier then DMT1, i.e. 5 hours after the treatment (1.6- and 1.3-
fold, respectively). It should be noted, that mRNA levels of Dcytb followed the trend 
of a significant increase 12 and 18 hours after quercetin IP treatment (2.4- and 3.9-
fold, respectively; see Figure 5–3). Furthermore, after double quercetin IP treatment 
with rats fed on an iron-deficient diet, analysis of the same genes in duodenum 
showed the opposite results. Specifically, DMT1, Dcytb and FPN mRNA levels 
significantly decreased (5.7-, 4.4- and 2.0-fold, respectively; see Figure 5–4; A). Rats 
fed on a normal iron diet (RMI) and treated with quercetin showed no significant 
change in examined duodenal genes (see Figure 5–4; B). 
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Figure 5–3 Effects of a single quercetin IP treatment on duodenal iron 
transporters and Dcytb gene expression in rats at different times. 
The effects of quercetin on duodenal gene expression was measured 0 or 2, 5, 12 and 
18 hours after a single IP containing quercetin (50 mg/kg body weight) or 10% 
DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per group; groups 
with no common letters are significantly different from each other (p<0.05). 
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Figure 5–4 Effects of double quercetin IP treatment on duodenal iron 
transporters and Dcytb gene expression in rats. 
The effects of quercetin on duodenal gene expression was measured in rats that were 
treated with quercetin (50 mg/kg body weight) or 10% DMSO (control) eighteen and 
then five hours before being sacrificed. Data are mean ± SEM; n=5 (A); 4 (B) rats 
per group; *denotes significant difference from the 10% DMSO control group 
(p<0.05). 
156 
Analysis of hepcidin gene expression in liver, spleen and kidney of rats fed on an 
iron-deficient diet and sacrificed 5 hours after IP treatment with different quercetin 
concentrations showed a notably increase of examined gene expression in liver (see 
Figure 5–5). In spleen and kidney hepcidin gene levels fluctuated but not in as large 
range as in liver (see Figure 5–5). Namely, maximal change in hepcidin mRNA 
levels in liver occurred 5 hours after quercetin treatment, when levels of mRNA 
showed a 175-fold increase (see Figure 5–5). Additionally, maximal change in 
hepcidin mRNA levels in kidney occurred 12 hours after quercetin treatment, when 
levels of mRNA showed a 35-fold increase (see Figure 5–5). The peak change of a 2-
fold increase in hepcidin mRNA levels in spleen happened 2 hours after quercetin 
treatment (see Figure 5–5). Furthermore, after double quercetin IP treatment with rats 
fed on an iron-deficient diet, analysis of the hepcidin gene in liver showed an 
enormous increase of 1031-fold (see ; A). Furthermore, in the same animals a vast 
increase of hepcidin mRNA in kidney also occurred (9.5-fold), while the same did 
not occur in spleen (see ; A). Double quercetin IP treatment, but with rats fed on a 
RM1 diet, also brought a significant change in hepcidin mRNA levels in liver (3-fold 
increase), however hepcidin mRNA levels in spleen and kidney decreased 
significantly (2.3- fold and 1.6-fold, respectively, see ; B). 
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Figure 5–5 Effects of a single quercetin IP treatment on hepcidin gene 
expression in liver, spleen and kidney in rats at different times. 
The effects of quercetin on hepcidin gene expression in liver, spleen and kidney was 
measured 0 or 2, 5, 12 and 18 hours after a single IP containing quercetin (50 mg/kg 
body weight) or 10% DMSO (control) given to rats. Data are mean ± SEM; n=4 rats 
per group; groups with no common letters are significantly different from each other 
(p<0.05).
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Figure 5–6 Effects of 
double quercetin IP 
treatment on hepcidin 
gene expression in liver, 
spleen and kidney in 
rats. 
The effects of quercetin on 
hepcidin gene expression 
in liver, spleen and kidney 
was measured in rats that 
were IP with quercetin (50 
mg/kg body weight) or 
10% DMSO (control) 
eighteen and then five 
hours before being 
sacrificed. Data are mean 
± SEM; n=5 (A); 4 (B) 
rats per group; *denotes 
significant difference from 
the 10% DMSO control 
group (p<0.05).  
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Liver HO–1 gene expression notably changed in rats fed on an iron-deficient diet and 
sacrificed at different times after quercetin treatment (see Figure 5–7). The maximal 
change in HO–1 mRNA levels in liver occurred 5 hours after quercetin treatment, 
when levels of mRNA showed a 13.3-fold increase (see Figure 5–7). Additionally, 
levels of liver FPN mRNA did not change after the same quercetin treatment. In 
contrast to liver FPN, mRNA levels of spleen FPN fluctuated during the experiment, 
and reached a maximal decrease 2 and 12 hours after quercetin treatment (1.3- and 
1.35-fold, respectively; see Figure 5–7). Furthermore, double quercetin IP treatment 
with rats fed on an iron-deficient diet, caused a significant increase in mRNA levels 
of HO–1, ferritin and QR in liver (11.8-, 1.8- and 1.7-fold, respectively; Figure 5–8; 
A). The same treatment provoked a significant decrease in FPN mRNA levels in both 
liver and spleen (1.5- and 1.8-fold, respectively; Figure 5–8; A). Double quercetin IP 
treatment, but with rats fed on RM1 diet, brought about a significant change in liver 
HO–1 and spleen FPN mRNA levels (3.9- fold and 1.5-fold increase, respectively; 
see Figure 5–8; B), while other examined genes were not affected with the treatment. 
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Figure 5–7 Effects of a single quercetin IP treatment on FPN and HO–1 gene 
expression in liver and spleen in rats at different times. 
The effects of quercetin on liver and splenic gene expression was measured 0 or 2, 5, 
12 and 18 hours after a single IP containing quercetin (50 mg/kg body weight) or 
10% DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per group; 
groups with no common letters are significantly different from each other (p<0.05). 
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Figure 5–8 Effects of double quercetin IP treatment on relevant gene expression 
in liver and spleen in rats. 
The effects of quercetin on liver and splenic gene expression was measured in rats 
that were IP with quercetin (50 mg/kg body weight) or 10% DMSO (control) 
eighteen and then five hours before being sacrificed. Data are mean ± SEM; n=5 (A); 
4 (B) rats per group; *denotes significant difference from the 10% DMSO control 
group (p<0.05). 
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5.2.1.3 Effect of quercetin on iron content in duodenum, liver and 
spleen 
Single quercetin IP administration, during different time intervals, affected the iron 
content of duodenum, liver and spleen of rats fed with an iron-deficient diet (see 
Figure 5–9). Namely, duodenal iron levels significantly increased 2 hours after 
quercetin IP treatment. After that, duodenal iron followed an upward trend and 
reached its maximum value 12 hours after the treatment (see Figure 5–9). However, 
liver iron stayed the same until 18 hours after the treatment, when a significant 
decrease occurred (see Figure 5–9). Furthermore, spleen iron increased during the 
experiment and reached its maximum value 5 hours after the treatment. After 5 
hours, levels of spleen iron dropped, but were still being significantly higher than at 
the start of experiment (see Figure 5–9). 
Moreover, duodenal and liver iron levels increased significantly, while the iron levels 
of spleen stayed the same, in rats which were fed on an iron-deficient diet and 
received double quercetin IP treatment (see ; A). However, only liver iron increased 
significantly, while iron levels of duodenum and spleen stayed the same, after the 
same treatment in rats fed on a diet with a regular iron content (see ; B). 
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Figure 5–9 Effects of a single quercetin IP treatment on iron content in 
duodenum, liver and spleen in rats at different times. 
The effects of quercetin on duodenal, liver and splenic iron content was measured 0 
or 2, 5, 12 and 18 hours after a single IP containing quercetin (50 mg/kg body 
weight) or 10% DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per 
group; groups with no common letters are significantly different from each 
otherp<0.05) 
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Figure 5–10 Effects of 
double quercetin IP 
treatment on iron 
content in duodenum, 
liver and spleen in rats. 
The effects of quercetin on 
duodenal, liver and splenic 
iron content was measured 
in rats that were IP with 
quercetin (50 mg/kg body 
weight) or 10% DMSO 
(control) eighteen and 
then five hours before 
being sacrificed. Data are 
mean ± SEM; n=5 (A); 4 
(B) rats per group; 
*denotes significant 
difference from the 10% 
DMSO control group 
(p<0.05). 
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5.2.2 Effects of different IP dose of quercetin on serum iron 
metabolism in vivo 
The effect of IP quercetin on iron methabolism was studied in vivo in rats 5 after a 
single IP containing different quercetin concentrations (0, 2, 5, 10 and 20 mg/kg 
body weight) or 10% DMSO (control). At the end of the experimental procedure 
animals were killed by administering a terminal dose of pentobarbitone sodium and 
blood samples were removed via cardiac puncture. Subsequentlly, serum was 
separated and used for serum iron and transferrin saturation measurements using 
stadard spectrophotometric methods. Additionally, duodenum, liver, spleen and 
kidney were removed and subsequently used for tissue non-haem iron 
spectrophotometric measurements and gene expression levels determination. 
Effect of IP quercetin on iron absorption in duodenum was sudied in rats treated by a 
single IP 5 hours or double IP 18 hours and then 5 hours before experiment 
containing quercetin (50 mg/kg body weight) or 10% DMSO (control). Afterwards, 
uptake studies were performed where 
59
Fe
2+
 was put inside the cannulated duodenum 
for 30 minutes while rats were anesthetized. After 30 minutes, blood samples were 
collected via cardiac puncture and duodenal mucosa was scraped away and 
subsequently gamma counted for determination of 
59
Fe activity. 
5.2.2.1 Effect of quercetin on serum iron and transferrin saturation 
Serum iron and transferrin saturation levels were affected by single dose of quercetin 
(0, 2, 5, 10 and 20 mg/kg) given by IP five hours before being sacrificed (see Figure 
5–11). Namely, after IP quercetin treatment of 5 mg/kg serum iron and transferrin 
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saturation levels increased significantly. Furthermore, after IP quercetin treatment of 
10 and 20 mg/kg, they dropped compared with the 5 mg/kg dose group, but were 
significantly higher compared with the control group or the group treated with the 2 
mg/kg dose of quercetin (see Figure 5–11). 
 
Figure 5–11 Effects of different IP dose of quercetin on serum iron and 
transferrin saturation in rats. 
The effects of quercetin on serum iron and transferrin saturation were measured 5 
hours after a single IP containing quercetin (2, 5, 10 or 20 mg/kg body weight) or 
10% DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per group; 
groups with no common letters are significantly different from each other (p<0.05). 
5.2.2.2 Effect of quercetin on gene expression in duodenum, liver, 
spleen and kidney 
Analysis of the mRNA expression of the iron transporters (DMT1, and FPN) and 
Dcytb in the duodenum of rats fed on an iron-deficient diet and sacrificed five hours 
after IP treatment with different quercetin concentrations generally showed a 
significant increase in Dcytb and FPN mRNA. Namely, a quercetin dose of 5 mg/kg 
and 20 mg/kg provoked the highest jump of mRNA levels (see Figure 5–12). 
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However, DMT1 levels either decreased significantly or stayed the same after 
treatment with different quercetin concentrations (see Figure 5–12). 
 
Figure 5–12 Effects of different IP dose of quercetin on duodenal iron 
transporters and Dcytb gene expression in rats. 
The effects of quercetin on duodenal gene expression was measured 5 hours after a 
single IP containing quercetin (2, 5, 10 or 20 mg/kg body weight) or 10% DMSO 
(control) given to rats. Data are mean ± SEM; n=4 rats per group; groups with no 
common letters are significantly different from each other (p<0.05). 
Analysis of hepcidin gene expression in liver, spleen and kidney of rats fed on an 
iron-deficient diet and treated with different quercetin IP concentration (0-20 mg/kg) 
after 5 hours showed a notable increase of the examined gene only in liver (see 
Figure 5–13). Namely, a maximal change in hepcidin mRNA levels in the liver 
occurred 5 hours after 10 mg/kg quercetin treatment, when levels of mRNA showed 
a 50-fold increase (see Figure 5–13). While after other doses, levels of liver hepcidin 
mRNA varied but not significantly. Generally, levels of splenic and kidney hepcidin 
mRNA levels fluctuated after IP quercetin but not significantly, except in spleen after 
IP quercetin 20 mg/kg and kidney IP quercetin 10 mg/kg, when it reduced 
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significantly. Additionally, after different IP quercetin concentrations splenic FPN 
was not altered, while the same in spleen was significantly up-regulated only after a 
quercetin concentration of 20 mg/kg (see Figure 5–14). Furthermore, HO-1 mRNA 
levels increased significantly after 10 and 20 mg/kg IP quercetin 8- and 3.2-fold, 
respectively, compared with control (see Figure 5–14). 
 
Figure 5–13 Effects of different IP dose of quercetin on hepcidin gene 
expression in liver, spleen and kidney in rats. 
The effects of quercetin on hepcidin gene expression in liver, spleen and kidney was 
measured 5 hours after a single IP containing quercetin (2, 5, 10 or 20 mg/kg body 
weight) or 10% DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per 
group; groups with no common letters are significantly different from each other 
(p<0.05). 
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Figure 5–14 Effects of different IP dose of quercetin on FPN and HO–1 gene 
expression in liver and spleen in rats. 
The effects of quercetin on liver and splenic gene expression was measured 5 hours 
after a single IP containing quercetin (2, 5, 10 or 20 mg/kg body weight) or 10% 
DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per group; groups 
with no common letters are significantly different from each other (p<0.05). 
5.2.2.3 Effect of quercetin on iron content in duodenum, liver and 
spleen 
Different concentrations of quercetin IP treatment affected differently the iron 
content of duodenum, liver and spleen of rats fed with an iron-deficient diet (see 
Figure 5–15). Duodenal iron levels fluctuated depending on the applied quercetin 
concentrations. Namely, after 2 mg/kg quercetin IP treatment iron levels significantly 
increased, while when higher concentrations of IP quercetin was applied it exhibited 
decreasing trend (see Figure 5–15). Liver iron levels significantly changed only after 
10 and 20 mg/kg quercetin IP treatment (1.6- and 1.2-fold decrease compared with 
control, respectively), while it stayed the same after other applied concentrations (see 
Figure 5–15). Furthermore, spleen iron levels significantly dropped after 2 mg/kg 
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quercetin IP treatment, while it stayed the same after other applied quercetin 
concentrations compared with control (see Figure 5–15). 
 
Figure 5–15 Effects of different IP dose of quercetin on iron content in 
duodenum, liver and spleen in rats. 
The effects of quercetin on duodenal, liver and splenic iron content was measured 5 
hours after a single IP containing quercetin (2, 5, 10 or 20 mg/kg body weight) or 
10% DMSO (control) given to rats. Data are mean ± SEM; n=4 rats per group; 
groups with no common letters are significantly different from each other (p<0.05). 
5.2.3 Distribution of quercetin metabolites in serum after quercetin 
IP administration 
Quantitative analysis of quercetin and five selected quercetin metabolites in the 
serum of the rats, after different IP quercetin treatments, was performed using the 
LC–MS/MS technique. The contents of the determined compounds are presented in 
Table 5–1. Among the examined compounds only quercetin–3–O–glucuronide, 
quercetin and isorhamnetin were detected, while other examined compounds were 
not identified. Namely, after different time of single quercetin IP treatments (rats 
were treated with a single dose of quercetin (50 mg/kg) in different time periods, 
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from 0 to 18 hours, before being sacrificed) the concentration of quercetin–3–O–
glucuronide declined from 90.78 to 27.77 ng/mL in serum, while after 12 hours no 
compound was detected. In the same group of animals, parental quercetin declined in 
the same way as quercetin–3–O–glucuronide, while isorhamnetin was detected only 
in animals sacrificed right away after IP quercetin treatment. In sets of animals that 
were treated with a double dose of quercetin, where one group was on an iron-
deficient diet and the other on a normal iron content diet, quercetin–3–O–
glucuronide, quercetin and isorhamnetin were detected in similar amounts. In the last 
set of animals that were treated with increasing quercetin concentrations, only 
quercetin–3–O–glucuronide (from 11.65 to 113.57 ng/mL of serum) and quercetin 
(from 1.42 to 25.43 ng/mL of serum) were detected. 
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Table 5–1 Determined concentrations of quercetin and selected quercetin metabolites in rat serum after IP quercetin treatment by LC–
MS/MS technique 
treatment 
content of quercetin and selected quercetin metabolites 
(ng/mL serum) 
quercetin–3,4’–di– 
O–glucoside 
quercetin–3– 
O–glucuronide 
isorhamnetin–3– 
O–glucoside 
quercetin isorhamnetin 
quercetin–3,5,7,3’,4’–
penthamethylether 
d
if
fe
re
n
t 
ti
m
e 
o
f 
q
u
er
ce
ti
n
 t
re
a
tm
en
t 
0 hours before experiment 
quercetin 
(50 mg/kg) 
iron-deficient 
diet 
nd 90.8 ± 7.23 nd 104 ± 5.98 66.7 ± 3.24 nd 
2 hours before experiment nd 41.3 ± 3.22 nd 6.61 ± 0.45 nd nd 
5 hours before experiment nd 27.8 ± 1.78 nd 0.48 ± 0.01 nd nd 
12 hours before 
experiment 
nd nd nd nd nd nd 
18 hours before 
experiment 
nd nd nd nd nd nd 
18 hours and then 5 hours 
before experiment 
10% DMSO 
(control) 
nd nd nd nd nd nd 
quercetin 
(50 mg/kg) 
nd 22.6 ± 0.94 nd 20.9 ± 1.23 3.43 ± 0.23 nd 
18 hours and then 5 hours 
before experiment 
10% DMSO 
(control) 
RM1 diet 
nd nd nd nd nd nd 
quercetin 
(50 mg/kg) 
nd 99.8 ± 3.67 nd 13.3 ± 0.65 5.08 ± 0.39 nd 
tr
ea
tm
en
t 
w
it
h
 d
if
fe
re
n
t 
d
o
se
 o
f 
q
u
er
ce
ti
n
 
5 hours before experiment 
10% DMSO 
(control) 
iron-deficient 
diet 
nd nd nd nd nd nd 
quercetin 
(2 mg/kg) 
nd 16.8 ± 0.65 nd nd nd nd 
quercetin 
(5 mg/kg) 
nd 60.3 ± 3.21 nd nd nd nd 
quercetin 
(10 mg/kg) 
nd 11.6 ± 0.87 nd 1.42 ± 0.12 nd nd 
quercetin 
(20 mg/kg) 
nd 113 ± 2.89 nd 25.4 ± 1.23 nd nd 
nd - not detected 
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5.2.4 Effects of quercetin IP administration on iron absorption in 
duodenum 
After a single or double IP quercetin treatment, mucosal uptake and transfer of 
59
Fe 
remained the same. However, even though a slight increase in mucosal 
59
Fe uptake 
and a decrease in mucosal 
59
Fe transfer can be seen compared with controls, neither 
change was significant (see Figure 5–16; A and B). 
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Figure 5–16 Effects of quercetin IP administration on iron absorption in rat 
duodenum. 
The effect of quercetin on iron absorption was measured after single or double IP 
containing quercetin (50 mg/kg body weight) or 10% DMSO (control) given to rats. 
Data are mean ± SEM; n=5 rats per group. 
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5.3 Discussion 
In this chapter the effect of quercetin given IP on iron metabolism in rats was 
investigated. Summarizing results obtained in this chapter, it is evident that different 
IP time and concentrations of quercetin had significant, but somewhat different, 
effects on iron homeostasis and gene expression. Table 5–2 sums all the results 
obtained within this study. Additionally, when comparing results from the previous 
two chapters (Chapter 3 and 4), where rats were treated by polyphenols orally, with 
results from this chapter it is evident that the route of quercetin application affects 
iron metabolism. Namely, IP treatment mainly affected systemic iron homeostasis, 
mostly by regulating hepcidin expression, while oral quercetin mainly affected iron 
absorption. 
Specifically, after single quercetin treatment (50 mg/kg) major up-regulation of 
hepcidin mRNA occurred in liver and kidney. A vast increase in liver hepcidin was 
evident just 2 hours after quercetin treatment, reaching a peak after 5 hours (122- and 
175-fold, respectively). Subsequent, hepatic mRNA hepcidin levels decreased after 
12 and 18 hours, but were still significantly higher compared with the start of 
experiment (25- and 8-fold, respectively). Kidney mRNA hepcidin levels increased 
significantly 12 hours after quercetin application (35-fold), after which they went 
down, but still were higher than at the beginning of experiment. In the same 
experiment the impact of quercetin on splenic hepcidin mRNA was different from 
the same in the kidney and the liver. Namely, it reached a significant maximum 2 
hours after quercetin treatment (2-fold), followed with attenuation, reaching 
significant minimum 18 hours later (2-fold). 
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Table 5–2 Sums of results obtained in experiments regarding effects of IP quercetin on iron homeostasis 
treatment obtained results 
d
if
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n
t 
ti
m
e 
o
f 
q
u
er
ce
ti
n
 t
re
a
tm
en
t 
0 hours before 
experiment 
quercetin 
(50 mg/kg) 
iron-
deficient 
diet 
A 
tissue/serum parameter 
time of quercetin IP treatment 
(hours) 
0 2 5 12 18 
serum 
iron 
a ab ↓b ↑c ↑cd 
transfferin saturation 
a ab ↓b ↑c ↑cd 
duodenum 
DMT1 
a a a ↑b ab 
Dcytb 
a a ↑b ↑b ↑b 
FPN 
ac a ↑bd cde ae 
iron 
a ↑b ↑bd ↑c ↑d 
liver 
hepcidin 
a ↑b ↑bd ↑bd ↑cd 
FPN 
ab ac a b bc 
HO–1 a ↑b ↑c ↑d ↑d 
iron 
a a a a ↓b 
spleen 
hepcidin 
a ↑b a a ↓c 
FPN 
a ↓b a ↓b ab 
iron 
a ↑b ↑b ↑b ↑b 
kidney hepcidin 
a a a ↑b ↑b 
 
2 hours before 
experiment 
5 hours before 
experiment 
12 hours before 
experiment 
18 hours before 
experiment 
18 hours and then  
5 hours before 
experiment 
10% DMSO 
(control) 
Serum: Iron↓*, transferrin saturation↓* 
Duodenum: DMT1↓*, FPN↓*, Dcytb↓*, Iron↓* 
Liver: Hepcidin↑*, FPN↓*, HO–1↑*, Ferritin↑*, QR↑*, GST↑, Iron↑* 
Spleen: Hepcidin↑, FPN↓*, Iron= 
Kidney: Hepcidin↑* 
quercetin 
(50 mg/kg) 
18 hours and then  
5 hours before 
experiment 
10% DMSO 
(control) 
RM1 diet 
Serum: Iron↓, transferrin saturation ↓ 
Duodenum: DMT1 no expression, Dcytb=, FPN↑, Iron↓ 
Liver: Hepcidin↑*, FPN=, HO–1↑*, Ferittin=, Iron↑* 
Spleen: Hepcidin↓*, FPN↑*, Iron↑ 
Kidney: Hepcidin↓* 
quercetin 
(50 mg/kg) 
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5 hours before 
experiment 
10% DMSO 
(control) 
iron-
deficient 
diet 
B 
tissue/serum parameter 
concentration of quercetin IP 
treatment (mg/kg) 
0 2 5 10 20 
serum 
iron 
a a ↑b ↑c ↑c 
transfferin saturation 
a a ↑b ↑b ↑b 
duodenum 
DMT1 
a ↓bc a a ac 
Dcytb 
a a ↑b a ↑b 
FPN 
a ac ↑bc ac ↑bc 
iron 
a ↑b ↑b abc ↓c 
liver 
hepcidin 
a a ab ↑b ab 
FPN 
a a a a a 
HO–1 a a ab ↑b ↑b 
iron 
a a ac ↓b ↓c 
spleen 
hepcidin 
a ab ab a ↓b 
FPN 
a a ab a ↑b 
iron 
a ↓b a a a 
kidney hepcidin 
a ab ab ↓b a 
 
quercetin 
(2 mg/kg) 
quercetin 
(5 mg/kg) 
quercetin 
(10 mg/kg) 
quercetin 
(20 mg/kg) 
in tables A and B ↑ indicates that the parameters significantly increased compared with the group treated with quercetin 0h before experiment or with 10% DMSO, 
respectively 
in tables A and B ↓ indicates that the parameters significantly decreased compared with the group treated with quercetin 0h before experiment or with 10% DMSO, 
respectively 
in tables A and B groups with no common letters are significantly different from each other (p<0.05) 
results in red and marked with * indicate that the parameters significantly differ from treated and control group 
↑ indicate that parameter increased, but not significantly, between treated and control group 
↓ indicate that parameter decreased, but not significantly, between treated and control group 
= indicate that parameter did not change in treated group compared with control group 
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However, when lower concentrations of quercetin were applied, the increase in hepcidin 
mRNA was not as elevated as after higher quercetin concentrations. Still, hepatic 
mRNA was increased 45-fold after a 10 mg/kg quercetin dose, while the hepcidin 
mRNA in spleen and kidney stayed the same or significantly decreased after 20 and 10 
mg/kg quercetin dose, respectively. The largest change in hepatic hepcidin mRNA 
occurred after double quercetin treatment in animals fed on iron-deficient diet. 
Specifically, hepatic hepcidin mRNA was up-regulated enormously, 1031-fold. The 
same pattern was followed by kidney hepcidin mRNA (9.5-fold), while no significant 
change occurred in splenic hepcidin. In the group that was on a RM1 diet, hepatic 
hepcidin mRNA increased, while in kidney and spleen it decreased significantly. 
Generally, hepatic and kidney mRNA hepcidin mainly expressed an upward trend after 
IP quercetin. However, differences in hepatic and kidney results are probably due to the 
different number of treatments (single and double), different quercetin concentrations 
(2–50 mg/kg) and different diets (RM1 and iron-deficient). In contrast to liver and 
kidney hepcidin, splenic mRNA hepcidin levels were significantly down-regulated or 
not altered by quercetin treatment. As mentioned in Chapter 3, the observation that 
hepcidin is regulated in a different way in different tissues is hitherto unknown. In the 
light of results from this thesis, it could be proposed that hepcidin is regulated in a 
tissue-specific manner by quercetin. However, based on these limited results it is very 
hard to give an explanation of different hepcidin expression in different tissues and 
additional work is needed to confirm and elucidate the mechanism of tissue-specific 
hepcidin transcriptional regulation. 
The massive increase of hepatic and kidney hepcidin mRNA levels in vivo after 
quercetin treatment observed in this study is surprising and not easy to explain. There 
are only two reports from the literature that reported a similar effect of polyphenols on 
hepcidin expression in liver. To be exact, Tang et al. (2014), showed in vivo that 
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quercetin efficiently supports hepcidin expression by intensification of the 
BMP6/SMAD4 signaling pathway, both suppressed by ethanol consumption. Of note, it 
is known that hepcidin transcription is mainly regulated by the BMP6/SMAD4 
signaling pathway (Ganz and Nemeth, 2012). Additionally, hepcidin suppression by 
alcohol abuse results in iron overload and predisposes the liver to more severe 
pathologies (Bridle et al., 2006). Tang et al. (2014) showed in mice that BMP6 and 
SMAD4 protein levels, as well as binding of SMAD4 to the HAMP promoter, were 
disabled by chronic alcohol exposure, directly leading to hepcidin suppression. 
Interestingly, quercetin treatment partially reset the ethanol effect on the 
BMP6/SMAD4 signaling pathway. Particularly, quercetin treatement after alcohol 
exposure was followed by increase in BMP6 and SMAD4 expression and SMAD4 
binding activity to the HAMP, subsequently leading to stimulation of hepcidin 
expression in liver and decrease of iron overload. In Tang et al. (2014), up-regulation of 
liver hepcidin, on both protein and mRNA levels, was documented after a 15 week long 
oral treatment with quercetin (100 mg/kg). Up-regulation of mRNA hepcidin levels was 
around 2-fold, which is not comparable with the vast increase of hepcidin mRNA 
evidenced within this study. Two results are hard to compare in the sense of the 
intensity of hepcidin up-regulation due to the different length and way of quercetin 
application. Additionally, results from this thesis showed that after IP treatment the 
concentration of quercetin and its metabolites in serum was higher compared with the 
oral treatment (see Table 3–2 and Table 5–1). Thus, quercetin applied IP could have a 
bigger impact on cell homeostasis due to its higher serum concentration. This could be a 
reason for the modest hepcidin increase after a 15 weeks long oral quercetin treatment 
compared with the opposite vast hepcidin up-regulation after double IP treatment. 
Vanhees et al. (2011) also confirmed in vivo quercetin-mediated regulation of hepcidin. 
Specifically, research showed that prenatal exposure to quercetin resulted in hepcidin 
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induction in adult mice. Authors hypothesized that after birth, when pups were no 
longer exposed to quercetin, improved bioavailability of dietary iron was experienced as 
an iron overload. Namely, the authors suspected that animals were ”developmentally 
programmed” to deal with lower iron levels in utero. The difference between the in 
utero and postnatal life conditions resulted in activating pathways for overcoming 
emerging ”iron overload”, such as hepcidin up-regulation. Again, it is hard to draw a 
parallel between the results from Vanhees et al. (2011) and results obtained in this thesis 
due to the distinct experimental design. However, there are a small number of studies 
reporting up-regulation of hepcidin by polyphenols. Thus some results in this study are 
hard to discuss and only preliminary explanation could be proposed. 
Apart from the suggestion that hepcidin is up-regulated by quercetin through the 
BMP6/SMAD4 signaling pathway, there are assumptions that it could also be regulated 
by the Nrf2–ARE signaling pathway. Namely, the liver, a main site of iron storage, is 
particularly exposed to the toxic effects of iron. The Nrf2–ARE signaling pathway plays 
a pivotal role in protecting the liver from disease induced by high iron. This pathway 
activates the transcription of a battery of cytoprotective genes encoding 
detoxification/antioxidant enzymes which terminate toxic iron effects. The important 
role of Nrf2 in inhibiting hepatic injury was shown in a couple in vivo models using 
Nrf2-null mice (Klaassen and Reisman, 2010). Furthermore, it was recently shown that 
Nrf2 protects mouse liver against toxicity and oxidative stress caused by iron overload 
(Silva–Gomes et al., 2014). Consequently, it could be proposed that Nrf2 signaling may 
coordinate hepcidin expression as an answer to iron overload and thus contribute to the 
prevention of hapatocytic cell injury. This hypothesis could be supported by parallel 
increases in the expression of the phase II genes HO–1 and QR recorded in this study 
after all the applied quercetin treatments (ranged from 13- to 2-fold). Of note, 
transcription of these enzymes is driven by the Nrf2–ARE signaling pathway as part of 
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a battery of cytoprotective machinery induced by oxidative stress (Klaassen and 
Reisman, 2010). These effects of quercetin are known from before (Williamson at el., 
1996; Liu et al., 2012; personal communication with Henry K. Bayele and Sara 
Balesaria). However, up-regulation of Nrf–2 by quercetin was also confirmed (Yao et 
al., 2007; Granado–Serrano et al., 2012). Based on the results from these thesis and 
observations of others, it could be proposed that the Nrf2 transcription factor was up-
regulated in the liver of examined animals by quercetin. Thus there is a great probability 
that the same signaling pathway induced hepcidin transcription. Furthermore, it was 
shown in vitro that HO–1 expression is also BMP6/SMAD4 dependent (Yan et al., 
2009). Thus, in the same manner as with above discussed Nrf2–ARE signaling pathway, 
this result indicates that hepcidin up-regulation could also go through the 
BMP6/SMAD4 pathway. However, these both hypotheses are only a sugestion and 
additional work is needed to confirm the discussed issues. Nevertheless, these results 
confirmed the well known fact that polyphenols, particularly quercetin, increase levels 
of antioxidant enzymes and support the body in its fight against destructive oxidative 
stress. 
Furthermore, an increase in hepcidin levels is expected to be followed by a reduction in 
FPN levels, mainly in spleen. Namely, the ”seesaw” relationship between hepcidin and 
FPN expression is well known (Nemeth et al., 2004; Ganz, 2011) and part of the results 
from this thesis are in agreement with this belief. Two and 12 hours after single 
quercetin treatment, levels of splenic FPN mRNA decreased while those of liver were 
unchanged. This confirmed previously reported views that spleen FPN is major target 
for hepcidin action (Chaston et al., 2008; Masaratana et al., 2011). The hepcidin effect 
on FPN was more pronounced after double quercetin treatment, where FPN mRNA 
levels declined in both liver and spleen, but in spleen more. However, in animals fed a 
RM1 diet this outcome was lacking. What is more, splenic FPN mRNA increased after 
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quercetin treatment, even though liver hepcidin mRNA increased in the same animal 
group. Similarly, the work of others also suggests that FPN itself may be up-regulated 
by antioxidants in vivo, which could partially explain the observed disagreement in 
results (Harada et al., 2011).  
High hepcidin, as well as reduction in FPN levels by hepcidin, should be followed by a 
retention of iron in tissue, precisely in liver and spleen. This pattern was followed after 
a double quercetin dose where iron levels in liver increased or were unchanged in 
spleen. Consequently, an increase in liver iron was followed by an increase in mRNA 
ferritin levels. However, after a single quercetin treatment, with a dose of 50 mg/kg, 
spleen iron was increased but liver iron decreased. Whereas, after a lower quercetin 
dose (ranging from 0 to 20 mg/kg) showed reduced iron stores both in liver and spleen. 
As mentioned before, differences in results of tissue iron levels could be due to the 
different number of treatments, different quercetin concentrations and different diets. 
Additionally, a reduction in iron stores by quercetin could be explained by its chelato 
properties. Particularly, it is confirmed in vivo that quercetin is able to decrease 
intracellular iron pools by chelating iron and taking it out from the cell. It is proposed 
that quercetin chelates iron and takes it out from the tissue to the blood stream and 
finally excretes it from the body (Morel et al., 1993; Zhao et al., 2005; Zhang et al., 
2006; Zhang et al., 2011; Baccan et al., 2012). These finding are of great importance for 
medicine as polyphenols, such as quercetin, could be use as chelator in iron 
redistribution therapy. 
An increase in hepcidin levels is proven to be followed by a decrease of intestinal iron 
absorption (Laftah et al., 2004; Mena et al., 2008). Particularly, it is proven that hepatic 
hepcidin expression is inversely proportional to expression of intestinal DMT1, Dcytb 
and FPN expression in vivo (Frazer et al., 2004; Yamaji et al., 2004; Chung et al., 2009; 
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Brasse–Lagnel et al., 2011). However, this occurrence was only partially confirmed in 
this thesis. Namely, after single quercetin treatment (dose 50 mg/kg) levels of duodenal 
mRNA DMT1, Dcytb and FPN stayed the same or were up-regulated 5 and more hours 
after treatment. Furthermore, after a single lower quercetin dose, the same pattern of 
duodenal genes’. regulation was followed. These results came as a surprise, because the 
opposite results were expected particularly in the light of detected increased hepcidin 
levels. Additionally, these results were in disagreement with observed increased iron 
duodenal levels. Namely, it would be expected that levels of DMT1 were down-
regulated by post-transcriptional the IRE/IRP control machinery, such that when iron 
levels in tissue are high, expression of DMT1 is inhibited (Muckenthaler et al., 2008). 
These contradictory results require more in-depth research in order to make clear 
conclusions as to why the iron transporters follow the observed pattern of expression. 
One of the possible explanations could be that quercetin expresses a direct effect on 
observed gene expression and that this mechanism could abolish the influence of 
hepcidin. However, after double quercetin treatment, where vast up-regulation of 
hepatic hepcidin occurred, duodenal mRNA levels of DMT1, Dcytb and FPN were 
significantly down-regulated, as well as duodenal iron levels. These results confirmed 
the results of earlier studies, where high hepcidin is followed by a reduction in iron 
transporters and absorption. 
Nevertheless, it would be expected that hepcidin up-regulation is followed by a 
reduction in serum iron and transferrin saturation (Kemna et al., 2005). Again, this 
principle was to some extent confirmed within this thesis. Namely, after a double 
quercetin dose, serum iron and transferrin saturation levels decreased as expected. 
Contrary, after a single quercetin treatment serum iron and transferrin saturation levels 
increased. This can partially be explained by reduced liver iron levels in some animal 
groups. In other words, iron could leave liver tissue through unaffected FPN and thus 
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increase iron serum levels. Also, increase in serum iron could indicate quercetin chelato 
property and its ability to take iron out from tissues. Additionally, as duodenal 
transporters were increased despite high hepcidin levels induced by quercetin, extra iron 
could come through intestinal absorption. 
On the other hand, uptake studies after IP quercetin treatment did not cause a change in 
mucosal iron uptake or transfer. These results came as a great surprise, especially after a 
double dose of quercetin, where quercetin enormously up-regulated mRNA hepcidin 
levels and affected iron transporter genes in the intestine. The results from uptake 
studies indicate that more in-depth studies need to be performed in order to confirm the 
exact affects of IP quercetin on iron absorption in vivo. 
On top of, it is shown that quercetin administrated IP at a concentration not less than 50 
gm/kg had the greatest effect on iron homeostasis 5 hours after single treatment. 
Additionally, double quercetin IP had a more distinct effect on iron homeostasis than 
single quercetin IP. Results from this Chapter, as well as from Chapter 3, point out that 
those animals kept on an iron-deficient diet are more suitable models for research in the 
field of iron metabolism, because they are more sensitive to the applied treatments and 
results are more pronounced. 
The aim of determination of quercetin and selected quercetin metabolites in rat serum 
after IP quercetin treatment by LC–MS/MS technique was to see which metabolites are 
present in the serum and at which concentrations. As it was mentioned in Chapter 3, this 
was important for subsequent experiments in which THP1 cells and HepG2 cells were 
treated with detected metabolites in order to investigate their potential role in expression 
of iron-metabolism related genes. Qualitative and quantitative studies showed that right 
after treatment quercetin was the dominant compound, but it was quickly metabolized to 
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quercetin–3–O–glucuronide and isorhamnetin. Higher concentrations of quercetin and 
its metabolites were observed in serum compared with the results of study after oral 
quercetin treatment, which confirms that quercetin absorbed in the intestine has a short 
half-life. Also, these results confirm that one of the dominant quercetin metabolites in 
serum is quercetin–glucuronide (Gee et al., 2004; Justino et al., 2004; Moon et al., 
2008). 
5.4 Conclusions 
In conclusion, IP administration of quercetin mainly affected systemic iron homeostasis, 
primary by a large up-regulation of hepatic and kidney mRNA hepcidin levels. This 
trend was not followed by splenic hepcidin mRNA, which suggest possible tissue-
specific hepcidin transcriptional regulation by quercetin. Furthermore, analysis of the 
presented data and previously  published results suggest that both BMP6/SMAD4 and 
Nrf2–ARE signaling pathways could be involved in dominant hepcidin up-regulation by 
polyphenols in vivo. Furthermore, after different administration times, single or double 
doses and different concentrations of quercetin, the organism reacted differently to high 
hepcidin levels. Generally, high hepcidin levels were followed by a reduction in mRNA 
FPN levels, mainly in the spleen. Additionally, it is confirmed that quercetin is able to 
decrease intracellular iron pools in vivo, possibly by chelating iron and taking it out of 
the cell. This fact could be particularly significant for new drug discoveries directed by 
natural product research targeting iron overload. Furthermore, results only partially 
confirmed that hepcidin reduces iron absorption. This fact points to a possible direct 
influence of polyphenols on the expression of duodenal genes involved in iron 
homeostasis. However, uptake studies after IP quercetin showed no change in iron 
absorption, even though significant change in genes involved in iron intestinal transport 
was observed. This indicates that more studies have to be done in order to explain the 
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quercetin effect on iron homeostasis, particularly iron absorption. Nevertheless, results 
confirmed the well-known fact that polyphenols, particularly quercetin, increase levels 
of antioxidant enzymes. This study provides a very good case for including hepcidin as 
an important factor involved in antioxidant effects, in addition to it being involved in 
the anti-inflammatory effects of quercetin. Above all, it is confirmed that polyphenols 
might be a new source of therapeutics for iron overload diseases and their role in iron-
removal therapy is worthy of further study. 
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6. EFFECT OF POLYPHENOLS ON GENE EXPRESSION 
OF IRON-RELATED PROTEINS IN HepG2 CELLS 
6.1 Introduction 
The main organ for regulation of systemic iron homeostasis is the liver. Apart from 
being the main site of hepcidin expression, it is also one of the main sites of iron 
storage. Hepcidin synthesis is stimulated by iron overload. Consequently, hepcidin 
binds to FPN and causes its degradation in order to prevent further iron export to the 
circulation (Ganz, 2011; Ganz and Nemeth, 2012). 
It was shown in previous chapters of this thesis that quercetin greatly affects iron 
metabolism in vivo, at the absorption stage and at the systemic level. However, it is 
difficult to decide whether it is quercetin or its metabolites that induce the observed 
effects. Furthermore, there is no literature data about a possible link between iron 
metabolism and quercetin metabolites. Bearing in mind the extensive metabolism of 
quercetin in the intestine and its short half-life (Gee et al., 2004; Justino et al., 2004; 
Moon et al., 2008), it was hypothesized that quercetin metabolites could be involved in 
changing iron metabolism. Thus, in order to get preliminary conclusions on these issues, 
the effect of quercetin and 6 chosen quercetin metabolites on hepcidin and FPN was 
studied in HepG2 cells, used as a hepatic in vitro model system. Furthermore, it was 
discussed in detail in Chapter 5 that two signalling pathways, Nrf2–ARE and 
BMP6/SMAD4, could regulate hepcidin expression. This is based on in vitro studies 
that show that HO–1 expression in response to polyphenol (quercetin) treatment is 
Nrf2–ARE- and BMP6/SMAD4-dependent (Yan et al., 2009; Klaassen and Reisman, 
2010). In order to see whether polyphenols other then quercetin can affect iron systemic 
metabolism in vitro, two polyphenols of diverse structure resveratrol and epicatechin 
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were also included in the study. Resveratrol and epicatechin are, as quercetin, abundant 
in a diet of plant origin and are potent antioxidant agents (Terao, 1999; Baur and 
Sinclair, 2006). In Chapter 4 it was shown that resveratrol does not affect iron 
absorption, however it was previously confirmed in vitro that (–)–epigallocatechin–3–
gallate and epicatechin–3–gallate, derivative epicatechin, inhibit non-haem iron 
absorption and decrease plasma iron (Thephinlap et al., 2007; Kim et al., 2008). A study 
of the effects of polyphenol of diverse structures could elucidate whether the well 
known fact that polyphenols inhibit iron absorption is due to their chelation or 
antioxidant properties, or both. 
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6.2 Results 
In this chapter the effect of polyphenols on gene expression of iron–related proteins, 
such as hepcidin, FPN and HO–1, in HepG2 cells was investigated. This study included 
quercetin and its metabolites that are identified in serum of animals treated with 
quercetin orally and IP (see Chapter 3 and 5). Also, metabolites that were not detected 
in serum in the scope of this thesis, but are known to be present in serum after 
consumption of quercetin, were included in this study. Additionally, resveratrol and 
epicatechin, polyphenols that are frequently consumed in a plant diet, were also the 
subject of this investigation. 
HepG2 cells were grown on 6-well plates for 24 hours and were treated with 
polyphenols (100 μM) for a further 5 hours. This was followed by RNA isolation and 
quantitative-PCR to measure changes in mRNA expression. 
In general, polyphenols induced a significant decrease in hepcidin mRNA levels. 
Namely, quercetin–3–O–glucuronide, isorhamnetin, tamarixetin, 3,4’–
dimethylquercetin, epicahtechin and resveratrol caused a 9-, 54-, 3.5-, 2-, 11- and 11-
fold decrease compared with the corresponding control, respectively (see Figure 6–1). 
In contrast, among all the investigated polyphenols only quercetin induced hepcidin 
mRNA levels of almost 3-fold compared with the control (see Figure 6–1). There was 
no significant effect of 3–O–methylquercetin and penta–methylquercetin on hepcidin 
expression. 
Furthermore, FPN mRNA was generaly significantly down regulated. To be exact, all 
investigated polyphenols, expect quercetin–3–O–glucuronide, 3–O–methylquercetin, 
resveratrol and penta–methylquercetin, decreased FPN mRNA levels (see Figure 6–2). 
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Contrary to what was expected, only epichatechin upregulated HO–1 mRNA levels in 
HepG2 cells, while other investigated polyphenols, such as quercetin, isorhamnetin, 
tamarixetin, 3,4’–dimethylquercetin and 3–O–methylquercetin, significantly decreased 
HO–1 gene expression (see Figure 6–3). 
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Figure 6–1 Effect of polyphenols on hepcidin mRNA expression in HepG2 cells 
HepG2 cells were treated with polyphenols (100 μM) for 5 hours. Instead of compounds 
DMSO (A), ethanol (B) or ethanol:DMSO (1:1) were added in corresponding control 
wells. Changes in mRNA expression were measured by qPCR. Data normalised to 
GAPDH. Data are mean ± SEM; n=3; groups with no common letters are significantly 
different from each other (p<0.05). 
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Figure 6–2 Effect of polyphenols on FPN mRNA expression in HepG2 cells 
HepG2 cells were treated with polyphenols (100 μM) for 5 hours. Instead of compounds 
DMSO (A), ethanol (B) or ethanol:DMSO (1:1) were added in corresponding control 
wells. Changes in mRNA expression were measured by qPCR. Data normalised to 
GAPDH. Data are mean ± SEM; n=3; groups with no common letters are significantly 
different from each other (p<0.05). 
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Figure 6–3 Effect of polyphenols on HO–1 mRNA expression in HepG2 cells 
HepG2 cells were treated with polyphenols (100 μM) for 5 hours. Instead of compounds 
DMSO (A), ethanol (B) or ethanol:DMSO (1:1) were added in corresponding control 
wells. Changes in mRNA expression were measured by qPCR. Data normalised to 
GAPDH. Data are mean ± SEM; n=3; groups with no common letters are significantly 
different from each other (p<0.05). 
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6.3 Discussion 
In this chapter the effect of quercetin, 6 quercetin metabolites, resveratrol and 
epichatechin on hepcidin, FPN and HO–1 expression was studied. Among the 
polyphenols investigated only quercetin induced a significant increase of hepcidin 
expression, while others mainly induced a significant decrease. It is discussed in 
Chapter 5 that hepcidin expression could be controlled by both the BMP6/SMAD4 and 
Nrf2–ARE signaling pathways. However, it is still unknown how quercetin, or other 
polyhenols, could affect these pathways and bring about an increase or decrease in 
hepcidin mRNA expression. It could be assumed that the answer could lie in the 
polyphenol structure. Namely, among investigated polyphenols, only quercetin has a 
free hydroxyl, carbonyl and galloyl group in close proximity (see Figure 6–4). This 
structural characteristic could be important for its interaction with signaling molecules 
controlling hepcidin expression and the final outcome could be dependent on it. This is 
only a preliminary assumption and the results and this hypothesis need to be confirmed 
in further research. Furthermore, this result is in accordance with previously presented 
results in this thesis. Namely, it was shown that liver and kidney hepcidin expression is 
up-regulated by IP quercetin in vivo (see Chapter 5.). In Chapter 5. possible ways of 
how quercetin could affect hepcidin expression are discussed in detail. 
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Figure 6–4 Structures of polyphenols included in this study 
Moreover, FPN expression was also affected by polyphenol treatment. Namely, only 
resveratrol significantly increased FPN mRNA levels, while quercetin, isorhamnetin, 
tamarixetin, 3,4ʼ–dimethylquercetin and epichatechin induced a significant decrease. 
Also, penta–methylquercetin induced an increase, while 3–O–methylquercetin induced 
a decrease, in FPN mRNA levels but it was not significant. It is difficult to explain why 
only resveratrol induced an increase in FPN mRNA levels. Again, structural differences 
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among the investigated polyphenols could have an important role in the observed 
increase (see Figure 6–4). Resveratrol and penta–methylquercetin are the only 
polyphenols, among those investigated, that could not chelate iron. This property could 
be important in the light of the fact that resveratrol and penta–methylquercetin cannot 
reduce intracellular iron. By chelating iron and lowering the intracellular liable iron 
pool, the IRE/IRP system could be activated in order to decrease FPN levels as the 
intracellular iron level is low (Muckenthaler et al., 2008). However, this is only a 
preliminary suggestion and this premise needs to be confirmed in further research. 
Furthermore, by this study again well known fact that high hepcidin induces FPN 
internalization is confirmed (Ganz, 2011). Namely, in HepG2 cells treated with 
quercetin, mRNA hepcidin was up-regulated which was followed by a reduction in FPN 
mRNA.  
Nonetheless, HO–1 mRNA levels were also followed in HepG2 cells after polyphenol 
treatment. However, the results came as a surprise. Namely, almost all polyphenols, 
except epichatechin, provoked a decrease in HO–1 mRNA levels. This is not in 
agreement with the well known fact that polyphenols support up-regulation of 
antioxidant enzymes, such as HO–1 (Ferrándiz and Devesa, 2008; Shah, et al., 2010). 
Also, these results are not in accordance with previous results from this thesis, where 
HO–1 mRNA levels were up-regulated in liver after both IP and oral quercetin 
treatment in vivo (see Chapter 3 and 5). It is discussed in detail in Chapter 5 that up-
regulation of HO–1 could be a confirmation that hepcidin expression is controlled by 
two pathways, Nrf2–ARE and BMP6/SMAD4. The results obtained with HepG2 cells 
argue against this hypothesis. However, future studies should focus on an in-depth 
analysis of this issue in order to determine the influence of polyphenols on hepcidin 
expression in hepatocytes. 
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6.4 Conclusions 
To summarise, the results presented give a preliminary indication that quercetin 
metabolites could have different effects on systemic iron metabolism compared to 
quercetin. Namely, it is shown that quercetin metabolites induce a reduction in hepcidin 
expression; while it was proven that quercetin induces a large great up-regulation in 
hepcidin levels both in vivo and in vitro. Furthermore, quercetin metabolites affected 
mRNA FPN levels in the same way as quercetin. This supports the belief that 
polyphenols affect intracellular iron metabolism by chelating iron and affecting the 
IRE/IRP machinery. Furthermore, it was shown that structurally diverse polyphenols 
could affect iron metabolism in a different way. Namely, it could be assumed that 
structural characteristics that enable iron chelation, in addition to general polyphenol 
antioxidant power due to free hydroxyl groups, could be of great importance in 
controlling iron metabolism. Surprisingly, the examined polyphenols did not induce up-
regulation of HO–1 mRNA levels, which is in great disagreement with previous 
research (Ferrándiz and Devesa, 2008; Shah, et al., 2010) and with results from this 
study (see Chapter 3 and 5).  
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7. EFFECT OF POLYPHENOLS ON GENE EXPRESSION 
OF IRON- AND INFLAMMATION-RELATED GENES 
IN THP1 CELLS 
7.1 Introduction 
Macrophages play a significant role in iron homeostasis. Namely, splenic and hepatic 
macrophages recycle senescent erythrocytes by which iron is released from haem by the 
action of HO‒1. Iron is effluxed into the circulation in response to systemic iron 
requirements. The release of iron from macrophages is mainly regulated by the 
interaction of the hormone hepcidin with the iron exporter FPN. Furthermore, 
macrophages are a key agent in inflammation-induced hypoferraemia. Namely, during 
infection and inflammation, IL–6 and other cytokines increase hepcidin synthesis, 
causing iron abstraction in macrophages. The resulting hypoferraemia limit the growth 
and pathogenicity of invading extracellular microbes and is an important means of host 
defence (Chung et al., 2009; Ganz, 2012). 
It was shown in previous chapters of this thesis that quercetin greatly affects iron 
metabolism in vivo, on both absorption and at the systemic level. However, it is hard to 
conclude whether quercetin or its metabolites induce the observed effects. In addition, 
there is no data in the literature about a possible link between iron metabolism and 
quercetin metabolites. Bearing in mind the extensive metabolism of quercetin in the 
intestine and its short half-life (Gee et al., 2004; Justino et al., 2004; Moon et al., 2008), 
it was hypothesized that quercetin metabolites could also be involved in affecting iron 
metabolism. In order to get preliminary data on the effect of quercetin and two chosen 
quercetin metabolites on macrophages regulated iron homeostasis, in vitro studies using 
THP1 cells were performed. THP1 cells are a human leukaemia monocytic cell line and 
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are an excellent in vitro model of human macrophages. In culture, these monocytes are a 
non-adherent cell type, but with the addition of PMA, the monocytes differentiate into 
macrophages and adhere to cell culture dishes. In the scope of this thesis effect of 
quercetin and two chosen quercetin metabolites on expression of hepcidin, FPN and 
inflammation related genes, such as IL–6, IL–1β, TNF–α, iNOS and COX–2, in THP1 
cells was studied. 
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7.2 Results 
The effect of polyphenols on gene expression of iron–related genes and inflammation-
related genes in THP1 cells were investigated. This study included quercetin and its 
metabolites that are identified in the serum of animals treated with quercetin orally and 
IP (see Chapter 3 and 5). 
THP1 cells were plated in 6-well plates for 24 hours and subsequently treated with 
PMA (100 nM) for a further 24 hours to promote differentiation of monocytes into 
macrophages. The PMA-containing medium was removed and replaced with serum-free 
medium for 24 hours before treatments with polyphenols. THP1 cells were treated with 
quercetin, quercetin-3-O-glucuronide and tamarixetin (30 µM) for 0, 5 and 18 hours. 
After treatment cells were subject to RNA isolation and gene expression analysis 
(hepcidin and FPN). 
Other batch of THP1 cells were treated with LPS in the presence or absence of 
quercetin, quercetin-3-O-glucuronide and tamarixetin (30 µM). Namely, LPS (500 
ng/mL) was added to cells 2 hours after polyphenols. Cells were treated with LPS for 18 
hours. This was followed by RNA isolation and quantitative-PCR to measure changes in 
mRNA expression of inflammation-related genes, such as IL-6, IL-1β, TNF-α, iNOS 
and COX-2. 
Generally, polyphenols induced a significant change in hepcidin mRNA levels. Among 
all the investigated polyphenols quercetin induced the greatest change in hepcidin 
mRNA levels in THP1 cells, with a 75-fold increase after 18 hours of treatment (see 
Figure 7–1). Quercetin–3–O–glucuronide, one of the main metabolites of quecetin, also 
induced an increase in the hepcidin mRNA level. However, that level was comparable 
with the hepcidin mRNA levels in control wells after 5 and 18 hours of treatment (see 
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Figure 7–1). The level of hepcidin mRNA fluctuated after tamarixetin treatment in 
THP1 cells. Firstly, after 5 hours it was significantly reduced (2.4-fold), and then 
significantly increased after 18 hours of treatment (1.4-fold) compared with untreated 
cells (see Figure 7–1). 
Furthermore, FPN mRNA oscillated during polyphenols’ treatment. In all treated wells 
mRNA FPN levels was significantly down-regulated after 5 hours (from 2- to 15-fold; 
see Figure 7–2). However, 18 hours after treatment quercetin and quercetin–3–O–
glucuronide induced a significant increase; while tamarixetin caused a significant 
decrease in FPN mRNA levels compared with the start of experiment (see Figure 7–2). 
 
Figure 7–1 Effect of polyphenols on hepcidin mRNA expression in THP1 cells 
THP1 cells were treated with polyphenols (30 μM) for 0, 5 and 18 hours. Instead of 
compounds DMSO was added in corresponding control wells. Changes in mRNA 
expression were measured by qPCR. Data normalised to GAPDH. Data are mean ± 
SEM; n=3; for the same treatment time groups with no common letters are significantly 
different from each other; for the same treatment groups with no common signs are 
significantly different from each other, (p<0.05). 
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Figure 7–2 Effect of polyphenols on FPN mRNA expression in THP1 cells 
THP1 cells were treated with polyphenols (30 μM) for 0, 5 and 18 hours. Instead of 
compounds DMSO was added in corresponding control wells. Changes in mRNA 
expression were measured by qPCR. Data normalised to GAPDH. Data are mean ± 
SEM; n=3; for the same treatment time groups with no common letters are significantly 
different from each other; for the same treatment groups with no common signs are 
significantly different from each other, (p<0.05). 
After LPS treatment, all the investigated inflammation-related genes were significantly 
up-regulated in differentiated THP1 cells. However, their levels were significantly 
altered with different polyphenol treatments. Namely, quercetin induced a significant 
down-regulation of IL–6, TNF–α, iNOS mRNA levels, while it induced a significant 
up-regulation of IL–1β and COX–2 mRNA levels in LPS stimulated THP1 cells (see 
Figure 7–3 to Figure 7–7). Furthermore, quercetin–3–O–glucuronide induced a 
significant down-regulation of TNF–α mRNA level, while it induced up-regulation of 
IL–6, IL–1β and iNOS mRNA levels in LPS stimulated THP1 cells (see Figure 7–3 to 
Figure 7–7). Tamarixetin induced a significant down-regulation only of IL–6 mRNA 
levels, while all other investigated mRNAlevels were significantly up-regulated (see 
Figure 7–3 to Figure 7–7). 
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Figure 7–3 Effect of polyphenols on IL–6 mRNA expression in THP1 cells 
THP1 cells were treated with LPS in the presence or absence of polyphenols (30 µM) 
for 18 hours. Instead of compounds DMSO was added in corresponding control wells. 
Changes in mRNA expression were measured by qPCR. Data normalised to GAPDH. 
Data are mean ± SEM; n=3; groups with no common letters are significantly different 
from each other (p<0.05). 
 
 
Figure 7–4 Effect of polyphenols on IL–1β mRNA expression in THP1 cells 
THP1 cells were treated with LPS in the presence or absence of polyphenols (30 µM) 
for 18 hours. Instead of compounds DMSO was added in corresponding control wells. 
Changes in mRNA expression were measured by qPCR. Data normalised to GAPDH. 
Data are mean ± SEM; n=3; groups with no common letters are significantly different 
from each other (p<0.05). 
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Figure 7–5 Effect of polyphenols on TNF–α mRNA expression in THP1 cells 
THP1 cells were treated with LPS in the presence or absence of polyphenols (30 µM) 
for 18 hours. Instead of compounds DMSO was added in corresponding control wells. 
Changes in mRNA expression were measured by qPCR. Data normalised to GAPDH. 
Data are mean ± SEM; n=3; groups with no common letters are significantly different 
from each other (p<0.05). 
 
 
Figure 7–6 Effect of polyphenols on iNOS mRNA expression in THP1 cells 
THP1 cells were treated with LPS in the presence or absence of polyphenols (30 µM) 
for 18 hours. Instead of compounds DMSO was added in corresponding control wells. 
Changes in mRNA expression were measured by qPCR. Data normalised to GAPDH. 
Data are mean ± SEM; n=3; groups with no common letters are significantly different 
from each other (p<0.05). 
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Figure 7–7 Effect of polyphenols on COX–2 mRNA expression in THP1 cells 
THP1 cells were treated with LPS in the presence or absence of polyphenols (30 µM) 
for 18 hours. Instead of compounds DMSO was added in corresponding control wells. 
Changes in mRNA expression were measured by qPCR. Data normalised to GAPDH. 
Data are mean ± SEM; n=3; groups with no common letters are significantly different 
from each other (p<0.05). 
7.3 Discussion 
In this chapter the effect of quercetin, quercetin–3–O–glucuronide and tamarixetin on 
expression of hepcidin, FPN and inflammation-related genes, such as IL–6, IL–1β, 
TNF–α, iNOS and COX–2, in THP1 cells was studied. 
Namely, all the investigated polyphenols induced significant changes in hepcidin and 
FPN mRNA levels. An increase in hepcidin mRNA levels after quercetin–3–O–
glucuronide and tamarixetin treatment was followed by a reduction in FPN mRNA 
levels. However, after quercetin treatment, when a significant change of hepcidin 
mRNA levels occurred (75-fold), FPN mRNA levels were also up-regulated. This result 
came as no surprise as similar results were observed in vivo in the spleen after quercetin 
treatment (Chapter 3 and 5). Specifically, the results from the in vivo studies suggested 
that hepcidin originating from spleen cannot cause internalization of FPN as hepatic 
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hepcidin does. The results from the in vitro studies with THP1 cells also support this 
hypothesis. Namely, it could be that hepatic hepcidin, mainly expressed by hepatocytes, 
is different from splenic hepcidin, mainly originating from macrophages. Nevertheless, 
the premise that hepcidin expresses different effects on FPN from different tissues is 
already known (Chaston et al., 2008). Moreover, it was known from before that 
macrophages express hepcidin and FPN (Nguyen, et al., 2006; Sow, et al., 2007), but 
this is the first result providing evidence that they can be affected by polyphenols. 
Twenty-five mg of iron per day from red blood cells is recycled by macrophages, which 
make them the major contributor to body iron turnover. Factors which can regulate this 
turnover might be important therapeutically for treating a number of iron-related 
disorders. In a view of this, results which indicate that polyphenols can affect iron-
related proteins in macrophages are of great importance. 
During infection and inflammation, hepcidin levels are increased as a host defense 
mechanism in order to reduce iron levels and make it non-available to invading 
microorganisms. It was proven in vivo that IL–6 has a stimulatory effect on hepcidin 
transcription and that it induces hypoferraemia during inflammation (Nemeth et al., 
2004; Kemna et al., 2005). Thus, it was worthwhile to make a parallel between proven 
hepcidin up-regulation by quercetin in vivo and polyphenols’ effect on inflammatory-
related genes in LPS-stimulated THP1 cells. In other words, the aim of this study was to 
investigate whether quercetin or its metabolites would induce expression of 
inflammatory-related genes that could be followed by an increase in hepcidin 
expression. Thus, expression of IL–6, IL–1β, TNF–α, iNOS and COX–2 mRNA in 
LPS-stimulated THP1 was followed after quercetin, quercetin–3–O–glucuronide and 
tamarixetin treatments. It was shown that all the investigated mRNAs were up-regulated 
at least after treatment of one of the investigated polyphenols. In general, tamarixetin- 
and quercetin–3–O–glucuronide-treatment caused greater up-regulation of the 
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investigated genes than quercetin. It is particularly interesting that IL–6 and IL–1β 
mRNA levels were greatly up-regulated by polyphenols’ treatment, because it is known 
that these cytokines up-regulate hepcidin expression (Lee et al., 2005). These findings 
indicate that polpyhenols could affect iron homeostasis by inducing inflammation. 
However, future studies should focus on an in-depth analysis of this issue in order to 
determine influence of polyphenols and their metabolites on iron homeostasis driven by 
inflammation in vivo. 
7.4 Conclusions 
To summarise, the results presented give a preliminary indication that quercetin and 
quercetin metabolites could have an effect on systemic iron metabolism by changing the 
expression of iron- and inflammation-related proteins in macrophages. Namely, it is 
shown that quercetin, quercetin–3–O–glucuronide and tamarixetin could affect 
expression of hepcidin and FPN mRNA levels in THP1 cells. Moreover, they induced 
expression of inflammatory-related genes in THP1 cells, which are proven to up-
regulate hepcidin expression (i.e. IL–6 and IL–1β). As macrophages play a significant 
role in iron homeostasis in health and during both infection and inflammation and iron-
related disorders, verified agents which could regulate iron metabolism in macrophages 
are of great importance. Thus, further research on how dietary polyphenols could 
interact with iron recycling and storage in macrophages is fully supported. 
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8. CONCLUSIONS 
8.1 General conclusions 
This thesis investigated the mechanisms underlying the effects of dietary polyphenols, 
particularly quercetin, which is one of the most dominant dietary polyphenol, on 
systemic iron regulation and iron absorption.  
From the reserach described in this thesis, it was concluded that: 
1. Oral administration of quercetin caused iron deficiency in rats, which was followed 
by increase in iron absorption rate and decrease in iron stores of liver and spleen. 
Specifically, oral quercetin treatment affected mRNA levels of duodenal DMT1, 
Dcytb and FPN. These results also indicated that oral quercetin has a great effect on 
iron absorption and a minor effect on systemic iron regulation. 
2. Polyphenols inhibit non-haem iron absorption in vivo by chelating it in duodenum. 
Specifically, by chelating iron quercetin prevents transepithelial non-haem iron 
transport across the enterocyte by increasing apical iron uptake and decreasing the 
basolateral iron release. 
3. IP administration of quercetin mainly affected systemic iron homeostasis, primary by 
a vast up-regulation of hepatic and kidney mRNA hepcidin levels and decreased 
intracellular iron pools. 
4. Different polyphenols and quercetin metabolites display different effects on the 
expression of iron-related genes in liver in vitro compared with quercetin. 
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5. Polyphenols express a significant effect on the expression of iron- and inflammation-
related genes in macrophages in vitro. 
8.2 Future work 
This thesis has investigated, discovered and proposed mechanisms of the action of 
polpyhenols, particularly quercetin, on iron metabolism in a well established in vivo 
model. In future, similar studies need to be carried out in humans to establish any 
possible benefits for those at risk of developing iron-related disorders. 
In this study, it has been shown that polyphenols, particularly quercetin, greatly affects 
mRNA levels of genes essential for iron absorption in the duodenum and systemic iron 
regulation. In further studies, western blotting of iron-related proteins in examined 
tissues should be performed in order to investigate changes in the examined proteins 
and thus confirm the proposed effects. 
It this thesis it was proven that polyphenols inhibit intestinal absorption of non-haem 
iron. However, it is still unknown how polyphenols affect haem iron absorption. Thus, 
further in vivo research should be done in order to investigate whether absorption of iron 
from a haem source could be affected by dietary polyphenols. 
In the present study it was proven that quercetin decreases the iron content of liver and 
spleen in vivo. Liver and spleen are the main iron storage organs, where during iron 
overload diseases a great increase in iron content occurs. Future research should 
confirm this beneficial effect of quercetin and other polyphenols in an iron overloaded 
mice model. 
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In this thesis it is observed that quercetin induces a great up-regulation of hepcidin in 
liver and kidney. However, the mechanism underlying this effect is not fully 
understood. In future, it should be investigated by which signalling pathway 
polyphenols, particularly quercetin, induce hepcidin up-regulation, with particular 
attention to the Nrf2–ARE and BMP6/SMAD4 signalling pathways. 
The ultimate goals of this kind of research are: 
 to examine the effects of dietary polyphenols on iron absorption and to establish 
a particular diet which will enhance iron absorption for patients affected with 
anaemia or inhibit iron absorption for patients diagnosed with iron-overload 
diseases; 
 to examine the therapeutic effects of polyphenols as chelato therapeutics for 
iron-redistribution therapy in human studies, focusing on patients with iron-
overload diseases. 
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